{"meta":{"query_hash":"367383d69e73","filters":{"venue":"Rheumatology and Therapy"},"cohort_total":122,"direct_labels_cover":0,"predictions_cover":122,"exported":122,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/367383d69e73","api":"https://metacan.xera.ac/api/v1/cohort?venue=Rheumatology+and+Therapy"},"results":[{"id":"W1613595294","doi":"10.1007/s40744-015-0016-9","title":"Rituximab for Rheumatoid Arthritis","year":2015,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Rituximab; Medicine; Hypogammaglobulinemia; Rheumatoid arthritis; Immunology; CD20; Progressive multifocal leukoencephalopathy; Methotrexate; Internal medicine; Lymphoma; Antibody; Virus","score_opus":0.061234917719439105,"score_gpt":0.3640471296806705,"score_spread":0.30281221196123137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1613595294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027574014,0.7921817,0.0030943693,0.031222546,0.01628277,0.000215605,0.0008600214,0.0010997177,0.15228602],"genre_scores_gemma":[0.057996273,0.527957,0.011358753,0.06289597,0.022946395,0.0005968238,0.0039002327,0.00041221763,0.31193632],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993042,0.00017508584,0.0000665072,0.000109463974,0.00023869557,0.00010602421],"domain_scores_gemma":[0.9993129,0.00012013283,0.00012035896,0.00005029836,0.00017744242,0.00021891536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008418309,0.0009789282,0.0009049795,0.0009945134,0.0005138056,0.0010159977,0.0007975971,0.0017662302,0.060088105],"category_scores_gemma":[0.0020079135,0.00016292723,0.0007242509,0.0006389143,0.00041804338,0.0007888915,0.0010452269,0.0023620797,0.054490842],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028147313,0.00011547491,0.00048686258,0.0018305661,0.00008131411,0.0011334661,0.000066317356,0.00006452419,0.0024868776,0.003753723,0.38586193,0.6038375],"study_design_scores_gemma":[0.00012624978,0.00012776245,0.00045893533,0.00038635544,0.000035218578,0.0029384415,0.000010652798,0.00002295689,0.00036358673,0.0010539846,0.994466,0.000009938055],"about_ca_topic_score_codex":0.0006205033,"about_ca_topic_score_gemma":0.0011093847,"teacher_disagreement_score":0.060088105,"about_ca_system_score_codex":0.00092505076,"about_ca_system_score_gemma":0.000903177,"threshold_uncertainty_score":0.2010147},"labels":[],"label_agreement":null},{"id":"W2307013176","doi":"10.1007/s40744-016-0025-3","title":"Chronic Diarrhea Associated with High Teriflunomide Blood Concentration","year":2016,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Université de Montréal","funders":"","keywords":"Teriflunomide; Diarrhea; Medicine; Chronic diarrhea; Internal medicine; Immunology; Multiple sclerosis","score_opus":0.008282392623788482,"score_gpt":0.2362358797215604,"score_spread":0.2279534870977719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307013176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98184663,0.0076841917,0.0019801385,0.0021590262,0.00024067344,0.00007834176,0.0001471836,0.00012331143,0.0057405555],"genre_scores_gemma":[0.9956455,0.0015822628,0.000621534,0.0009907333,0.0002514529,0.00001061663,0.000077678305,0.000011830296,0.000808382],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99970406,0.000039371105,0.000035902984,0.00006494548,0.000030493635,0.00012524503],"domain_scores_gemma":[0.9992124,0.00015102653,0.00023988423,0.00004205635,0.00006257736,0.00029202833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019781626,0.0009248891,0.0008511839,0.0007793512,0.0015377253,0.00085764076,0.00041366142,0.0019099932,0.0016912412],"category_scores_gemma":[0.001330529,0.0005390034,0.0007582747,0.0007172105,0.0005014825,0.0010596168,0.0006955625,0.0017013022,0.00047913232],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019939699,0.00010307022,0.039515257,0.00007732275,0.000024264575,0.9535812,0.00022966963,0.00009481302,0.0026292542,0.000103356164,0.00051523955,0.002927094],"study_design_scores_gemma":[0.000039864455,0.0002370372,0.011090561,0.000024374905,0.000031110252,0.9863755,0.00016093206,0.00023744423,0.00067596097,0.000068710855,0.0010461136,0.000012337083],"about_ca_topic_score_codex":0.0010245206,"about_ca_topic_score_gemma":0.0011994124,"teacher_disagreement_score":0.0019099932,"about_ca_system_score_codex":0.000577075,"about_ca_system_score_gemma":0.00049831707,"threshold_uncertainty_score":0.005657792},"labels":[],"label_agreement":null},{"id":"W2470479127","doi":"10.1007/s40744-016-0036-0","title":"Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil","year":2016,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Division of Graduate Education; Fundação de Amparo à Pesquisa do Estado de Minas Gerais; Universidade Federal de Minas Gerais; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Medicine; Adalimumab; Etanercept; Ankylosing spondylitis; Infliximab; Cohort; Retrospective cohort study; Internal medicine; Population; Physical therapy; Disease; Rheumatoid arthritis; Environmental health","score_opus":0.006255116176306747,"score_gpt":0.24056880872538436,"score_spread":0.2343136925490776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470479127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753876,0.013487433,0.00017836534,0.0017757678,0.000018206367,0.00005711771,0.0054620905,0.0000061450623,0.0036272453],"genre_scores_gemma":[0.9944537,0.004004227,0.00015953032,0.00009116633,0.000013328234,0.0000205407,0.0011862633,0.0000015431699,0.00006974749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989636,0.00033178547,0.000210918,0.000099757344,0.0002658083,0.00012811026],"domain_scores_gemma":[0.99724823,0.00036934583,0.0019850445,0.000045199067,0.0001966598,0.00015544081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006309102,0.00018856826,0.00033888736,0.0012716322,0.00024527125,0.0008877432,0.00038145515,0.00025044475,0.0012467372],"category_scores_gemma":[0.004536274,0.00017770735,0.00078720675,0.0030719186,0.00020817605,0.0004227835,0.0005100617,0.00032090745,0.00007456575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014953653,0.000050986768,0.9788383,0.00054937776,0.00040207946,0.0005624904,0.00023854883,0.0005512335,0.00016715351,0.0005524663,0.0010692679,0.016868543],"study_design_scores_gemma":[0.000047551915,0.000087596745,0.99220395,0.0005487712,0.000251854,0.0014510533,0.00061739906,0.0012826155,0.000083842315,0.00030504254,0.00310813,0.000012186107],"about_ca_topic_score_codex":0.06299685,"about_ca_topic_score_gemma":0.056632757,"teacher_disagreement_score":0.06299685,"about_ca_system_score_codex":0.0029479547,"about_ca_system_score_gemma":0.0017678139,"threshold_uncertainty_score":0.12526035},"labels":[],"label_agreement":null},{"id":"W2513381414","doi":"10.1007/s40744-016-0041-3","title":"Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis","year":2016,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Tolerability; Visual analogue scale; Randomized controlled trial; McGill Pain Questionnaire; Injection site; Crossover study; Anesthesia; Surgery; Adverse effect; Placebo; Internal medicine","score_opus":0.011321142352978927,"score_gpt":0.2703180193316968,"score_spread":0.25899687697871787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513381414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885261,0.002017236,0.0007209462,0.00027570705,0.0007996662,0.0057884753,0.00052383216,0.0000958156,0.0012521603],"genre_scores_gemma":[0.9824362,0.0015652572,0.0022486628,0.00071441743,0.0006551669,0.009123867,0.0005782721,0.000026212074,0.0026519892],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979201,0.0011450055,0.00019365911,0.00035630082,0.00014267875,0.00024227667],"domain_scores_gemma":[0.9975229,0.0008124898,0.00059122656,0.0002771845,0.0002532326,0.0005429391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033774744,0.0020486338,0.0041332752,0.0006643295,0.0005684345,0.0013338462,0.0011157272,0.0023124018,0.008920717],"category_scores_gemma":[0.003440132,0.0014820236,0.0021401036,0.0006579041,0.0013243367,0.0013917243,0.0005172816,0.0025617771,0.0014118046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9823383,0.011396333,0.00022104863,0.0001986159,0.0003032149,0.000014735865,0.000039672337,0.000081204314,0.0017823734,0.00003477485,0.0001278113,0.0034620091],"study_design_scores_gemma":[0.8579696,0.14021282,0.00093142706,0.000012905337,0.00022320176,0.000009540524,0.000016453401,0.00014127903,0.00022729927,0.00004891393,0.0001956893,0.000010987308],"about_ca_topic_score_codex":0.0009935398,"about_ca_topic_score_gemma":0.0015883634,"teacher_disagreement_score":0.008920717,"about_ca_system_score_codex":0.0008606095,"about_ca_system_score_gemma":0.0016079808,"threshold_uncertainty_score":0.029842794},"labels":[],"label_agreement":null},{"id":"W2754119638","doi":"10.1007/s40744-017-0079-x","title":"Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment","year":2017,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Amgen (Canada); Centre hospitalier universitaire de Québec","funders":"Amgen","keywords":"Adalimumab; Medicine; Etanercept; Rheumatoid arthritis; Internal medicine; Clinical endpoint; Rheumatology; Adverse effect; Confidence interval; Clinical trial","score_opus":0.016428371575907753,"score_gpt":0.2667307663602153,"score_spread":0.25030239478430755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754119638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930686,0.0025188448,0.00036062565,0.00021331875,0.00018307891,0.0021345743,0.00054314686,0.000035727353,0.00094220595],"genre_scores_gemma":[0.993895,0.0006915755,0.0005055447,0.00050899514,0.000330579,0.002660281,0.000604603,0.0000058379183,0.0007976361],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9982533,0.00091482763,0.00015860447,0.00025486934,0.00017420041,0.00024416082],"domain_scores_gemma":[0.99751794,0.00049947004,0.00050714926,0.00023058715,0.00020580634,0.0010390508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003571442,0.0015597742,0.004638824,0.0004233037,0.0006577762,0.0012106755,0.0006071201,0.0017105459,0.0042153196],"category_scores_gemma":[0.0032542648,0.00073227787,0.0023134735,0.0004069077,0.0006434403,0.00089270953,0.0004979823,0.0020252282,0.00086542877],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9495465,0.011847729,0.021604994,0.00040463547,0.0022677707,0.00013905318,0.00012004363,0.00030778977,0.0014423066,0.00005639875,0.00050908385,0.011753713],"study_design_scores_gemma":[0.61949044,0.32252988,0.053717505,0.000059798196,0.001149964,0.00020907218,0.000058298552,0.0008895709,0.00028690163,0.00011109874,0.001460754,0.000036647063],"about_ca_topic_score_codex":0.00048043363,"about_ca_topic_score_gemma":0.0008253381,"teacher_disagreement_score":0.004638824,"about_ca_system_score_codex":0.0005723316,"about_ca_system_score_gemma":0.0010684865,"threshold_uncertainty_score":0.018887758},"labels":[],"label_agreement":null},{"id":"W2757516511","doi":"10.1007/s40744-017-0080-4","title":"Chronic Disease and Self-Injection: Ethnographic Investigations into the Patient Experience During Treatment","year":2017,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Antibiotic Use and Resistance","field":"Immunology and Microbiology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"UCB Pharma","keywords":"Medicine; Context (archaeology); Empowerment; Health care; Patient experience; Nursing","score_opus":0.011672039111155144,"score_gpt":0.25060873445333554,"score_spread":0.2389366953421804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757516511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994743,0.0005022586,0.00096497627,0.0011313758,0.000025718076,0.000084209314,0.00007422777,0.000008783426,0.002465366],"genre_scores_gemma":[0.99692553,0.00082159176,0.0006768407,0.0005084603,0.000023664874,0.000111766785,0.000054343604,0.0000131973875,0.00086452666],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99017006,0.0077705164,0.00029098935,0.0003852726,0.00045451245,0.0009286416],"domain_scores_gemma":[0.9832866,0.013132091,0.0011046882,0.0004814994,0.0008082322,0.001186875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007460689,0.00047027314,0.0006177624,0.0014756675,0.005107794,0.0037724015,0.0011686382,0.001516493,0.0016651215],"category_scores_gemma":[0.017214382,0.0006056403,0.00037622234,0.0012255476,0.004977518,0.0039425953,0.0042831637,0.0023550077,0.00021144138],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023206363,0.00004229953,0.006275206,0.00004770609,0.000004118395,0.00035050808,0.9894148,0.000018805851,0.00026894078,0.00024812942,0.0002087828,0.0030974075],"study_design_scores_gemma":[0.0000046688697,0.00007187947,0.003857954,0.00008563677,0.0000051669376,0.000337956,0.9912144,0.00008900928,0.000146415,0.00012568597,0.0040480196,0.000013176383],"about_ca_topic_score_codex":0.008370089,"about_ca_topic_score_gemma":0.013955035,"teacher_disagreement_score":0.008370089,"about_ca_system_score_codex":0.0026405714,"about_ca_system_score_gemma":0.0026931649,"threshold_uncertainty_score":0.039456308},"labels":[],"label_agreement":null},{"id":"W2765105454","doi":"10.1007/s40744-017-0087-x","title":"A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States","year":2017,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Retrospective cohort study; Internal medicine; Medical record; Dermatomyositis; Rheumatoid arthritis; Polymyositis; Psoriatic arthritis; Cohort; Rheumatology; Systemic lupus erythematosus; Physical therapy; Disease","score_opus":0.016613590251796057,"score_gpt":0.2747546394899367,"score_spread":0.2581410492381407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765105454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917019,0.0018913517,0.00013273333,0.00011140871,0.000008391373,0.0001276987,0.005256925,0.000008799528,0.00076074083],"genre_scores_gemma":[0.99435115,0.0010263628,0.00042367357,0.00017045742,0.00002238155,0.00013700794,0.0037573809,0.0000032241157,0.00010828559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974094,0.0006272098,0.00089257205,0.00042446828,0.00045810628,0.0001881737],"domain_scores_gemma":[0.9884206,0.002828857,0.0066574835,0.00045067217,0.0011840742,0.0004583126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013910625,0.00015595797,0.0004655575,0.0025429246,0.0005534442,0.00071763195,0.00045167498,0.0004328216,0.001002382],"category_scores_gemma":[0.0058350596,0.00031361703,0.000402233,0.0041307756,0.00034897667,0.00062539586,0.0005373445,0.00041150782,0.00019280921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038313072,0.000029717701,0.99748117,0.00008911456,0.000043872737,0.00014450848,0.00018905482,0.000016383572,0.0000821217,0.000010901985,0.0003192152,0.0015555052],"study_design_scores_gemma":[0.000008472705,0.00008623151,0.9977859,0.00007520973,0.000039294737,0.00043864216,0.00074744667,0.00010521194,0.000084145635,0.0000066493453,0.0006184277,0.000004289342],"about_ca_topic_score_codex":0.017188046,"about_ca_topic_score_gemma":0.018467722,"teacher_disagreement_score":0.017188046,"about_ca_system_score_codex":0.00094416866,"about_ca_system_score_gemma":0.0017687525,"threshold_uncertainty_score":0.034175992},"labels":[],"label_agreement":null},{"id":"W2796965324","doi":"10.1007/s40744-018-0109-3","title":"Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Southlake Regional Health Center; ABB (Canada); University of Toronto; St. Michael's Hospital; Université Laval","funders":"European League Against Rheumatism; AbbVie","keywords":"Ankylosing spondylitis; Adalimumab; Medicine; Spondylitis; Physical therapy; Internal medicine; Disease","score_opus":0.047056853314772704,"score_gpt":0.38990517998430324,"score_spread":0.3428483266695305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796965324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814117,0.0003368,0.00003264877,0.000111068024,0.00001253008,0.000029317514,0.0009019986,0.000003931324,0.00043059673],"genre_scores_gemma":[0.99773395,0.00015466826,0.00009019534,0.00008671901,0.000032609598,0.000047459944,0.0015928444,0.000003589056,0.0002580275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967674,0.0018245672,0.00028997165,0.00045759117,0.00040836475,0.0002521512],"domain_scores_gemma":[0.98799163,0.00401635,0.0038059708,0.0011683353,0.0011870532,0.001830613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059580603,0.0003342203,0.00062168605,0.0005595549,0.00040666555,0.0009675679,0.00067707617,0.0006910889,0.0018027219],"category_scores_gemma":[0.014049921,0.00021376829,0.0019970813,0.0007982266,0.00028126125,0.0008339874,0.0010804408,0.0008426452,0.00030708947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019527186,0.0015497814,0.95939857,0.000189685,0.0019177769,0.00008551599,0.00029619437,0.00031203995,0.00010686074,0.000078396384,0.0014234587,0.015114514],"study_design_scores_gemma":[0.0007881206,0.0035099762,0.9935221,0.00004321463,0.0007672303,0.000070715934,0.00017831843,0.00054413284,0.000041569885,0.0000435453,0.0004784795,0.000012597313],"about_ca_topic_score_codex":0.013691319,"about_ca_topic_score_gemma":0.011190914,"teacher_disagreement_score":0.013691319,"about_ca_system_score_codex":0.00085669255,"about_ca_system_score_gemma":0.0011306836,"threshold_uncertainty_score":0.031509638},"labels":[],"label_agreement":null},{"id":"W2897834691","doi":"10.1007/s40744-018-0129-z","title":"Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Gilead Sciences; Momenta Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Horizon Pharma; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ankylosing spondylitis; Discontinuation; Psoriatic arthritis; Internal medicine; BASDAI; Observational study; Adverse effect; Psoriasis; Physical therapy; Rheumatoid arthritis; Dermatology","score_opus":0.03990032350989552,"score_gpt":0.2904200426353766,"score_spread":0.25051971912548104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897834691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695826,0.00060137856,0.000087278415,0.00008715349,0.000011813201,0.0000310439,0.0017270294,0.0000039844717,0.0004921698],"genre_scores_gemma":[0.99756914,0.00029628308,0.000082839346,0.00010373323,0.00002105084,0.00004329489,0.001796049,0.0000032452251,0.000084337575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974523,0.0007105843,0.00048740176,0.00056634645,0.0005067601,0.00027657952],"domain_scores_gemma":[0.9930214,0.0007638635,0.0047445693,0.00056122,0.0004513382,0.000457587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002294662,0.00025748493,0.00064560433,0.00089785416,0.0005827586,0.00104765,0.00070053316,0.00050843315,0.0012445836],"category_scores_gemma":[0.005888031,0.00046922537,0.0008637091,0.0023633621,0.00030800872,0.0008620992,0.00084819144,0.0010173687,0.00029456368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012214766,0.000033563578,0.9990085,0.000017098744,0.000089009685,0.000034186087,0.00006488302,0.000016145872,0.000029749186,0.000012429747,0.00019923873,0.00037303328],"study_design_scores_gemma":[0.000038416092,0.00011486462,0.99833256,0.00003971099,0.00010062342,0.00029434016,0.000367222,0.00017216765,0.000033706106,0.000015103155,0.00048470395,0.0000065271706],"about_ca_topic_score_codex":0.011675043,"about_ca_topic_score_gemma":0.014090238,"teacher_disagreement_score":0.011675043,"about_ca_system_score_codex":0.0006627214,"about_ca_system_score_gemma":0.0010774517,"threshold_uncertainty_score":0.023214161},"labels":[],"label_agreement":null},{"id":"W2898156360","doi":"10.1007/s40744-018-0130-6","title":"Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; University of British Columbia; Roche (Canada); William Osler Health System; Université de Montréal","funders":"F. Hoffmann-La Roche","keywords":"Tocilizumab; Medicine; Rheumatoid arthritis; Internal medicine; Adverse effect; Observational study; Combination therapy; Clinical endpoint; Surgery; Clinical trial","score_opus":0.041763053982573115,"score_gpt":0.292740038678264,"score_spread":0.25097698469569085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898156360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975514,0.00031176137,0.00006628148,0.000071421266,0.0000043958603,0.00006956085,0.0015038424,0.0000042187257,0.00041715335],"genre_scores_gemma":[0.99785185,0.00026825955,0.0001701495,0.00009917741,0.000011415385,0.000053833806,0.0013812217,0.000002399195,0.0001616616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977882,0.00046101448,0.00023742265,0.00032531866,0.0008497138,0.00033824527],"domain_scores_gemma":[0.99177986,0.000628183,0.003560692,0.00023626455,0.0026450045,0.0011499042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001454806,0.0003557169,0.00054762047,0.0009233777,0.0013514078,0.0010970676,0.0008411826,0.0005617788,0.00092631025],"category_scores_gemma":[0.0045118653,0.00035326192,0.0006729856,0.0029411805,0.0007157537,0.00044867216,0.0006952977,0.000734337,0.00019994902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019524443,0.000101987825,0.99791425,0.000029112163,0.00007958493,0.000030753206,0.00022819008,0.000032358275,0.00007795687,0.0000071668665,0.000121978155,0.0011814414],"study_design_scores_gemma":[0.000029900228,0.00012387166,0.9992079,0.000010808304,0.000033917957,0.00003907151,0.00024029278,0.00010438992,0.00002741309,0.0000036066265,0.00017214289,0.000006772164],"about_ca_topic_score_codex":0.8028788,"about_ca_topic_score_gemma":0.8031326,"teacher_disagreement_score":0.1971212,"about_ca_system_score_codex":0.00807894,"about_ca_system_score_gemma":0.008694851,"threshold_uncertainty_score":0.39656413},"labels":[],"label_agreement":null},{"id":"W2899718933","doi":"10.1007/s40744-018-0131-5","title":"Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Psoriatic arthritis; Internal medicine; Dactylitis; Placebo; Enthesitis; Clinical endpoint; Psoriasis; Rheumatology; Psoriasis Area and Severity Index; Arthritis; Rheumatoid arthritis; Dermatology; Surgery; Gastroenterology; Randomized controlled trial; Pathology","score_opus":0.040418028691758666,"score_gpt":0.3785333373867725,"score_spread":0.3381153086950138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899718933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47621024,0.46584594,0.015121195,0.001001638,0.00096341514,0.0052971137,0.029454509,0.0006765388,0.005429474],"genre_scores_gemma":[0.9488391,0.029702377,0.004986078,0.00092848606,0.00047667706,0.0037750707,0.010384687,0.00016187463,0.000745604],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97293967,0.017344702,0.0038817185,0.00243147,0.0028442598,0.00055810506],"domain_scores_gemma":[0.9703002,0.016970972,0.008182513,0.0021986987,0.0018618207,0.0004857866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.038332097,0.0027006161,0.010202238,0.0036498518,0.00042318163,0.0030403042,0.00093400455,0.0015585583,0.0030580186],"category_scores_gemma":[0.032561447,0.0010326422,0.031400263,0.0038421294,0.00048548263,0.0013074497,0.0013714652,0.0010486331,0.00032848652],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079735726,0.00017895455,0.023199115,0.012200202,0.8539852,0.00012497306,0.00008531596,0.0017833671,0.0017283907,0.00007504232,0.001282388,0.025621336],"study_design_scores_gemma":[0.02140217,0.007695792,0.07905132,0.0012019572,0.8836351,0.0003026659,0.00007589376,0.0012626195,0.001047704,0.00048249683,0.0037213543,0.000120902354],"about_ca_topic_score_codex":0.0009615949,"about_ca_topic_score_gemma":0.0019275564,"teacher_disagreement_score":0.038332097,"about_ca_system_score_codex":0.0010289282,"about_ca_system_score_gemma":0.0018158841,"threshold_uncertainty_score":0.2027219},"labels":[],"label_agreement":null},{"id":"W2912852188","doi":"10.1007/s40744-019-0145-7","title":"An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiography; Osteoarthritis; Rheumatology; Physical therapy; Internal medicine; Interphalangeal Joint; Radiological weapon; Grip strength; Radiology; Surgery; Pathology","score_opus":0.010712757509467468,"score_gpt":0.29100130488664755,"score_spread":0.28028854737718006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912852188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969893,0.0011620604,0.00042377875,0.00003753643,0.0000109408,0.00005632693,0.00022521813,0.000010936482,0.0010838931],"genre_scores_gemma":[0.9985707,0.00029687939,0.00053113524,0.000020660149,0.000028232507,0.000035541347,0.00024559573,0.0000011064377,0.00027022025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945253,0.00015407358,0.000095798016,0.000088846005,0.00016320894,0.000045546192],"domain_scores_gemma":[0.99889344,0.00015876672,0.00048731474,0.0000431268,0.00021143546,0.00020596321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074394426,0.00035794647,0.00045874063,0.0009440316,0.00016438801,0.0003538236,0.00021496683,0.00032254503,0.0022317106],"category_scores_gemma":[0.0012367618,0.0001049277,0.00018563807,0.0004857185,0.00021274734,0.00032686366,0.00034562452,0.00025059283,0.0003564072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038509746,0.0001721681,0.98755705,0.00007773676,0.00007461696,0.00023686596,0.00004229216,0.000046577,0.0037171699,0.000012883935,0.00009578221,0.007581674],"study_design_scores_gemma":[0.000025720548,0.0013169711,0.9948367,0.00001613739,0.000035154815,0.0027754956,0.0000901163,0.00013093813,0.00047869878,0.000018816692,0.00026909713,0.000006129205],"about_ca_topic_score_codex":0.00020449773,"about_ca_topic_score_gemma":0.00033580954,"teacher_disagreement_score":0.0022317106,"about_ca_system_score_codex":0.00010623328,"about_ca_system_score_gemma":0.00015332771,"threshold_uncertainty_score":0.0074658394},"labels":[],"label_agreement":null},{"id":"W2913202798","doi":"10.1007/s40744-019-0140-z","title":"Safety and Efficacy of Repeat Administration of Triamcinolone Acetonide Extended-release in Osteoarthritis of the Knee: A Phase 3b, Open-label Study","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Sanofi; Musculoskeletal Transplant Foundation","keywords":"Medicine; Osteoarthritis; WOMAC; Triamcinolone acetonide; Adverse effect; Dosing; Clinical trial; Quality of life (healthcare); Surgery; Anesthesia; Internal medicine","score_opus":0.0210760317936827,"score_gpt":0.31563577953656363,"score_spread":0.2945597477428809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913202798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344456,0.0031510775,0.0006449121,0.00012881026,0.00006415113,0.0015086182,0.00050415244,0.000068009576,0.0004856758],"genre_scores_gemma":[0.99146515,0.0019565935,0.0015634801,0.00049974024,0.00021827119,0.0022710827,0.00080856984,0.000024123774,0.001193074],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999204,0.00035949508,0.000071131675,0.0001370844,0.00012876904,0.000099646124],"domain_scores_gemma":[0.998209,0.0003872196,0.00073032465,0.00020131706,0.00015010234,0.00032208717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00285396,0.0011869344,0.0023192964,0.00041993184,0.0003757444,0.0008229237,0.0008957697,0.0013816456,0.0035262809],"category_scores_gemma":[0.0014876832,0.0005076966,0.0015248255,0.0003920573,0.0006770442,0.0007956044,0.00027195306,0.0020379624,0.0009487735],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7613273,0.08671715,0.0065062633,0.0016699722,0.0018272296,0.0002332629,0.00025865296,0.0009819189,0.045299176,0.00007947853,0.0011528882,0.09394675],"study_design_scores_gemma":[0.30386353,0.6780844,0.012476309,0.000065132095,0.00044093037,0.00026754788,0.000040377967,0.0005731327,0.0029642978,0.00006075439,0.0011295741,0.000033992386],"about_ca_topic_score_codex":0.00028848872,"about_ca_topic_score_gemma":0.0007521534,"teacher_disagreement_score":0.0035262809,"about_ca_system_score_codex":0.00041706522,"about_ca_system_score_gemma":0.00090420764,"threshold_uncertainty_score":0.015093386},"labels":[],"label_agreement":null},{"id":"W2920976889","doi":"10.1007/s40744-019-0150-x","title":"Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"European League Against Rheumatism; F. Hoffmann-La Roche; Bristol-Myers Squibb","keywords":"Medicine; Tocilizumab; Discontinuation; Adverse effect; Rheumatoid arthritis; Internal medicine; Incidence (geometry); Biologic Agents","score_opus":0.026683295699599048,"score_gpt":0.29622415566303195,"score_spread":0.2695408599634329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920976889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709606,0.0017068308,0.00015415395,0.000029282264,0.0000031539819,0.00003721351,0.00062608416,0.0000054146185,0.00034175377],"genre_scores_gemma":[0.99864095,0.00034622423,0.0002063688,0.000037451387,0.000009615147,0.000035164943,0.0006740495,0.0000020207658,0.000048127436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967451,0.0014828084,0.00062954536,0.00041693347,0.00055711635,0.00016849187],"domain_scores_gemma":[0.9841611,0.004702767,0.008033468,0.0011180736,0.0014641428,0.00052048825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050412505,0.00029383274,0.0005865476,0.0010050539,0.00039322398,0.0008860374,0.00034625625,0.00035441405,0.0011018006],"category_scores_gemma":[0.0075876107,0.00022429871,0.0009332742,0.0016768107,0.00034527722,0.00041514143,0.000489462,0.00028905337,0.00025381203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000952672,0.00007626389,0.99303097,0.00008302085,0.00068565307,0.000025992505,0.00008797589,0.000039675135,0.00033770516,0.0000044077215,0.00005704693,0.004618749],"study_design_scores_gemma":[0.00007969748,0.0006401983,0.9982016,0.000023884835,0.00032809548,0.00019586284,0.0000868948,0.00006596293,0.00015921303,0.000006489894,0.00020673453,0.0000053708477],"about_ca_topic_score_codex":0.0016103695,"about_ca_topic_score_gemma":0.0020899493,"teacher_disagreement_score":0.0050412505,"about_ca_system_score_codex":0.00038943806,"about_ca_system_score_gemma":0.00046719442,"threshold_uncertainty_score":0.026661038},"labels":[],"label_agreement":null},{"id":"W2922151066","doi":"10.1007/s40744-019-0149-3","title":"Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Momenta Pharmaceuticals; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Genentech; Horizon Pharma; Celgene; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Abatacept; Internal medicine; Rheumatoid arthritis; Cohort; Etanercept; Propensity score matching; Rheumatology; Serostatus; Rheumatoid factor; Oncology; Physical therapy; Immunology; Rituximab; Human immunodeficiency virus (HIV)","score_opus":0.010808186754837322,"score_gpt":0.2590551601920899,"score_spread":0.24824697343725258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922151066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954834,0.002051815,0.00013733724,0.00006373577,0.00002328479,0.00007612287,0.0015153908,0.0000055126034,0.00064345595],"genre_scores_gemma":[0.9977533,0.0005637327,0.00014142062,0.00008597782,0.00002935328,0.00007093627,0.0012427823,0.0000027025562,0.000109714965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779713,0.0009659186,0.00031995922,0.0004867966,0.0002884994,0.0001417897],"domain_scores_gemma":[0.997012,0.0009120899,0.0013988039,0.00023566265,0.00017083925,0.00027068114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001733268,0.00017978372,0.0006719294,0.00046259587,0.00020196453,0.00052853307,0.00046137578,0.00034361923,0.001274174],"category_scores_gemma":[0.0037519543,0.00020520382,0.0013063871,0.00071318063,0.0002526683,0.00030155183,0.00031249455,0.00033480165,0.00021040766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03650114,0.00056830765,0.9388066,0.000495393,0.0035535118,0.00013004536,0.00011233984,0.0006533696,0.00070180336,0.00012655619,0.001178622,0.017172374],"study_design_scores_gemma":[0.006601006,0.009255964,0.975047,0.00016376308,0.0038041521,0.00059363316,0.00023251776,0.0015409682,0.00051898527,0.00012457973,0.0020872473,0.000030180205],"about_ca_topic_score_codex":0.0034806908,"about_ca_topic_score_gemma":0.006006109,"teacher_disagreement_score":0.0034806908,"about_ca_system_score_codex":0.0007224838,"about_ca_system_score_gemma":0.0008986626,"threshold_uncertainty_score":0.009166539},"labels":[],"label_agreement":null},{"id":"W2953184093","doi":"10.1007/s40744-019-0164-4","title":"Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care","funders":"Incyte; Eli Lilly and Company","keywords":"Rheumatoid arthritis; Productivity; Work productivity; Medicine; Work (physics); Physical therapy; Physical medicine and rehabilitation; Internal medicine; Engineering; Economics; Mechanical engineering","score_opus":0.012382154287976042,"score_gpt":0.25954808196014073,"score_spread":0.2471659276721647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953184093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500595,0.040639944,0.00032495885,0.0010894145,0.00025866376,0.00045818544,0.0033448578,0.000047693637,0.0037767764],"genre_scores_gemma":[0.9908634,0.004299816,0.0002271782,0.00044088977,0.0002948609,0.00040675123,0.002877961,0.000007710631,0.0005814808],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99912983,0.00048176904,0.00007020349,0.00011429499,0.00011223087,0.00009175456],"domain_scores_gemma":[0.9985876,0.00062682194,0.00043717073,0.000082520484,0.00009140956,0.00017454915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028772028,0.0005920711,0.0017813483,0.00019814755,0.0002834039,0.00083928596,0.00047827375,0.00064493367,0.0042630294],"category_scores_gemma":[0.0027324243,0.0001960039,0.0015013602,0.00035247454,0.00027492922,0.00034203116,0.00024200637,0.0012003948,0.00030298266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8812392,0.0011158485,0.0297253,0.0037554752,0.0113900425,0.000103060294,0.000059194404,0.0017661308,0.002756313,0.00020192104,0.005245539,0.06264197],"study_design_scores_gemma":[0.6295549,0.0684907,0.2642206,0.0009928918,0.024463814,0.0006571946,0.0000965397,0.0025642037,0.0015100759,0.00070468447,0.006654693,0.00008965117],"about_ca_topic_score_codex":0.0005952456,"about_ca_topic_score_gemma":0.0016853638,"teacher_disagreement_score":0.0042630294,"about_ca_system_score_codex":0.00038064673,"about_ca_system_score_gemma":0.00043856783,"threshold_uncertainty_score":0.015216291},"labels":[],"label_agreement":null},{"id":"W2955483855","doi":"10.1007/s40744-019-0165-3","title":"Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"School of Medicine; University of Utah; Genentech; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company; KU Leuven; U.S. Department of Veterans Affairs","keywords":"Ixekizumab; Medicine; Ankylosing spondylitis; Placebo; Physical therapy; Repeated measures design; Internal medicine; Clinical trial; Clinical endpoint; Secukinumab; Disease; Psoriatic arthritis; Alternative medicine","score_opus":0.040982229017327114,"score_gpt":0.39421691062771264,"score_spread":0.3532346816103855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955483855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943475,0.03264406,0.0055976124,0.0033539548,0.0007992858,0.0037964608,0.0038613486,0.00017584857,0.0062964945],"genre_scores_gemma":[0.9849423,0.0022802567,0.0057956176,0.00077760295,0.0003343571,0.003743583,0.0016022716,0.00003649207,0.00048739646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9366619,0.047167074,0.0077280896,0.003043614,0.004715323,0.0006840048],"domain_scores_gemma":[0.9211498,0.04753044,0.021337517,0.0032313445,0.005405031,0.0013458224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08010166,0.0005952842,0.0017710482,0.00093354774,0.00034832835,0.0020873137,0.00059853244,0.0007055763,0.0023335568],"category_scores_gemma":[0.10548254,0.00037163388,0.00234807,0.0019723028,0.00083166966,0.0010223716,0.0014206722,0.0010469571,0.0003481833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20130192,0.001979048,0.42013282,0.013988428,0.022031942,0.0001263034,0.001905611,0.005603175,0.004459634,0.0015734198,0.008142309,0.31875545],"study_design_scores_gemma":[0.06364156,0.051400386,0.8390359,0.0027637924,0.013373899,0.00032429054,0.0005582479,0.0077628507,0.0039424743,0.002517614,0.014526418,0.00015260513],"about_ca_topic_score_codex":0.00047761612,"about_ca_topic_score_gemma":0.000535201,"teacher_disagreement_score":0.08010166,"about_ca_system_score_codex":0.0008248204,"about_ca_system_score_gemma":0.0024765886,"threshold_uncertainty_score":0.42362314},"labels":[],"label_agreement":null},{"id":"W3000625420","doi":"10.1007/s40744-019-00190-7","title":"Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?","year":2020,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"AbbVie","keywords":"Nocebo Effect; Biosimilar; Nocebo; Discontinuation; Medicine; Adverse effect; Intensive care medicine; Internal medicine; Alternative medicine; Placebo; Pathology","score_opus":0.017435544185724097,"score_gpt":0.3083887121203034,"score_spread":0.2909531679345793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000625420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007043639,0.99949765,0.000028951978,0.00020689478,0.000053092783,0.0000020038744,0.0000041730445,6.6385786e-7,0.00013607042],"genre_scores_gemma":[0.0012644267,0.99818665,0.0000684665,0.00027936636,0.00011367047,0.000004664499,0.000007792904,4.941282e-7,0.00007444709],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99905175,0.00034878822,0.00022418245,0.00010440048,0.00022753654,0.000043323027],"domain_scores_gemma":[0.99512464,0.0037510039,0.0006966913,0.000046316305,0.00033335338,0.00004799664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017931397,0.0005686599,0.0014693835,0.0023607542,0.00028443523,0.0014368438,0.0007689353,0.0017210542,0.0022803457],"category_scores_gemma":[0.0057541328,0.00027250565,0.0013276164,0.0020520496,0.0007210431,0.0014871648,0.0005353612,0.0016059154,0.00037014956],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018264921,0.000055739878,0.0008113091,0.14061047,0.00066821644,0.00037804706,0.00029365948,0.00029239708,0.00038676648,0.005306008,0.01196013,0.83905464],"study_design_scores_gemma":[0.00012312196,0.00034737238,0.0061481777,0.1657487,0.003398646,0.007664637,0.0008225495,0.00037613837,0.00067731354,0.0077223056,0.80689484,0.00007631879],"about_ca_topic_score_codex":0.0016283644,"about_ca_topic_score_gemma":0.003120526,"teacher_disagreement_score":0.0023607542,"about_ca_system_score_codex":0.00089483516,"about_ca_system_score_gemma":0.0026328745,"threshold_uncertainty_score":0.009483159},"labels":[],"label_agreement":null},{"id":"W3011220016","doi":"10.1007/s40744-020-00199-3","title":"Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Rheumatoid arthritis; Randomized controlled trial; Medicine; Physical therapy; Internal medicine","score_opus":0.013864430913574366,"score_gpt":0.2721957997660841,"score_spread":0.25833136885250974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011220016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646552,0.023030132,0.00095971144,0.000987493,0.00079456565,0.006565484,0.0007551588,0.00015071672,0.002101546],"genre_scores_gemma":[0.97647494,0.009551789,0.0016807099,0.0013636346,0.0010143187,0.00710898,0.00065103377,0.000018334265,0.0021362503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992822,0.0004090296,0.000058339985,0.0000984239,0.0000854728,0.00006648672],"domain_scores_gemma":[0.9988697,0.00037392846,0.00034577618,0.00007588396,0.000071007045,0.00026368283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021409101,0.00094811525,0.0030864726,0.00037591724,0.0004189584,0.00087991386,0.00078226044,0.0014774244,0.005282141],"category_scores_gemma":[0.0015694915,0.00036586527,0.0012370864,0.0004558292,0.00093162304,0.00061316736,0.00030438486,0.0017603148,0.00064348505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96137464,0.005165901,0.00064605486,0.0016537497,0.00085402385,0.00009783483,0.000065800814,0.00014132097,0.0021719967,0.00012205248,0.0006715692,0.027035095],"study_design_scores_gemma":[0.96762073,0.030730091,0.0007506031,0.000056859284,0.00023358015,0.000027767484,0.000009828728,0.00011054885,0.00010035845,0.000042758755,0.00031097056,0.0000059468885],"about_ca_topic_score_codex":0.0005180738,"about_ca_topic_score_gemma":0.0012651134,"teacher_disagreement_score":0.005282141,"about_ca_system_score_codex":0.00042984105,"about_ca_system_score_gemma":0.0012674031,"threshold_uncertainty_score":0.017670512},"labels":[],"label_agreement":null},{"id":"W3019766834","doi":"10.1007/s40744-020-00207-6","title":"Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation","year":2020,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Psoriatic arthritis; Medicine; Depression (economics); Alexithymia; Population; Anxiety; Quality of life (healthcare); Disease; Anhedonia; Psoriasis; Comorbidity; Intensive care medicine; Internal medicine; Psychiatry; Immunology","score_opus":0.015603135096680794,"score_gpt":0.27557333320969546,"score_spread":0.25997019811301464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019766834","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00077968114,0.99824333,0.00008086533,0.0004335325,0.00006768424,0.000012555083,0.000061677834,0.0000014936393,0.0003191041],"genre_scores_gemma":[0.010076194,0.98904735,0.00021438792,0.00033912892,0.00012381258,0.000028886307,0.00006701667,7.295301e-7,0.00010247172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887186,0.00043443454,0.00033291563,0.00009988221,0.00021618592,0.000044640914],"domain_scores_gemma":[0.996332,0.0026903588,0.00062084873,0.000034334065,0.00028048301,0.000041952913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013443283,0.00046778395,0.0012619969,0.0020805984,0.00029818155,0.001495147,0.00040387502,0.00073097204,0.0015870194],"category_scores_gemma":[0.006372499,0.0002469113,0.0017078186,0.0026513026,0.00037313197,0.0007291099,0.0007533094,0.00088220905,0.00015098405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002873372,0.000056667668,0.008917903,0.22987498,0.003069325,0.00031510481,0.0006840933,0.00046167136,0.00040949005,0.0029065704,0.012101873,0.74091506],"study_design_scores_gemma":[0.00025833203,0.00057814835,0.10336785,0.5662099,0.021488965,0.0061166994,0.0018709139,0.00097085343,0.00051073416,0.008492017,0.2900003,0.00013531662],"about_ca_topic_score_codex":0.00431332,"about_ca_topic_score_gemma":0.010837269,"teacher_disagreement_score":0.00431332,"about_ca_system_score_codex":0.0007699344,"about_ca_system_score_gemma":0.0016016664,"threshold_uncertainty_score":0.008576453},"labels":[],"label_agreement":null},{"id":"W3033326213","doi":"10.1007/s40744-020-00209-4","title":"Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Toronto Western Hospital; University of Toronto","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Psoriatic arthritis; Tolerability; Adverse effect; Discontinuation; Internal medicine; Concomitant; Incidence (geometry); Interim analysis; Surgery; Arthritis; Clinical trial; Rheumatoid arthritis","score_opus":0.024974779527172475,"score_gpt":0.3090752962793566,"score_spread":0.2841005167521841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033326213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791429,0.004691406,0.002014643,0.00040946883,0.00014268876,0.0018273954,0.0066251447,0.00020706243,0.0049392735],"genre_scores_gemma":[0.98260134,0.0008087356,0.0021497225,0.0007141316,0.00021956945,0.0021568574,0.009223698,0.000047843143,0.002078068],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9982079,0.00075827364,0.00014046006,0.00023245596,0.00037005774,0.00029086886],"domain_scores_gemma":[0.99551696,0.0010098481,0.0015950203,0.00063034805,0.0004986131,0.00074915605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008197949,0.0010216569,0.001987233,0.0005376765,0.0006492414,0.0015304426,0.00060251314,0.00092898874,0.0037171654],"category_scores_gemma":[0.0047870027,0.0004239868,0.0032901666,0.0005616829,0.00045238354,0.0012535374,0.0004907858,0.0025915906,0.00094676623],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7841225,0.00852755,0.085979015,0.00093767006,0.005262306,0.0005239191,0.00024042222,0.0018674536,0.012500194,0.00024077305,0.005802354,0.09399572],"study_design_scores_gemma":[0.23448408,0.34839365,0.36977336,0.00028086893,0.0119060865,0.0019413297,0.00023660921,0.004868205,0.011158403,0.0015416121,0.015233307,0.00018247127],"about_ca_topic_score_codex":0.00024078011,"about_ca_topic_score_gemma":0.0005271992,"teacher_disagreement_score":0.008197949,"about_ca_system_score_codex":0.0005189407,"about_ca_system_score_gemma":0.0012667321,"threshold_uncertainty_score":0.043355405},"labels":[],"label_agreement":null},{"id":"W3064100784","doi":"10.1007/s40744-020-00225-4","title":"Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Memorial University of Newfoundland","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Ixekizumab; Presenteeism; Ankylosing spondylitis; Work productivity; Medicine; Absenteeism; Productivity; Internal medicine; Clinical trial; Physical therapy; Disease; Secukinumab; Psoriatic arthritis; Psychology","score_opus":0.030837431832355388,"score_gpt":0.2825535190057654,"score_spread":0.25171608717341004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3064100784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707664,0.025120655,0.00015660135,0.0005743331,0.00014822478,0.00040059598,0.0008376736,0.000030511985,0.0019649724],"genre_scores_gemma":[0.99058187,0.0060814163,0.00029755154,0.00048207093,0.00016859201,0.00040460678,0.0009553055,0.000008015448,0.0010205418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992642,0.0003823501,0.00008575833,0.000091800335,0.00007041685,0.00010551533],"domain_scores_gemma":[0.998577,0.00042403425,0.00048537474,0.00010661368,0.0001186973,0.0002883812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002479835,0.00070124085,0.0014598687,0.000240569,0.00029334347,0.0008241291,0.00050609803,0.0008910838,0.0022207121],"category_scores_gemma":[0.0017520313,0.00025625748,0.0024265123,0.00033085726,0.00050438376,0.0006228642,0.000301388,0.0017771306,0.00034970287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80486226,0.0068157506,0.014242047,0.00392788,0.005756151,0.00013578091,0.00033294625,0.0014291223,0.007633108,0.00019153384,0.003952513,0.15072091],"study_design_scores_gemma":[0.67267936,0.26347494,0.051703822,0.0006215828,0.0036660745,0.0003801977,0.00017645462,0.0008529713,0.0019787692,0.0002603535,0.0041529373,0.000052557454],"about_ca_topic_score_codex":0.00075785647,"about_ca_topic_score_gemma":0.0017593899,"teacher_disagreement_score":0.002479835,"about_ca_system_score_codex":0.00053351023,"about_ca_system_score_gemma":0.00071701535,"threshold_uncertainty_score":0.01311481},"labels":[],"label_agreement":null},{"id":"W3091166611","doi":"10.1007/s40744-020-00236-1","title":"Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Placebo; Prednisone; Internal medicine; Adverse effect; Rash; Glucocorticoid; Randomized controlled trial; Population; Gastroenterology; Pathology","score_opus":0.04255996117976809,"score_gpt":0.32144535498710275,"score_spread":0.2788853938073347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091166611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9407412,0.045957793,0.0011455271,0.0014949982,0.001141944,0.004735258,0.0013790957,0.00026568735,0.0031385438],"genre_scores_gemma":[0.97285795,0.014562872,0.0022484823,0.0015750289,0.0007303444,0.0046224934,0.0010821392,0.000029587298,0.0022910724],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994161,0.00030971254,0.000039002214,0.00010573386,0.00006358541,0.000065852175],"domain_scores_gemma":[0.9992711,0.00022667933,0.0002402092,0.000047210768,0.00005625194,0.00015868005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017989419,0.0012316745,0.002410448,0.00033992893,0.00029231608,0.0010967086,0.00062630844,0.0014796857,0.005004188],"category_scores_gemma":[0.001360696,0.00039925685,0.0014961326,0.000364469,0.0008187246,0.00066948956,0.0002527905,0.0018662688,0.00088165986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96181005,0.0036292458,0.0006555159,0.002488657,0.0021529922,0.00006733194,0.000050607894,0.0001844859,0.004332549,0.00009852497,0.0010291942,0.023500854],"study_design_scores_gemma":[0.9686762,0.02826223,0.0014143576,0.00009783127,0.0005974468,0.00003585674,0.00001237061,0.00013845888,0.00022600626,0.000047265854,0.00048373008,0.000008248481],"about_ca_topic_score_codex":0.000423582,"about_ca_topic_score_gemma":0.00096393994,"teacher_disagreement_score":0.005004188,"about_ca_system_score_codex":0.0004991438,"about_ca_system_score_gemma":0.0008960198,"threshold_uncertainty_score":0.01674068},"labels":[],"label_agreement":null},{"id":"W3091964420","doi":"10.1007/s40744-020-00237-0","title":"Implementation and Evaluation of Audit and Feedback for Monitoring Treat-to-Target (T2T) Strategies in Rheumatoid Arthritis Using Performance Measures","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Research Canada; University of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Audit; Family medicine; Quality management; Documentation; Rheumatoid arthritis; Session (web analytics); Medical record; Physical therapy; Internal medicine","score_opus":0.06428389117864781,"score_gpt":0.35609303158028777,"score_spread":0.29180914040163997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091964420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421956,0.00031025388,0.008906934,0.000757795,0.00006783683,0.011121331,0.00037049188,0.0003811903,0.0038646553],"genre_scores_gemma":[0.9546321,0.00028680766,0.03757261,0.00019242281,0.000033183267,0.0060693063,0.00036711182,0.000034641937,0.00081175216],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9037635,0.07032086,0.005831558,0.0020626436,0.014994028,0.0030274126],"domain_scores_gemma":[0.82218236,0.08705109,0.027325079,0.010678381,0.044934202,0.007828897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11117918,0.0008091076,0.0006219966,0.0020312944,0.0018840474,0.0020540063,0.0020559554,0.0007667701,0.00096376584],"category_scores_gemma":[0.15786453,0.0005927715,0.0006979487,0.001623283,0.0009936894,0.0011856423,0.002346624,0.0010514235,0.00031153462],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041383463,0.015411006,0.1989618,0.0029279157,0.00019073588,0.00040175972,0.0555011,0.0026249245,0.0045596454,0.0004246631,0.004531427,0.7103267],"study_design_scores_gemma":[0.0028763942,0.054091163,0.84771675,0.002861869,0.0004984039,0.0005562688,0.03843002,0.01740996,0.018074352,0.0006154508,0.016541079,0.0003282728],"about_ca_topic_score_codex":0.018115927,"about_ca_topic_score_gemma":0.023986317,"teacher_disagreement_score":0.11117918,"about_ca_system_score_codex":0.0074501494,"about_ca_system_score_gemma":0.018399334,"threshold_uncertainty_score":0.5879787},"labels":[],"label_agreement":null},{"id":"W3092509408","doi":"10.1007/s40744-020-00242-3","title":"Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Enthesitis; Dactylitis; Medicine; Psoriatic arthritis; Physical therapy; Quality of life (healthcare); Internal medicine; Disease; Nursing","score_opus":0.03384471145853712,"score_gpt":0.29172543293249303,"score_spread":0.2578807214739559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092509408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976624,0.00022045728,0.000047150457,0.000098883495,0.0000025480645,0.00001837236,0.0014173582,0.0000034690406,0.0005294104],"genre_scores_gemma":[0.99886924,0.00010978772,0.00009420403,0.000060064973,0.000006571432,0.000022834693,0.0007683816,0.0000011443607,0.00006776486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758816,0.0010282091,0.00038802886,0.00020881894,0.0006236962,0.00016307159],"domain_scores_gemma":[0.9902901,0.0020108968,0.005692481,0.00035373628,0.0007621734,0.0008906576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030686506,0.00013772053,0.0003446325,0.0008114367,0.00027858128,0.0004948294,0.0002548273,0.0002868418,0.0015132063],"category_scores_gemma":[0.0073217424,0.00015012056,0.00047734444,0.0016187871,0.0002673775,0.00041362902,0.0005041367,0.00042770198,0.00022895398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043835003,0.000028460317,0.9988136,0.000014612441,0.00003255305,0.000010827153,0.00007231693,0.000023337345,0.000031735337,0.0000037235736,0.000092207374,0.00083282846],"study_design_scores_gemma":[0.000006011618,0.00005956982,0.99956876,0.000006748693,0.000010776002,0.000057310906,0.00010848848,0.000061816114,0.00001604894,0.0000034839027,0.00009896356,0.0000020021928],"about_ca_topic_score_codex":0.00612232,"about_ca_topic_score_gemma":0.008101973,"teacher_disagreement_score":0.00612232,"about_ca_system_score_codex":0.00037493394,"about_ca_system_score_gemma":0.00051349273,"threshold_uncertainty_score":0.016228795},"labels":[],"label_agreement":null},{"id":"W3101920302","doi":"10.1007/s40744-020-00243-2","title":"Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Belimumab; Medicine; Post-hoc analysis; Internal medicine; Population; Systemic lupus erythematosus; Physical therapy; Disease; B-cell activating factor; Immunology; Antibody; Environmental health","score_opus":0.09989543768074156,"score_gpt":0.37124507036748305,"score_spread":0.2713496326867415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101920302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9091658,0.06716822,0.006168227,0.0005522418,0.00016749406,0.0004233567,0.014715828,0.00010775686,0.0015311752],"genre_scores_gemma":[0.98941153,0.004400696,0.0015026248,0.0001453973,0.00008740789,0.0002660889,0.004065699,0.000023655684,0.00009695603],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9450164,0.043497194,0.0051109972,0.003310442,0.0024405038,0.0006243641],"domain_scores_gemma":[0.9265824,0.042260148,0.021124275,0.00717258,0.0022356478,0.00062493706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.054873265,0.001278422,0.0043705995,0.0026535932,0.000312387,0.002443511,0.0008081109,0.000767684,0.0012633397],"category_scores_gemma":[0.042695276,0.0007356685,0.012420211,0.003760005,0.00063406926,0.000862944,0.0016292732,0.0006443006,0.00014074733],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02196614,0.00014416712,0.5396955,0.005210852,0.41034535,0.00012825817,0.00026310305,0.0040496658,0.00088893704,0.00017722276,0.001004622,0.016126253],"study_design_scores_gemma":[0.0035280092,0.004379788,0.70911753,0.001147986,0.27343056,0.00035449213,0.0004178912,0.0021703825,0.0011495993,0.00035094633,0.0038412893,0.0001114471],"about_ca_topic_score_codex":0.0014468982,"about_ca_topic_score_gemma":0.0020921712,"teacher_disagreement_score":0.054873265,"about_ca_system_score_codex":0.00063261576,"about_ca_system_score_gemma":0.00079536374,"threshold_uncertainty_score":0.29020107},"labels":[],"label_agreement":null},{"id":"W3111593935","doi":"10.1007/s40744-020-00254-z","title":"Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Axial spondyloarthritis; Physical therapy; Placebo; Internal medicine; Randomized controlled trial; Back pain; Low back pain; Repeated measures design; Ankylosing spondylitis; Disease; Alternative medicine","score_opus":0.018398617010719136,"score_gpt":0.2573371668712168,"score_spread":0.2389385498604977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111593935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774505,0.018136878,0.00015056485,0.0005215779,0.00009708088,0.0003035148,0.0013170183,0.00003039822,0.0019925092],"genre_scores_gemma":[0.98941237,0.0055202954,0.0004908834,0.00061503437,0.00020254699,0.0005043796,0.0022133533,0.000014090271,0.0010270647],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99876654,0.0007192963,0.00013910788,0.00015514552,0.00011872628,0.00010131207],"domain_scores_gemma":[0.9980129,0.0005605922,0.0007914157,0.00016892963,0.00016448172,0.00030163195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031841055,0.0006325874,0.0017162045,0.00015121241,0.00024304996,0.00075644796,0.0005586993,0.00068682834,0.0023808584],"category_scores_gemma":[0.0023947912,0.00019722377,0.0017329545,0.0003038305,0.00051525905,0.00044409474,0.00032040518,0.0014426648,0.0002840244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8543548,0.0031083932,0.038242728,0.0041519003,0.00818037,0.00016327063,0.00023516352,0.0010770657,0.005217662,0.00030858922,0.0063890307,0.07857112],"study_design_scores_gemma":[0.70889235,0.11356009,0.15845789,0.0007847062,0.008424945,0.00059041544,0.00014768566,0.001280892,0.0019131859,0.00040893647,0.005477542,0.000061436396],"about_ca_topic_score_codex":0.0006081284,"about_ca_topic_score_gemma":0.0010623221,"teacher_disagreement_score":0.0031841055,"about_ca_system_score_codex":0.00036452856,"about_ca_system_score_gemma":0.0005839312,"threshold_uncertainty_score":0.016839385},"labels":[],"label_agreement":null},{"id":"W3119698067","doi":"10.1007/s40744-020-00272-x","title":"Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Cohort; Pharmacy; Internal medicine; Comorbidity; Rheumatoid arthritis; Rheumatology; Cohort study; Logistic regression; Odds ratio; Retrospective cohort study; Database; Emergency medicine; Family medicine","score_opus":0.005957307256912728,"score_gpt":0.22848344373231863,"score_spread":0.2225261364754059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119698067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979619,0.00013969536,0.00005462286,0.00003724689,0.0000023565485,0.00001211337,0.0016057622,0.0000032572796,0.00018300912],"genre_scores_gemma":[0.998069,0.000057447025,0.00007266557,0.000024123294,0.000008471514,0.000015415146,0.0017124568,0.0000016430314,0.000038793794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987105,0.00026510665,0.00030187616,0.00030322568,0.00025234657,0.00016687076],"domain_scores_gemma":[0.99486583,0.001049237,0.0029193596,0.00032507995,0.00033050327,0.0005099987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012716219,0.00023861905,0.0005862994,0.0014615906,0.00038800598,0.0009927257,0.00059971673,0.0006641785,0.0012519325],"category_scores_gemma":[0.0038718914,0.00038182698,0.00088821445,0.0029828672,0.00024108494,0.0007257841,0.0006792872,0.0009221731,0.00020251081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009868339,0.000030990483,0.999302,0.0000049508553,0.000051612373,0.00002469069,0.000018710009,0.000059677353,0.000044270942,0.00000907588,0.00006382924,0.00029151636],"study_design_scores_gemma":[0.000014782993,0.000064961976,0.9988287,0.0000063732873,0.00003942455,0.00013413891,0.00010021823,0.00067576964,0.00003280983,0.000011925778,0.00008626303,0.000004672309],"about_ca_topic_score_codex":0.008588466,"about_ca_topic_score_gemma":0.007510787,"teacher_disagreement_score":0.008588466,"about_ca_system_score_codex":0.00065469346,"about_ca_system_score_gemma":0.0005977662,"threshold_uncertainty_score":0.01707697},"labels":[],"label_agreement":null},{"id":"W3133061598","doi":"10.1007/s40744-021-00287-y","title":"Human Osteochondral Explants: Reliable Biomimetic Models to Investigate Disease Mechanisms and Develop Personalized Treatments for Osteoarthritis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"ReumaNederland; ZonMw; Dutch Arthritis Society; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Universiteit Leiden; Arthritis Society","keywords":"Chondrocyte; Cartilage; Downregulation and upregulation; Osteoarthritis; Catabolism; Muscle hypertrophy; Anabolism; Matrix Metalloproteinase 3; Chemistry; Cell biology; Endocrinology; Internal medicine; Medicine; Matrix metalloproteinase; Pathology; Biology; Anatomy; Biochemistry; Gene; Metabolism","score_opus":0.033478837144118465,"score_gpt":0.2733837220021514,"score_spread":0.2399048848580329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133061598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7373352,0.124749064,0.11888898,0.001721716,0.00097340153,0.0008078445,0.0049575516,0.0005534065,0.010012811],"genre_scores_gemma":[0.9115705,0.03543088,0.04182829,0.00044227322,0.00021101708,0.00086358556,0.003146968,0.0000908862,0.0064155827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993092,0.0001641431,0.0000654401,0.00009512784,0.00029695785,0.00006914621],"domain_scores_gemma":[0.9995833,0.000075749245,0.000113751375,0.00007056217,0.00009420918,0.00006237812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010122113,0.0006100958,0.0005875662,0.00051406916,0.00025760994,0.000670716,0.00039807678,0.0008559794,0.0016314711],"category_scores_gemma":[0.00031855787,0.0002611221,0.0005123072,0.0003932257,0.0005016551,0.00036520266,0.00049958646,0.0010884518,0.0008122594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011706012,0.00005029414,0.00035575958,0.00036160738,0.000014958337,0.0000953147,0.00003640894,0.00016069048,0.99453825,0.00013796684,0.00016185461,0.0039699147],"study_design_scores_gemma":[0.00009233893,0.0032060756,0.011681155,0.0003044523,0.00016893607,0.0012894364,0.00030623205,0.0021973655,0.95487595,0.0006216978,0.025204346,0.000052045576],"about_ca_topic_score_codex":0.00066103245,"about_ca_topic_score_gemma":0.0021149453,"teacher_disagreement_score":0.0016314711,"about_ca_system_score_codex":0.0002640935,"about_ca_system_score_gemma":0.00043980038,"threshold_uncertainty_score":0.0054578185},"labels":[],"label_agreement":null},{"id":"W3135181020","doi":"10.1007/s40744-021-00294-z","title":"Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Galderma; Mallinckrodt Pharmaceuticals","keywords":"Medicine; Placebo; Systemic lupus erythematosus; Internal medicine; Post-hoc analysis; Prednisone; Adverse effect; Rheumatology; Lupus erythematosus; Rash; Quality of life (healthcare); Immunology; Disease; Pathology","score_opus":0.03281445817817048,"score_gpt":0.3216902380331188,"score_spread":0.28887577985494833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135181020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98333436,0.0075281407,0.000407052,0.0005858394,0.00036364826,0.003321229,0.0022119766,0.000103679486,0.0021441092],"genre_scores_gemma":[0.9861422,0.0028213703,0.0010946043,0.0009921013,0.00042963296,0.004769613,0.0018756023,0.000019837531,0.0018549277],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990594,0.0005160247,0.00006984002,0.00015306502,0.000076060394,0.00012569956],"domain_scores_gemma":[0.9985409,0.00044205572,0.000494985,0.000068570014,0.00011260789,0.00034090754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021399183,0.0018628218,0.0029732282,0.00042805905,0.00048300507,0.0010343066,0.00084752496,0.001937875,0.007282921],"category_scores_gemma":[0.0022286738,0.0005961458,0.0018079369,0.00038658528,0.0008895756,0.0008742769,0.0003741475,0.0031978667,0.0008116238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98247176,0.004620749,0.00069093576,0.00082874106,0.0013240442,0.000029488936,0.00003155553,0.00023274592,0.0015061583,0.00003893969,0.0006278907,0.0075970334],"study_design_scores_gemma":[0.9592532,0.03666427,0.0025846893,0.00003315368,0.0007064513,0.000020523448,0.000011602374,0.00018423464,0.00021585663,0.000045707286,0.00026966078,0.000010471172],"about_ca_topic_score_codex":0.0006337578,"about_ca_topic_score_gemma":0.0012985151,"teacher_disagreement_score":0.007282921,"about_ca_system_score_codex":0.00058312673,"about_ca_system_score_gemma":0.0008752134,"threshold_uncertainty_score":0.024363756},"labels":[],"label_agreement":null},{"id":"W3157970781","doi":"10.1007/s40744-021-00305-z","title":"Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Placebo; Rheumatology; Randomized controlled trial; Psoriasis Area and Severity Index; Psoriasis; Arthritis; Immunology","score_opus":0.02216772253260031,"score_gpt":0.2913959754540664,"score_spread":0.2692282529214661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157970781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699809,0.015735524,0.0016376036,0.00085118826,0.00032837378,0.0037323795,0.004560212,0.00015664872,0.003017156],"genre_scores_gemma":[0.9833724,0.004934531,0.0016299023,0.0010792277,0.00026321225,0.0031772628,0.004073955,0.00003581846,0.0014337793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759126,0.0015209932,0.00022082642,0.00022568919,0.00027661832,0.00016458887],"domain_scores_gemma":[0.996151,0.0012311217,0.0013950391,0.00041460432,0.00033460892,0.00047360992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061799004,0.0010804666,0.0026234302,0.00032073708,0.00046801832,0.0009277991,0.00062342605,0.0012489122,0.004422382],"category_scores_gemma":[0.0040127775,0.0004980132,0.0029933015,0.0005229339,0.0005509279,0.0007313096,0.0004066584,0.0020502352,0.0006711666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9545608,0.004263717,0.0038579325,0.0014095181,0.003313137,0.00007416974,0.00006563796,0.00064979645,0.0027139557,0.00006951149,0.002395769,0.02662594],"study_design_scores_gemma":[0.89672637,0.07995038,0.01587571,0.00017180902,0.0026029337,0.00019504377,0.000027997956,0.0006338842,0.0010909343,0.00015723992,0.0025280677,0.000039642327],"about_ca_topic_score_codex":0.00047001027,"about_ca_topic_score_gemma":0.0012445688,"teacher_disagreement_score":0.0061799004,"about_ca_system_score_codex":0.00047436205,"about_ca_system_score_gemma":0.0010359032,"threshold_uncertainty_score":0.032682836},"labels":[],"label_agreement":null},{"id":"W3164210226","doi":"10.1007/s40744-021-00310-2","title":"Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Abatacept; Rheumatoid arthritis; Internal medicine; Tofacitinib; Rheumatoid factor; Physical therapy","score_opus":0.026074776716786464,"score_gpt":0.3388522481739808,"score_spread":0.3127774714571943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164210226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99932504,0.00022014613,0.00007541983,0.000010413799,0.0000042154275,0.000016998592,0.00022394287,0.0000018293151,0.00012213383],"genre_scores_gemma":[0.9991511,0.000052407486,0.00010184202,0.00001934179,0.000013509766,0.00002360461,0.00056260615,0.0000014904009,0.000074071155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974376,0.001240244,0.00028204382,0.00051710877,0.00030286517,0.00022008394],"domain_scores_gemma":[0.9945452,0.0016939689,0.0024896727,0.00042916657,0.00025555003,0.00058658107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023611598,0.00039422576,0.00090689445,0.0006820139,0.00030532767,0.0010166919,0.0005681152,0.0007607678,0.0011768445],"category_scores_gemma":[0.00402601,0.00028893573,0.0011122794,0.00082200445,0.0004976924,0.000862692,0.00058204227,0.0007445634,0.00026506017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007034895,0.00033445796,0.9891465,0.000049683495,0.0006117854,0.00010568663,0.0000839926,0.0002514685,0.0006148187,0.00001835828,0.00008542349,0.0016630361],"study_design_scores_gemma":[0.00018345538,0.0025120114,0.99525684,0.0000072066314,0.00015785641,0.0004555913,0.0001420352,0.00086143,0.00013070555,0.000025627647,0.00024922108,0.00001800338],"about_ca_topic_score_codex":0.0006215708,"about_ca_topic_score_gemma":0.00067809486,"teacher_disagreement_score":0.0023611598,"about_ca_system_score_codex":0.00038509633,"about_ca_system_score_gemma":0.00022144658,"threshold_uncertainty_score":0.012487173},"labels":[],"label_agreement":null},{"id":"W3165653864","doi":"10.1007/s40744-021-00317-9","title":"Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Post-hoc analysis; Population; Physical therapy; Gastroenterology","score_opus":0.01965324299131082,"score_gpt":0.31472868373473734,"score_spread":0.2950754407434265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165653864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883366,0.0058116517,0.0011522421,0.00022311154,0.00024749292,0.0018905287,0.0015839759,0.00008646638,0.00066783075],"genre_scores_gemma":[0.9936207,0.00086958986,0.0010922558,0.0002266147,0.00018272584,0.0019580296,0.00133039,0.000026036383,0.00069367845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911355,0.0058853123,0.00070184696,0.0011301835,0.00066690234,0.00048030092],"domain_scores_gemma":[0.9869148,0.0061247433,0.003359879,0.0016704609,0.00096103497,0.0009690534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018128209,0.0018884265,0.0049526365,0.0005619555,0.00052689575,0.0019212398,0.0011471556,0.001292599,0.0027389666],"category_scores_gemma":[0.009492732,0.00079224043,0.008138489,0.00066143356,0.0010681028,0.0012813971,0.00080450287,0.002027314,0.0004142774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96222454,0.0016415111,0.0049447604,0.00071954855,0.021726271,0.000031454718,0.000048509995,0.0004972452,0.0020583193,0.000027362705,0.00028817976,0.0057923673],"study_design_scores_gemma":[0.66014713,0.20206647,0.08004728,0.00014209098,0.049779024,0.00013394411,0.00009129623,0.0026298242,0.0029179265,0.0002157297,0.001703914,0.00012528776],"about_ca_topic_score_codex":0.0005326566,"about_ca_topic_score_gemma":0.0012905699,"teacher_disagreement_score":0.018128209,"about_ca_system_score_codex":0.00095726835,"about_ca_system_score_gemma":0.0016667403,"threshold_uncertainty_score":0.09587222},"labels":[],"label_agreement":null},{"id":"W3178990742","doi":"10.1007/s40744-021-00340-w","title":"Self-Reported Weather Sensitivity is Associated with Clinical Symptoms and Structural Abnormalities in Patients with Knee Osteoarthritis: A Cross-Sectional Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Jiangxi University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; National Natural Science Foundation of China","keywords":"Osteoarthritis; Medicine; WOMAC; Cross-sectional study; Magnetic resonance imaging; Body mass index; Knee pain; Internal medicine; Cohort; Cohort study; Physical therapy; Pathology; Radiology","score_opus":0.0233569987962932,"score_gpt":0.3027387448625437,"score_spread":0.2793817460662505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178990742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998882,0.00041716758,0.00012219779,0.000025268359,0.000008917789,0.000013972837,0.00029486776,0.0000021196904,0.00023334238],"genre_scores_gemma":[0.99939716,0.00010494517,0.00009760411,0.000035305056,0.0000133512285,0.0000153025,0.00026877056,9.4300566e-7,0.00006665576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992681,0.00024203015,0.0001205584,0.00016311239,0.00013072445,0.00007556694],"domain_scores_gemma":[0.9980623,0.00035301203,0.00088048563,0.00015701572,0.00027524942,0.00027204395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013223516,0.00031576937,0.00046515363,0.00076913787,0.0004133738,0.0005570307,0.00025504045,0.00051604497,0.0012648122],"category_scores_gemma":[0.0022551557,0.00038682672,0.00064528047,0.00088067335,0.00025271456,0.0005551393,0.00047134171,0.00046904403,0.000277536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052317897,0.000035158722,0.99933124,0.00001072394,0.000081401624,0.000019135146,0.00004559564,0.000008938245,0.0000975384,0.0000033453339,0.00002133463,0.0002933365],"study_design_scores_gemma":[0.0000050135905,0.00012842866,0.99947506,0.000004322677,0.00003912869,0.00010718393,0.00010358282,0.000053446834,0.000018160124,0.0000068046256,0.00005640757,0.0000025449638],"about_ca_topic_score_codex":0.0017247701,"about_ca_topic_score_gemma":0.0021175062,"teacher_disagreement_score":0.0017247701,"about_ca_system_score_codex":0.00012905142,"about_ca_system_score_gemma":0.00018986056,"threshold_uncertainty_score":0.006993413},"labels":[],"label_agreement":null},{"id":"W3180838433","doi":"10.1007/s40744-021-00337-5","title":"Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Placebo; Internal medicine; Psoriasis; Tumor necrosis factor alpha; TNF inhibitor; Certolizumab pegol; Arthritis; Oncology; Immunology; Etanercept; Pathology; Alternative medicine","score_opus":0.03344847966845219,"score_gpt":0.31787157241101904,"score_spread":0.28442309274256683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180838433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6312369,0.3546142,0.0051745125,0.00030406815,0.00042283454,0.0007552466,0.005420273,0.00024102727,0.0018308703],"genre_scores_gemma":[0.9808945,0.014709943,0.0012193989,0.00026929856,0.000146951,0.00042714152,0.0020317452,0.00004018854,0.00026071907],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9816675,0.012155458,0.0028583477,0.0015570631,0.0013540544,0.00040755738],"domain_scores_gemma":[0.98339707,0.009894099,0.0038252852,0.0015481514,0.0010302034,0.0003050944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025007319,0.0019944422,0.010208885,0.0025543482,0.00032372616,0.002385115,0.00077484146,0.001485515,0.0015762773],"category_scores_gemma":[0.018562516,0.0010651082,0.029319273,0.0028159195,0.00051399885,0.0011267891,0.0014257175,0.0010419958,0.0002082914],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08797059,0.00013682494,0.04387317,0.010193481,0.8275799,0.00015117534,0.00015108324,0.0018906237,0.00209774,0.00007047767,0.0006445047,0.02524047],"study_design_scores_gemma":[0.014399426,0.007532588,0.13396549,0.0009515361,0.8378776,0.00029116086,0.00011779006,0.0015650871,0.00090312905,0.00030617928,0.0019851055,0.00010494074],"about_ca_topic_score_codex":0.0009174629,"about_ca_topic_score_gemma":0.0022701307,"teacher_disagreement_score":0.025007319,"about_ca_system_score_codex":0.000534593,"about_ca_system_score_gemma":0.00077062246,"threshold_uncertainty_score":0.13225293},"labels":[],"label_agreement":null},{"id":"W3182483969","doi":"10.1007/s40744-021-00339-3","title":"Nurse-Led Care for Stable Patients with Rheumatoid Arthritis: Quality of Care in Routine Practice Compared to the Traditional Rheumatologist-Led Model","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Calgary","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"Medicine; Rheumatoid arthritis; Clinical Practice; Family medicine; Internal medicine; Nursing; Intensive care medicine","score_opus":0.02428735887086365,"score_gpt":0.30719682648317587,"score_spread":0.2829094676123122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182483969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946361,0.00071413204,0.0010464692,0.00054461416,0.000058288122,0.0012120828,0.00010180347,0.000015858875,0.0016706453],"genre_scores_gemma":[0.99688005,0.0001863465,0.001816281,0.00020978211,0.000045145553,0.00068550924,0.0000680646,0.0000029770729,0.000105742416],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9763689,0.017748484,0.001031693,0.0012790766,0.0028525158,0.00071926723],"domain_scores_gemma":[0.98205644,0.008823285,0.0038660346,0.0011134285,0.0013604083,0.0027805443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016887903,0.000285008,0.0009073789,0.0004740285,0.00053249416,0.0014472172,0.00085528183,0.00089803175,0.002759733],"category_scores_gemma":[0.022874095,0.00023187602,0.0010833812,0.0006400101,0.0009345035,0.0011245619,0.0015733908,0.0008162456,0.00016811922],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15029238,0.045344744,0.2880741,0.0042213784,0.0033837985,0.00020375702,0.0033637038,0.010637837,0.0018155834,0.0022273152,0.002468101,0.48796737],"study_design_scores_gemma":[0.13239631,0.39517957,0.4175679,0.0017653691,0.002123617,0.00035184927,0.0022434925,0.03745298,0.0016006881,0.0028153835,0.0062850765,0.00021771652],"about_ca_topic_score_codex":0.0042349384,"about_ca_topic_score_gemma":0.0055284807,"teacher_disagreement_score":0.016887903,"about_ca_system_score_codex":0.004413961,"about_ca_system_score_gemma":0.0048243776,"threshold_uncertainty_score":0.08931285},"labels":[],"label_agreement":null},{"id":"W3183606991","doi":"10.1007/s40744-021-00331-x","title":"Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto; Alberta Health Services; Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Alberta Innovates; Arthritis Society; Children's Hospital Foundation; Alberta Children's Hospital Foundation; ZonMw; Canadian Institutes of Health Research; Genome Canada","keywords":"Medicine; Cohort; Health care; Emergency medicine; Emergency department; Retrospective cohort study; Pediatrics; Physical therapy; Internal medicine","score_opus":0.025759305721385566,"score_gpt":0.31591480354515916,"score_spread":0.2901554978237736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183606991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854622,0.0007580295,0.00017454033,0.00019792352,0.000009521118,0.00011143035,0.012218731,0.000010792328,0.0010567696],"genre_scores_gemma":[0.9925932,0.00062569557,0.00040215589,0.00009870106,0.000009596437,0.00007085514,0.005949351,0.0000072572957,0.00024312352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794656,0.0001841037,0.00022592768,0.00038197375,0.0007503401,0.0005111349],"domain_scores_gemma":[0.99473923,0.00031412765,0.0019149061,0.00031284874,0.0020434782,0.000675423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018355105,0.00064150203,0.00068434153,0.0029686748,0.0022636005,0.0015282037,0.0016889065,0.00061139127,0.0015795061],"category_scores_gemma":[0.004187375,0.00056566775,0.0015015962,0.007935569,0.00066940725,0.0006092312,0.0010898302,0.0010039451,0.00021541638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028596583,0.000011966493,0.9986589,0.000021947875,0.000068113266,0.000047203583,0.00010331786,0.00006582664,0.000022022432,0.000042699823,0.00034410902,0.0005853227],"study_design_scores_gemma":[0.000008425775,0.00001892667,0.99865294,0.000027965136,0.000041793654,0.000113194015,0.00030595603,0.00031952377,0.00001890358,0.00001062173,0.00047151805,0.000010129093],"about_ca_topic_score_codex":0.9693424,"about_ca_topic_score_gemma":0.97009987,"teacher_disagreement_score":0.03065759,"about_ca_system_score_codex":0.02218047,"about_ca_system_score_gemma":0.021460775,"threshold_uncertainty_score":0.16093129},"labels":[],"label_agreement":null},{"id":"W3184531276","doi":"10.1007/s40744-021-00346-4","title":"Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eli Lilly and Company","keywords":"Medicine; Renal function; Rheumatoid arthritis; Kidney disease; Internal medicine; Population; Retrospective cohort study; Cohort; Creatinine; Surgery; Environmental health","score_opus":0.010194751418540569,"score_gpt":0.2729724678159526,"score_spread":0.262777716397412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184531276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99826616,0.0003506326,0.000106210755,0.000039394905,0.00000308676,0.000011762778,0.0009334245,0.0000043474993,0.00028495234],"genre_scores_gemma":[0.9992144,0.000110434084,0.000055555804,0.000028172655,0.0000068768018,0.000008853707,0.0005457294,8.6679626e-7,0.000029038385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900657,0.00021378946,0.00016983658,0.0002538648,0.00025389116,0.00010212839],"domain_scores_gemma":[0.9977696,0.00024077784,0.0013457946,0.00019803879,0.0002673441,0.00017842701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010853177,0.00021115085,0.00026913715,0.0011344105,0.00031466948,0.00064417964,0.0004269168,0.0003266188,0.000759185],"category_scores_gemma":[0.0019759987,0.00028226865,0.00048609386,0.0017656107,0.0003539884,0.00045184075,0.00054327596,0.0003739104,0.00015336207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013619529,0.000005725083,0.99959236,0.0000044716144,0.00003213939,0.000015481786,0.000019504369,0.000010920111,0.000024850064,0.00000365952,0.00004323665,0.00023393985],"study_design_scores_gemma":[0.0000029164878,0.00001920529,0.9995034,0.000005353637,0.000024939132,0.00013601282,0.00008053637,0.000112881775,0.000028470275,0.0000058730616,0.00007841353,0.0000019879333],"about_ca_topic_score_codex":0.013457573,"about_ca_topic_score_gemma":0.011702999,"teacher_disagreement_score":0.013457573,"about_ca_system_score_codex":0.00041502193,"about_ca_system_score_gemma":0.00040356175,"threshold_uncertainty_score":0.026758492},"labels":[],"label_agreement":null},{"id":"W3193683700","doi":"10.1007/s40744-021-00355-3","title":"Patient-Reported Outcome Measures in Takayasu Arteritis: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Physical therapy; Anxiety; Strictly standardized mean difference; Cochrane Library; Mood; MEDLINE; Randomized controlled trial; Observational study; Quality of life (healthcare); Psychiatry","score_opus":0.10513623567748936,"score_gpt":0.3555354420390121,"score_spread":0.25039920636152274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193683700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028814059,0.9956654,0.00037067966,0.0001400478,0.00009953841,0.0003953043,0.00032538807,0.000012705254,0.00010966992],"genre_scores_gemma":[0.09566091,0.8968417,0.00300142,0.0006678115,0.0002464162,0.0027014634,0.0006713821,0.00001900562,0.0001899175],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9832063,0.008212982,0.0049226857,0.0012208578,0.0020368085,0.0004003527],"domain_scores_gemma":[0.97339433,0.0191006,0.0046102856,0.0006171058,0.0020184617,0.00025921158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020675937,0.0030288673,0.022353731,0.010478763,0.0007571736,0.0034112742,0.002232574,0.0023620427,0.0027493695],"category_scores_gemma":[0.03949346,0.0017294572,0.03474541,0.009469548,0.0007828525,0.0021486497,0.001908899,0.0016416393,0.0002123965],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008595354,0.000030150928,0.0022300638,0.68979853,0.2930827,0.000126563,0.00010100264,0.00041618737,0.00015158013,0.00012970158,0.00042131075,0.012652684],"study_design_scores_gemma":[0.00074202014,0.00036736444,0.0039095604,0.09439435,0.89739436,0.0001777659,0.00008713152,0.00023325342,0.00013169635,0.00021898407,0.0023068208,0.00003669541],"about_ca_topic_score_codex":0.00546232,"about_ca_topic_score_gemma":0.013332969,"teacher_disagreement_score":0.022353731,"about_ca_system_score_codex":0.0033592612,"about_ca_system_score_gemma":0.005661634,"threshold_uncertainty_score":0.10934615},"labels":[],"label_agreement":null},{"id":"W3197844272","doi":"10.1007/s40744-021-00367-z","title":"Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Institute for Health and Care Research; Incyte; Horizon Pharma; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Medicine; Psoriatic arthritis; Family medicine; Physical therapy; Internal medicine; Rheumatoid arthritis","score_opus":0.08832795041247882,"score_gpt":0.32570483340535006,"score_spread":0.23737688299287124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197844272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850595,0.00016540932,0.00007561704,0.00021979061,0.00000626459,0.000022935536,0.0002931384,0.0000043779037,0.0007064066],"genre_scores_gemma":[0.9990095,0.00015264745,0.00019244896,0.00018102457,0.00001667593,0.000033599994,0.00028041645,0.0000024421367,0.00013124254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995751,0.0023121452,0.0006728742,0.00024973202,0.0006721135,0.0003420937],"domain_scores_gemma":[0.9792132,0.009501735,0.0072938674,0.00045620068,0.001863494,0.0016715712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004941365,0.00020873437,0.00042091613,0.0009138184,0.00037822878,0.000864373,0.0002898979,0.00068027194,0.0014343904],"category_scores_gemma":[0.016666055,0.00022992416,0.00055945036,0.0009830006,0.0003540753,0.0009469778,0.0010282255,0.00074370427,0.00024560682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001474899,0.00015764269,0.98746675,0.000087409295,0.00010723879,0.000078761186,0.0026623523,0.00008065111,0.00020728914,0.000019837824,0.0004639929,0.008520552],"study_design_scores_gemma":[0.000022923057,0.00035143795,0.9953394,0.000027320584,0.00003520815,0.00020409637,0.003024501,0.00026274638,0.000073747,0.000019905,0.0006240604,0.000014695542],"about_ca_topic_score_codex":0.0019260882,"about_ca_topic_score_gemma":0.0022598838,"teacher_disagreement_score":0.004941365,"about_ca_system_score_codex":0.0004579585,"about_ca_system_score_gemma":0.00042503697,"threshold_uncertainty_score":0.026132703},"labels":[],"label_agreement":null},{"id":"W3203140217","doi":"10.1007/s40744-021-00372-2","title":"Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Department of Health and Social Care; National Institute for Health and Care Research; Leeds Biomedical Research Centre; Pfizer; Eli Lilly and Company","keywords":"Osteoarthritis; Composite number; Medicine; Internal medicine; Materials science; Pathology; Composite material; Alternative medicine","score_opus":0.008219133328378626,"score_gpt":0.2202051131008637,"score_spread":0.21198597977248507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203140217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6954979,0.27083454,0.010217151,0.0007698851,0.00057841936,0.0019998048,0.01572488,0.00029139908,0.0040860553],"genre_scores_gemma":[0.9801906,0.011263894,0.002203071,0.00034224734,0.00036785495,0.001034556,0.004268914,0.000039611503,0.00028929382],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9819233,0.011571703,0.0028128894,0.0015700748,0.0017983074,0.0003237037],"domain_scores_gemma":[0.98395556,0.0075423955,0.0048173307,0.0019181488,0.0014894644,0.00027712464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03058571,0.0017181606,0.0065149055,0.0028233484,0.0002832032,0.0020090367,0.0006473871,0.00092634506,0.0016349801],"category_scores_gemma":[0.028506441,0.00070073316,0.011928542,0.0022441724,0.0004227605,0.0012537446,0.001074966,0.0007390671,0.00024468708],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11479597,0.00038439248,0.1604864,0.020653803,0.6038552,0.00018377074,0.00035972297,0.0028869633,0.004632351,0.00023252252,0.0026840768,0.08884488],"study_design_scores_gemma":[0.022990672,0.016791895,0.39503667,0.0023866708,0.54746187,0.0008595399,0.0002962055,0.0026601783,0.002611935,0.0011866356,0.0074659926,0.000251694],"about_ca_topic_score_codex":0.0008015961,"about_ca_topic_score_gemma":0.0016510157,"teacher_disagreement_score":0.03058571,"about_ca_system_score_codex":0.00047688803,"about_ca_system_score_gemma":0.0010678275,"threshold_uncertainty_score":0.16175461},"labels":[],"label_agreement":null},{"id":"W3205906452","doi":"10.1007/s40744-021-00386-w","title":"Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19","year":2021,"lang":"en","type":"letter","venue":"Rheumatology and Therapy","topic":"Vagus Nerve Stimulation Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rheumatoid arthritis; Tumor necrosis factor alpha; Tumor necrosis factor α; Medicine; Internal medicine; Oncology","score_opus":0.053915058923763234,"score_gpt":0.3057772729268409,"score_spread":0.2518622140030777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205906452","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025841274,0.0019477798,0.000074863856,0.9735711,0.023215763,0.00000866784,0.000059049216,0.000022134609,0.00084223767],"genre_scores_gemma":[0.0029681437,0.0012267986,0.000199932,0.92978626,0.06449966,0.00002750645,0.000032014297,0.000014620146,0.0012450478],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99448097,0.0020115625,0.0009984879,0.0007232549,0.0013729758,0.00041282023],"domain_scores_gemma":[0.97946906,0.013388391,0.0009362657,0.00047984594,0.004098223,0.0016281632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006762259,0.001129706,0.0025813412,0.0009340695,0.0033320896,0.0025578435,0.0033589546,0.050685767,0.003277734],"category_scores_gemma":[0.035438705,0.0008130353,0.0017629317,0.0011593937,0.003103886,0.0038794023,0.0011685331,0.043969836,0.005917273],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016731332,0.000038068316,0.00086879934,0.00008195121,0.000029336146,0.0012633238,0.000081453705,0.000070173504,0.00015545156,0.0011882863,0.98699355,0.009062318],"study_design_scores_gemma":[0.0008907073,0.00035788346,0.004758846,0.0012466677,0.00022214158,0.006791953,0.00075595727,0.0017851136,0.0008701666,0.019312125,0.9627428,0.00026573456],"about_ca_topic_score_codex":0.010291614,"about_ca_topic_score_gemma":0.015838642,"teacher_disagreement_score":0.050685767,"about_ca_system_score_codex":0.0049006226,"about_ca_system_score_gemma":0.004482731,"threshold_uncertainty_score":0.035762727},"labels":[],"label_agreement":null},{"id":"W3207340776","doi":"10.1007/s40744-021-00379-9","title":"Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital","funders":"AbbVie","keywords":"Medicine; Adalimumab; Placebo; Minimal clinically important difference; Psoriatic arthritis; Internal medicine; Psoriasis Area and Severity Index; Ankylosing spondylitis; Physical therapy; Randomized controlled trial; Rheumatoid arthritis; Psoriasis; Immunology","score_opus":0.011917436474358637,"score_gpt":0.2431157939151935,"score_spread":0.23119835744083486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207340776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882075,0.009707253,0.00015633764,0.00013840804,0.000059369417,0.00027760456,0.0006295416,0.000024200253,0.0007997772],"genre_scores_gemma":[0.99616325,0.0021771186,0.00029362133,0.00016913771,0.0001074039,0.0002254704,0.0006059025,0.000003245303,0.00025487063],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99921846,0.00042798233,0.00006901951,0.00009108256,0.00013197606,0.000061453415],"domain_scores_gemma":[0.99885356,0.00033694942,0.00047246096,0.000054397115,0.00010863047,0.00017405034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017383546,0.00058893143,0.001559783,0.00029471453,0.00021996534,0.0005820226,0.00028329153,0.0004955839,0.0023432216],"category_scores_gemma":[0.0013729165,0.00019381191,0.0016480263,0.00037000456,0.00030439004,0.00028979537,0.00023674539,0.0008086548,0.0002488068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8367862,0.0074271713,0.026216708,0.0024771423,0.0054785786,0.000086102315,0.00013622735,0.00072533294,0.006009804,0.00006113399,0.0013113881,0.11328414],"study_design_scores_gemma":[0.30868968,0.43795595,0.22956999,0.0004823001,0.011980858,0.0005715354,0.00019056529,0.0017613916,0.00543734,0.00018836938,0.0030932168,0.000078975325],"about_ca_topic_score_codex":0.0004459745,"about_ca_topic_score_gemma":0.001048706,"teacher_disagreement_score":0.0023432216,"about_ca_system_score_codex":0.00032238394,"about_ca_system_score_gemma":0.00050745416,"threshold_uncertainty_score":0.00919342},"labels":[],"label_agreement":null},{"id":"W3208988466","doi":"10.1007/s40744-021-00388-8","title":"Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Adalimumab; Psoriatic arthritis; Psoriasis; Post-hoc analysis; Dermatology; Drug; Arthritis; Pharmacology; Internal medicine; Disease; Secukinumab","score_opus":0.02560367786290212,"score_gpt":0.26404507703939595,"score_spread":0.23844139917649382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208988466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971656,0.00040024077,0.00028410717,0.000115555675,0.00010777991,0.0006903393,0.00071187684,0.000050971434,0.00047344534],"genre_scores_gemma":[0.9944389,0.00031763638,0.001046578,0.00024314134,0.00031048586,0.0009166831,0.0014694335,0.000037575115,0.0012195837],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99718815,0.0016507276,0.00019204186,0.0004077974,0.00020185884,0.0003593999],"domain_scores_gemma":[0.9963225,0.0011049059,0.0008664784,0.0006740725,0.0003015461,0.0007305677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064661787,0.001854954,0.004038467,0.00046733225,0.00037528863,0.0010929899,0.0010705027,0.0010414901,0.00479745],"category_scores_gemma":[0.0037718548,0.00076325046,0.0040111635,0.00036931492,0.0012098622,0.0011005842,0.0007359315,0.002789369,0.0007496168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9698693,0.013902104,0.0010994433,0.00018097056,0.0012860532,0.000019412093,0.00005699979,0.00042153226,0.005851224,0.000023028482,0.00044501497,0.006845042],"study_design_scores_gemma":[0.5396196,0.4400101,0.013534681,0.000018452416,0.0017396454,0.000042947777,0.00004689485,0.001000779,0.003352423,0.000088029876,0.0005097308,0.000036831258],"about_ca_topic_score_codex":0.0008415415,"about_ca_topic_score_gemma":0.001723353,"teacher_disagreement_score":0.0064661787,"about_ca_system_score_codex":0.0007905546,"about_ca_system_score_gemma":0.0015170779,"threshold_uncertainty_score":0.034196854},"labels":[],"label_agreement":null},{"id":"W4200209300","doi":"10.1007/s40744-021-00351-7","title":"Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Placebo; Biomarker; Internal medicine; Immunology; Gastroenterology; Post-hoc analysis; Pathology","score_opus":0.05249104156641909,"score_gpt":0.36216949100233553,"score_spread":0.30967844943591644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200209300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98760766,0.0026809073,0.0012086055,0.0002744474,0.0004183279,0.005216388,0.00139702,0.00012957117,0.0010670729],"genre_scores_gemma":[0.9795027,0.001158055,0.004019299,0.00071337254,0.00058131426,0.009393061,0.0020164803,0.00006848118,0.0025473312],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967415,0.0018277687,0.00027600446,0.00055254507,0.0002085663,0.00039363577],"domain_scores_gemma":[0.99616987,0.0015424374,0.0009445362,0.00040846455,0.00039244397,0.00054218224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062501705,0.002890951,0.0049357223,0.00063773955,0.0006527895,0.0012373173,0.0009347969,0.001888245,0.005649104],"category_scores_gemma":[0.004713219,0.000926327,0.003045306,0.0004975885,0.0012385761,0.0010976691,0.00047363326,0.0024681743,0.00070599775],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9823698,0.004606597,0.000550273,0.00032235673,0.0012246828,0.000028499622,0.000029360586,0.0001857004,0.0061820704,0.000030427167,0.00026853403,0.0042016227],"study_design_scores_gemma":[0.800573,0.1889781,0.004575305,0.000019040748,0.0022199063,0.000028398215,0.000017762966,0.00044797218,0.0023998376,0.000107322056,0.0006070009,0.000026332802],"about_ca_topic_score_codex":0.0003552162,"about_ca_topic_score_gemma":0.00088060455,"teacher_disagreement_score":0.0062501705,"about_ca_system_score_codex":0.00062884873,"about_ca_system_score_gemma":0.0015655964,"threshold_uncertainty_score":0.03305447},"labels":[],"label_agreement":null},{"id":"W4200357740","doi":"10.1007/s40744-021-00405-w","title":"Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Pfizer (Canada)","funders":"Celgene; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Tofacitinib; Discontinuation; Janus kinase inhibitor; Nausea; Adverse effect; Internal medicine; Placebo; Rheumatoid arthritis; Vomiting; Incidence (geometry); Gastroenterology","score_opus":0.005117525276364914,"score_gpt":0.21830132155952292,"score_spread":0.213183796283158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200357740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880469,0.00943888,0.0004283468,0.00005397943,0.000027571075,0.00017290293,0.000982732,0.000009352297,0.0008393184],"genre_scores_gemma":[0.99757475,0.0009141822,0.00030319262,0.000060837032,0.00004853035,0.00012425121,0.0007427406,0.000003040181,0.00022855318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957682,0.0018862158,0.0008965165,0.000458639,0.00070829515,0.0002822027],"domain_scores_gemma":[0.9891344,0.0060298145,0.0035583149,0.0003414051,0.00051191257,0.00042428423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063115084,0.00038552756,0.0020067922,0.0010603706,0.00029784968,0.0006280222,0.00025296552,0.00043778424,0.0013510643],"category_scores_gemma":[0.006494251,0.0002656081,0.004650848,0.0011915631,0.00017908345,0.00053235056,0.00033206725,0.0008155929,0.000084989406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06885682,0.0004494973,0.86734116,0.0014017184,0.01278172,0.0004033889,0.00021582485,0.0010282709,0.0028800918,0.00006809798,0.00040553565,0.044167966],"study_design_scores_gemma":[0.0017324748,0.008191963,0.98455423,0.00006618814,0.0029840802,0.00063471607,0.000060649847,0.00056558626,0.00037075797,0.00008535732,0.0007270146,0.000026960834],"about_ca_topic_score_codex":0.0005966452,"about_ca_topic_score_gemma":0.0013842474,"teacher_disagreement_score":0.0063115084,"about_ca_system_score_codex":0.0003637348,"about_ca_system_score_gemma":0.00043490692,"threshold_uncertainty_score":0.03337884},"labels":[],"label_agreement":null},{"id":"W4206718482","doi":"10.1007/s40744-021-00415-8","title":"Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"UCB Pharma; Sanofi Genzyme; Incyte; Regeneron Pharmaceuticals; Gilead Sciences; Sanofi; Amgen; Pfizer; Canadian Rheumatology Association; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Post-hoc analysis; Rheumatoid arthritis; Post hoc; Medicine; Physical therapy; Internal medicine; Phase (matter); Clinical trial","score_opus":0.028062979523669526,"score_gpt":0.3322063269093806,"score_spread":0.3041433473857111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206718482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812758,0.008866211,0.0015118351,0.0003421301,0.00024745776,0.0030019747,0.0031632783,0.00011906954,0.0014723248],"genre_scores_gemma":[0.98929346,0.0011315104,0.0014658174,0.0003968227,0.00018854065,0.0038980136,0.0027746896,0.00004208167,0.0008090679],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98779416,0.008588407,0.0010535563,0.0010276791,0.0008454809,0.000690654],"domain_scores_gemma":[0.9799296,0.010717829,0.005103062,0.0019055489,0.0012724799,0.0010715381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025782408,0.0019759387,0.0045623244,0.00072315196,0.00059761066,0.0016342283,0.0011737333,0.0013299228,0.0038068187],"category_scores_gemma":[0.016541716,0.0005743719,0.010408186,0.0009804164,0.00092367287,0.0013707842,0.00086683256,0.0023435939,0.0004950357],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94991916,0.0021558884,0.0081845345,0.0010065638,0.02426969,0.000067349705,0.00009732946,0.0010901074,0.0022300298,0.000040999686,0.000788739,0.010149679],"study_design_scores_gemma":[0.5273995,0.29723275,0.117186375,0.00020824267,0.04765853,0.00028489766,0.0001449652,0.0032301475,0.003126993,0.00039835734,0.0029606314,0.00016859935],"about_ca_topic_score_codex":0.0006349059,"about_ca_topic_score_gemma":0.001546717,"teacher_disagreement_score":0.025782408,"about_ca_system_score_codex":0.0008510428,"about_ca_system_score_gemma":0.001812255,"threshold_uncertainty_score":0.136352},"labels":[],"label_agreement":null},{"id":"W4212822641","doi":"10.1007/s40744-022-00429-w","title":"Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Post-hoc analysis; Internal medicine; Rheumatoid arthritis; Erythrocyte sedimentation rate; Placebo; Post hoc; Demographics; Clinical trial; Osteoarthritis; Gastroenterology; Pathology","score_opus":0.015913924057114205,"score_gpt":0.306031817797459,"score_spread":0.2901178937403448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212822641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99880505,0.0002120362,0.00036901495,0.000052082072,0.000030003232,0.00010451365,0.00019144863,0.000020694324,0.0002151975],"genre_scores_gemma":[0.9983193,0.000046866775,0.00056230027,0.000033652632,0.000042295043,0.00016114229,0.0003709177,0.0000069189246,0.00045646963],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99810874,0.001261165,0.00008617241,0.00020497541,0.00016918157,0.00016979579],"domain_scores_gemma":[0.99345934,0.004618202,0.0008515138,0.0003460305,0.00028134926,0.00044350378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032181528,0.000507223,0.0009822475,0.00028636333,0.00012902558,0.00043244817,0.00036862178,0.00038100124,0.0024466258],"category_scores_gemma":[0.004926464,0.00015609722,0.00088586565,0.00021978859,0.0002875737,0.00033207136,0.00023028837,0.0008155692,0.00027437226],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57873374,0.0062502753,0.3324164,0.0004345949,0.0028838345,0.0003004814,0.00026481805,0.0015991972,0.010890249,0.00013430255,0.001865106,0.06422701],"study_design_scores_gemma":[0.023414358,0.2605235,0.69086236,0.000039421622,0.0025469146,0.0003425655,0.00022132313,0.011902029,0.00802983,0.00021458598,0.0018614922,0.000041631338],"about_ca_topic_score_codex":0.0003640087,"about_ca_topic_score_gemma":0.00048002994,"teacher_disagreement_score":0.0032181528,"about_ca_system_score_codex":0.00028235718,"about_ca_system_score_gemma":0.0005892116,"threshold_uncertainty_score":0.01701945},"labels":[],"label_agreement":null},{"id":"W4220972031","doi":"10.1007/s40744-022-00433-0","title":"Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Hospital for Sick Children; University of Toronto","funders":"Swedish Orphan Biovitrum; OPKO Health; F. Hoffmann-La Roche","keywords":"Granulomatosis with polyangiitis; Rituximab; Microscopic polyangiitis; Medicine; Immunology; Antibody; Vasculitis; Dermatology; Pathology; Disease","score_opus":0.011317587977648548,"score_gpt":0.2596496005984515,"score_spread":0.24833201262080296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220972031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999074,0.00047333696,0.00007308481,0.000019417346,0.0000022670097,0.000009061097,0.00002930288,0.0000028692803,0.0003166136],"genre_scores_gemma":[0.9995857,0.00016646965,0.0001374227,0.00001581295,0.000005418606,0.0000049882606,0.00004525816,6.473188e-7,0.000038319577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961096,0.00012595765,0.000046739602,0.0000507416,0.00008790947,0.00007770883],"domain_scores_gemma":[0.99880266,0.00019837073,0.00065018644,0.000025620318,0.00008453379,0.00023858763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054165657,0.0002667748,0.0003526643,0.000339822,0.0002718595,0.00043233216,0.00018389133,0.00024743355,0.0007720429],"category_scores_gemma":[0.0014104673,0.00015383147,0.00028210023,0.00026495304,0.00024709667,0.00034614536,0.00025869464,0.0003888393,0.000103345155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015018503,0.000021822025,0.99592847,0.000013708616,0.000013445699,0.00089235493,0.00006145961,0.000032137752,0.0003554268,0.000006580923,0.00003645969,0.0024878923],"study_design_scores_gemma":[0.000010754204,0.0014626561,0.9887799,0.000023212404,0.0000478237,0.008367027,0.00027538047,0.00024572486,0.00046859702,0.000012857367,0.0003019094,0.0000042451816],"about_ca_topic_score_codex":0.00074408564,"about_ca_topic_score_gemma":0.001227014,"teacher_disagreement_score":0.0007720429,"about_ca_system_score_codex":0.00031361915,"about_ca_system_score_gemma":0.0003427936,"threshold_uncertainty_score":0.0028645992},"labels":[],"label_agreement":null},{"id":"W4220985222","doi":"10.1007/s40744-022-00435-y","title":"Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Psoriatic arthritis; Disease; Health care; Family medicine; Demography; Patient satisfaction; Internal medicine; Surgery","score_opus":0.012206181359198718,"score_gpt":0.2621634408837821,"score_spread":0.24995725952458336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220985222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996896,0.0005436932,0.000064239764,0.00024617845,0.000007866607,0.000016380083,0.00070730085,0.0000043520367,0.0015140392],"genre_scores_gemma":[0.99882644,0.00021069344,0.000093946,0.00019644127,0.000009517137,0.000019638102,0.00050582364,0.0000019165113,0.00013557168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982077,0.00085599837,0.00025046733,0.0001457092,0.00036918485,0.00017090945],"domain_scores_gemma":[0.9950772,0.001266721,0.0021747265,0.00011833838,0.0007057993,0.000657301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021679993,0.0001546287,0.00035148434,0.0009514894,0.00030759964,0.00069851626,0.0001843773,0.00039549262,0.0013834401],"category_scores_gemma":[0.004482997,0.00010706853,0.00055580615,0.001763217,0.00029973092,0.0006001024,0.0008232441,0.00037093586,0.00018367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011938459,0.00005485297,0.9926475,0.000045901095,0.000096926065,0.00005203345,0.0010955797,0.000065432396,0.00010112375,0.000017230092,0.0005209184,0.0051831603],"study_design_scores_gemma":[0.000008845126,0.00009910481,0.99739337,0.000019033421,0.000019829826,0.00012959128,0.0016303859,0.00006983842,0.000024313535,0.000007787981,0.0005926813,0.0000052207706],"about_ca_topic_score_codex":0.0075139296,"about_ca_topic_score_gemma":0.009457132,"teacher_disagreement_score":0.0075139296,"about_ca_system_score_codex":0.00047711263,"about_ca_system_score_gemma":0.00037372828,"threshold_uncertainty_score":0.014940381},"labels":[],"label_agreement":null},{"id":"W4223530465","doi":"10.1007/s40744-022-00445-w","title":"Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Internal medicine; Enthesitis; Rheumatology; Randomized controlled trial; Physical therapy; Body mass index; Arthritis; Secukinumab","score_opus":0.04814159111236015,"score_gpt":0.3781690111166092,"score_spread":0.33002742000424906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223530465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86820734,0.11173615,0.0024960088,0.0025342407,0.00067270425,0.0043523945,0.0042121196,0.00015907048,0.0056299143],"genre_scores_gemma":[0.9669991,0.018818384,0.0024045089,0.0031136277,0.0007648231,0.00452983,0.00229724,0.000038769937,0.0010336732],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99470127,0.0032033506,0.0007117253,0.0005719476,0.0005911182,0.00022068428],"domain_scores_gemma":[0.99244374,0.003146278,0.0028476112,0.00052196404,0.0005161669,0.0005242406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012391181,0.0009220602,0.0032126997,0.0005117655,0.00046517115,0.0013549228,0.00053651026,0.0014626574,0.0045174803],"category_scores_gemma":[0.011358646,0.0004142,0.004960056,0.00073879946,0.00074734504,0.0008567052,0.00049772084,0.0015159552,0.00044593817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8220935,0.0050585866,0.01664016,0.0068410696,0.025482012,0.00011205959,0.00023989816,0.0004928925,0.004220326,0.000294115,0.0026492905,0.11587613],"study_design_scores_gemma":[0.815557,0.11150813,0.044231948,0.00094643293,0.019404104,0.0003398711,0.00012703447,0.00044794625,0.0013383807,0.00055724476,0.0054650162,0.00007683706],"about_ca_topic_score_codex":0.00027547628,"about_ca_topic_score_gemma":0.0009029481,"teacher_disagreement_score":0.012391181,"about_ca_system_score_codex":0.0005882232,"about_ca_system_score_gemma":0.0011763502,"threshold_uncertainty_score":0.06553161},"labels":[],"label_agreement":null},{"id":"W4229007735","doi":"10.1007/s40744-022-00447-8","title":"Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”","year":2022,"lang":"en","type":"letter","venue":"Rheumatology and Therapy","topic":"Shoulder Injury and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Capsulitis; Adhesive; Medicine; Orthodontics; Materials science; Radiology; Composite material","score_opus":0.015271759486481155,"score_gpt":0.27891443279883865,"score_spread":0.2636426733123575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229007735","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002659092,0.0024540802,0.00016829168,0.9345368,0.050039586,0.000031273037,0.000074454554,0.000057307418,0.009979177],"genre_scores_gemma":[0.034880836,0.003353881,0.00049615506,0.76345384,0.1819885,0.000060430913,0.000080808604,0.000075316086,0.015610209],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792373,0.0007702671,0.00025985623,0.0002603829,0.00044093354,0.00034473618],"domain_scores_gemma":[0.9960147,0.0019642666,0.00039633215,0.00013306239,0.0007753334,0.00071626244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015673746,0.001080378,0.0014009892,0.0011083775,0.0026343912,0.002775539,0.0016775874,0.030886263,0.006313311],"category_scores_gemma":[0.020453263,0.0008686909,0.00095500005,0.0007094953,0.0017767941,0.0022987078,0.00082980935,0.016234757,0.003803941],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015936469,0.00010172927,0.0025078328,0.00011468061,0.00004039732,0.079782836,0.0002096638,0.00016352179,0.00031913893,0.0016897114,0.90930927,0.0056019705],"study_design_scores_gemma":[0.00048354003,0.00020912988,0.0076603116,0.0010405239,0.0001742621,0.121691026,0.0013899072,0.0023391044,0.0007234497,0.008731147,0.85538054,0.00017701848],"about_ca_topic_score_codex":0.0036169584,"about_ca_topic_score_gemma":0.0045663174,"teacher_disagreement_score":0.030886263,"about_ca_system_score_codex":0.0025013897,"about_ca_system_score_gemma":0.0024897535,"threshold_uncertainty_score":0.02112019},"labels":[],"label_agreement":null},{"id":"W4281252987","doi":"10.1007/s40744-022-00454-9","title":"Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review","year":2022,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"GlaxoSmithKline","keywords":"Belimumab; Medicine; Observational study; Prednisone; Internal medicine; Randomized controlled trial; Systematic review; Clinical trial; Meta-analysis; MEDLINE; Immunology; Antibody; B-cell activating factor; B cell","score_opus":0.033347838248144676,"score_gpt":0.3527322264854972,"score_spread":0.3193843882373525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281252987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017073344,0.996642,0.00016580144,0.00031846913,0.00008049713,0.0003568982,0.0004963268,0.0000083868645,0.0002243244],"genre_scores_gemma":[0.043150578,0.95310515,0.0010113538,0.0008459401,0.0001602957,0.0010855923,0.0005308406,0.000009387584,0.000100828205],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9839796,0.006119989,0.0060760844,0.0010896111,0.0023447198,0.00038995416],"domain_scores_gemma":[0.9396912,0.04304149,0.0114642335,0.0007604434,0.0045489375,0.0004937632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016513804,0.0018947781,0.011574761,0.014816057,0.00070464367,0.0032564928,0.0021098685,0.0021745265,0.0049998686],"category_scores_gemma":[0.061394352,0.0012260303,0.012143754,0.012991991,0.0010063886,0.002772277,0.0017693326,0.0013056439,0.00031412515],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024027108,0.000015551497,0.0012637534,0.9572914,0.025743464,0.00009253853,0.000110336645,0.00010711281,0.000085583175,0.00013517942,0.0006531151,0.0142616],"study_design_scores_gemma":[0.00043108198,0.00028545488,0.00602714,0.744391,0.23898374,0.00040302338,0.00027077872,0.00015620142,0.0001637428,0.00036807678,0.008465706,0.00005415337],"about_ca_topic_score_codex":0.006093258,"about_ca_topic_score_gemma":0.015936008,"teacher_disagreement_score":0.016513804,"about_ca_system_score_codex":0.0047796844,"about_ca_system_score_gemma":0.012064288,"threshold_uncertainty_score":0.087334394},"labels":[],"label_agreement":null},{"id":"W4281385143","doi":"10.1007/s40744-022-00449-6","title":"Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"Gilead Sciences; AbbVie; Sanofi; Sun Pharma; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Post-hoc analysis; Medicine; Placebo; Internal medicine; Post hoc; Disease; Oncology; Pathology; Alternative medicine","score_opus":0.006328893737726416,"score_gpt":0.24811055344896543,"score_spread":0.24178165971123902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281385143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97984076,0.009238046,0.0018124746,0.0005187607,0.00051758805,0.0034424355,0.0027154002,0.00014244854,0.0017720561],"genre_scores_gemma":[0.9893477,0.0017604048,0.0019679202,0.00048965955,0.00035196813,0.0027111315,0.0019665647,0.00006422194,0.0013404465],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99060446,0.006915097,0.00063871784,0.00071246177,0.00052434957,0.0006048583],"domain_scores_gemma":[0.9916583,0.0048469943,0.001644354,0.00078160194,0.0005463662,0.0005223984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013334713,0.0018323541,0.005477305,0.0006373759,0.00035525518,0.0016229955,0.0007006347,0.0012378831,0.0038215327],"category_scores_gemma":[0.008836807,0.0005879718,0.0089216195,0.0007337022,0.0008161056,0.0012563542,0.00061486714,0.0023425194,0.00046540823],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96652025,0.0013441339,0.0017507887,0.0011526238,0.014583257,0.000061040606,0.00007108847,0.00079720805,0.0023741499,0.000090783346,0.00089730136,0.010357293],"study_design_scores_gemma":[0.7588699,0.16957298,0.024876093,0.00019067214,0.035264697,0.00019946949,0.00012342918,0.00315073,0.004023487,0.00044429486,0.0031804026,0.00010376705],"about_ca_topic_score_codex":0.00051842653,"about_ca_topic_score_gemma":0.0014571936,"teacher_disagreement_score":0.013334713,"about_ca_system_score_codex":0.00074873114,"about_ca_system_score_gemma":0.0015918146,"threshold_uncertainty_score":0.07052153},"labels":[],"label_agreement":null},{"id":"W4289912960","doi":"10.1007/s40744-022-00474-5","title":"Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie; Boehringer Ingelheim","keywords":"Medicine; Placebo; Internal medicine; Rheumatology; Psoriatic arthritis; Randomized controlled trial; Adverse effect; Clinical endpoint; Psoriasis Area and Severity Index; Psoriasis; Gastroenterology; Arthritis; Physical therapy; Dermatology; Pathology","score_opus":0.010314349004259685,"score_gpt":0.2628086861174515,"score_spread":0.2524943371131918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289912960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825186,0.006516434,0.0005093686,0.00046610594,0.00020565138,0.0018282798,0.0008780681,0.00006545576,0.0012787554],"genre_scores_gemma":[0.98634106,0.0040065004,0.0018739314,0.0008375641,0.00041646752,0.002986457,0.0012456233,0.000017497203,0.0022748928],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99873465,0.00069871475,0.00011896265,0.00018417496,0.00014813333,0.00011542534],"domain_scores_gemma":[0.99837506,0.00040582492,0.0005412023,0.0001414529,0.00009607652,0.0004403898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038728975,0.0011240231,0.0021495414,0.0002451901,0.0003935906,0.0008744181,0.00065022724,0.0012181278,0.004974994],"category_scores_gemma":[0.0018715842,0.00047984396,0.001987083,0.00029810707,0.0007352483,0.00086841156,0.00038542502,0.0021429658,0.0008918021],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95891404,0.007505177,0.001859028,0.00079165905,0.001547706,0.000052854637,0.0000635083,0.00043172136,0.0038755783,0.000056690853,0.000661631,0.02424043],"study_design_scores_gemma":[0.9070104,0.08518615,0.005339923,0.000047991296,0.0007327991,0.00005848446,0.000015491667,0.0002399638,0.0006064554,0.00007233558,0.0006703013,0.000019671035],"about_ca_topic_score_codex":0.0003300042,"about_ca_topic_score_gemma":0.0009370989,"teacher_disagreement_score":0.004974994,"about_ca_system_score_codex":0.0006019667,"about_ca_system_score_gemma":0.0010539438,"threshold_uncertainty_score":0.020482123},"labels":[],"label_agreement":null},{"id":"W4294123158","doi":"10.1007/s40744-022-00485-2","title":"Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada)","funders":"","keywords":"Medicine; Apremilast; Golimumab; Tofacitinib; Secukinumab; Tocilizumab; Abatacept; Psoriatic arthritis; Ustekinumab; Internal medicine; Adalimumab; Rheumatoid arthritis; Rituximab","score_opus":0.012558214626956528,"score_gpt":0.2444003840956414,"score_spread":0.23184216946868488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294123158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98994523,0.00089024595,0.00009968685,0.00022069193,0.000007995375,0.000087988104,0.0069703166,0.000009073506,0.0017687214],"genre_scores_gemma":[0.99685824,0.00042498446,0.00017738371,0.00013618107,0.0000071941395,0.00003264713,0.0020248345,0.0000020436512,0.0003364704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983425,0.000113734735,0.00019498372,0.00025365467,0.0007860917,0.00030903364],"domain_scores_gemma":[0.9970169,0.00012984118,0.0014242135,0.00008173548,0.00093383185,0.00041353027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064023765,0.00025673973,0.00037303314,0.0011742942,0.0014636026,0.0009759858,0.00083375454,0.00042892768,0.0012926876],"category_scores_gemma":[0.0023428046,0.00020949202,0.0005569041,0.00359879,0.0004514896,0.0002783256,0.00051046466,0.0006913069,0.00015870067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045406352,0.0000393907,0.9972186,0.000034920264,0.00003912261,0.000025807296,0.00014494713,0.000049596125,0.000071490445,0.000029118239,0.0003420638,0.0019595996],"study_design_scores_gemma":[0.000009639727,0.000049127808,0.9984097,0.000031130836,0.000029182893,0.000080477635,0.0003072395,0.000221891,0.00007815238,0.000009970141,0.0007670838,0.0000065137074],"about_ca_topic_score_codex":0.9596035,"about_ca_topic_score_gemma":0.9613153,"teacher_disagreement_score":0.04039651,"about_ca_system_score_codex":0.014963269,"about_ca_system_score_gemma":0.017865095,"threshold_uncertainty_score":0.10856664},"labels":[],"label_agreement":null},{"id":"W4294970515","doi":"10.1007/s40744-022-00482-5","title":"Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Enthesitis; Medicine; Psoriasis Area and Severity Index; Internal medicine; Psoriatic arthritis; Psoriasis; Arthritis; Placebo; Dermatology; Gastroenterology; Rheumatoid arthritis; Pathology","score_opus":0.011728116135810375,"score_gpt":0.24505841220178645,"score_spread":0.23333029606597608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294970515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9013266,0.020275293,0.06173035,0.004190566,0.00049678824,0.001996975,0.0052430904,0.0003240506,0.0044162283],"genre_scores_gemma":[0.98862785,0.0012365516,0.007294019,0.00029240435,0.00009358211,0.0011626611,0.00061130954,0.000022218457,0.0006594108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96337324,0.03172301,0.0008832541,0.0018459844,0.0013071215,0.00086739386],"domain_scores_gemma":[0.9437241,0.050279293,0.0026138923,0.0018750882,0.0010962732,0.0004113648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.042294703,0.0021009494,0.0024801253,0.0015925317,0.00064940663,0.0016747039,0.0018963766,0.0009789696,0.0067532207],"category_scores_gemma":[0.04491489,0.0007353219,0.014216958,0.0017660267,0.0007524646,0.0010683556,0.0023338743,0.0020065238,0.00035875954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021271357,0.0021731735,0.67112327,0.0045243977,0.14647166,0.0006190113,0.0020270948,0.021348273,0.0025764727,0.007817424,0.0029534686,0.117094435],"study_design_scores_gemma":[0.007599747,0.02643033,0.4907166,0.0019713445,0.23494312,0.00094665017,0.0026004235,0.18846919,0.005607607,0.0254063,0.014938819,0.0003698981],"about_ca_topic_score_codex":0.004989759,"about_ca_topic_score_gemma":0.0035995678,"teacher_disagreement_score":0.042294703,"about_ca_system_score_codex":0.0011039107,"about_ca_system_score_gemma":0.0028916192,"threshold_uncertainty_score":0.22367841},"labels":[],"label_agreement":null},{"id":"W4296161978","doi":"10.1007/s40744-022-00487-0","title":"Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren’s","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Physical therapy; Internal medicine; Perspective (graphical); Patient-reported outcome; Clinical psychology; Quality of life (healthcare)","score_opus":0.4302436541809335,"score_gpt":0.43518523397959574,"score_spread":0.004941579798662221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296161978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9229082,0.0033585008,0.026580157,0.01544922,0.0005613697,0.010153731,0.0023271167,0.00008962063,0.018572113],"genre_scores_gemma":[0.9376306,0.002146027,0.025835717,0.0052837925,0.00009651418,0.022402909,0.0006489665,0.000074518735,0.0058809808],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.953935,0.038364895,0.001492077,0.0018463038,0.0020526492,0.002309117],"domain_scores_gemma":[0.86230123,0.11786204,0.00472382,0.0028543212,0.01016322,0.0020953498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05714475,0.00079158804,0.0012267675,0.0035268671,0.0066961925,0.0045220777,0.002087847,0.0021247247,0.005727373],"category_scores_gemma":[0.08682446,0.00073403935,0.00078270526,0.0036323816,0.008635781,0.004005302,0.005570707,0.0036731686,0.00068246253],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009163889,0.00006575183,0.0015615813,0.00071122515,0.000008240314,0.0002657905,0.9842621,0.00008875586,0.0006621701,0.002549536,0.0010755081,0.008657682],"study_design_scores_gemma":[0.00006475399,0.00012287445,0.0014570518,0.0012064417,0.00001351483,0.00013705126,0.97700226,0.0003016412,0.0006447685,0.0030932997,0.015924627,0.000031706],"about_ca_topic_score_codex":0.0069960933,"about_ca_topic_score_gemma":0.010381395,"teacher_disagreement_score":0.05714475,"about_ca_system_score_codex":0.011105767,"about_ca_system_score_gemma":0.011268974,"threshold_uncertainty_score":0.3022139},"labels":[],"label_agreement":null},{"id":"W4296929673","doi":"10.1007/s40744-022-00489-y","title":"Content Validity of Sjögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’s","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Novartis Pharma","keywords":"Content validity; Medicine; Population; Qualitative research; Physical therapy; Psychology; Family medicine; Clinical psychology; Psychometrics","score_opus":0.04063145435845555,"score_gpt":0.2585249252789308,"score_spread":0.21789347092047523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296929673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98955476,0.0012094303,0.0021417362,0.0011253328,0.00009541144,0.0014418401,0.0007897615,0.000011587543,0.0036300994],"genre_scores_gemma":[0.9937348,0.0003761559,0.0033435025,0.0003227044,0.00002742558,0.001492999,0.00049949106,0.000009304798,0.00019359872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9603565,0.023216711,0.006105514,0.001853551,0.0075445,0.00092332385],"domain_scores_gemma":[0.8836351,0.08572991,0.011645193,0.0038182915,0.014462791,0.0007087058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.044682276,0.00022045727,0.0010322365,0.002784151,0.0010369982,0.0019698997,0.00077463954,0.0006769358,0.00088481704],"category_scores_gemma":[0.12716115,0.00029076927,0.0013015982,0.0022625776,0.0020739834,0.0015381441,0.0029414783,0.00088620087,0.00013855829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086837757,0.00030733694,0.675068,0.0031439818,0.00050081196,0.00032490396,0.21307601,0.0005553619,0.0027922713,0.0015931224,0.0014447571,0.100324966],"study_design_scores_gemma":[0.0002067862,0.00080316555,0.8719865,0.003140148,0.00036139225,0.00087320927,0.10288534,0.0037978406,0.0018266903,0.0028236236,0.011138404,0.00015683156],"about_ca_topic_score_codex":0.0040651364,"about_ca_topic_score_gemma":0.004074824,"teacher_disagreement_score":0.044682276,"about_ca_system_score_codex":0.0044119204,"about_ca_system_score_gemma":0.004147559,"threshold_uncertainty_score":0.2363053},"labels":[],"label_agreement":null},{"id":"W4303859853","doi":"10.1007/s40744-022-00498-x","title":"Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Gilead Sciences","keywords":"Post-hoc analysis; Post hoc; Medicine; Internal medicine; Oncology","score_opus":0.007263990919716048,"score_gpt":0.2490476914079439,"score_spread":0.24178370048822784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303859853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741274,0.0008064174,0.00016621157,0.00008056106,0.000027755266,0.00022065619,0.0007503719,0.000018392811,0.0005169519],"genre_scores_gemma":[0.99814546,0.00009265238,0.00025122656,0.000099385856,0.000050216993,0.00015888842,0.00076152233,0.0000066783105,0.00043406233],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970964,0.0016331625,0.000107362204,0.00045835835,0.00030615026,0.0003985898],"domain_scores_gemma":[0.9969222,0.0014030478,0.00064902235,0.00041248114,0.000241661,0.00037163773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064452896,0.0014778122,0.002434888,0.00042023757,0.0005899587,0.0008336183,0.00084968033,0.00071460597,0.0031810163],"category_scores_gemma":[0.0035501383,0.00034776164,0.0044147284,0.00036517813,0.00066322245,0.000633772,0.0006383945,0.0013943578,0.00026858525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75297254,0.0026142097,0.18490654,0.000814358,0.02361362,0.00034554445,0.00023669534,0.002337929,0.004917546,0.000157053,0.0023245562,0.02475941],"study_design_scores_gemma":[0.09767037,0.18635061,0.67941415,0.00014165661,0.023117363,0.00049699785,0.0002639844,0.0050961473,0.003860099,0.00039473898,0.0030355533,0.00015841353],"about_ca_topic_score_codex":0.0024859891,"about_ca_topic_score_gemma":0.0059548756,"teacher_disagreement_score":0.0064452896,"about_ca_system_score_codex":0.0012069771,"about_ca_system_score_gemma":0.0018752945,"threshold_uncertainty_score":0.034086347},"labels":[],"label_agreement":null},{"id":"W4306294863","doi":"10.1007/s40744-022-00499-w","title":"Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group; McMaster University","funders":"AbbVie","keywords":"Psoriatic arthritis; Medicine; Dermatology; Phase (matter); Internal medicine; Oncology; Arthritis; Chemistry","score_opus":0.009607918117707422,"score_gpt":0.2528416980567992,"score_spread":0.24323377993909176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306294863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891878,0.006193003,0.0005306105,0.0003017872,0.000043343098,0.0005417908,0.0017327503,0.00006561111,0.0014032018],"genre_scores_gemma":[0.9916687,0.002113326,0.0007528293,0.0006496711,0.00012857791,0.0004949267,0.0035183663,0.00001746407,0.00065610174],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991314,0.0004078555,0.000058377762,0.000080169666,0.00022284669,0.00009944826],"domain_scores_gemma":[0.9980434,0.0004777363,0.0007004283,0.00012458501,0.0002496866,0.00040406798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004084373,0.00070475345,0.0015390825,0.00024469174,0.00034083656,0.0009091768,0.0003684293,0.00067038473,0.0015879263],"category_scores_gemma":[0.0020525195,0.0002336334,0.0012701821,0.0003984145,0.000345513,0.00055281736,0.0003107758,0.0015369069,0.0003625035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6433288,0.020966329,0.07574883,0.0018476413,0.005866894,0.00043723613,0.00042511916,0.0034183061,0.017557697,0.00020284696,0.009107832,0.22109248],"study_design_scores_gemma":[0.28029543,0.37845063,0.31501308,0.00026386956,0.005620463,0.0014838666,0.00017454542,0.0036025378,0.0066854414,0.00037849986,0.007907963,0.00012363179],"about_ca_topic_score_codex":0.00051189575,"about_ca_topic_score_gemma":0.001290986,"teacher_disagreement_score":0.004084373,"about_ca_system_score_codex":0.0005468678,"about_ca_system_score_gemma":0.0011163433,"threshold_uncertainty_score":0.021600544},"labels":[],"label_agreement":null},{"id":"W4311927297","doi":"10.1007/s40744-022-00511-3","title":"Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Montreal Clinical Research Institute","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Rheumatoid arthritis; Methotrexate; Erythrocyte sedimentation rate; Internal medicine; Gastroenterology","score_opus":0.012924978512339091,"score_gpt":0.2704188013543953,"score_spread":0.2574938228420562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311927297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871576,0.0007127931,0.00015181191,0.000022734692,0.000004497301,0.00006253606,0.00015192038,0.0000034247444,0.00017454925],"genre_scores_gemma":[0.99918777,0.00011671452,0.00016124247,0.000028627584,0.000014414155,0.00006666989,0.00032935746,0.0000012498399,0.00009401173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736315,0.0014546955,0.0003023537,0.00026068147,0.0004941881,0.00012486968],"domain_scores_gemma":[0.9956558,0.0011913552,0.0021798208,0.00021722037,0.00033799317,0.0004178428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039495933,0.0004148467,0.001171683,0.0005756162,0.00030938958,0.0005440424,0.00033050796,0.000327172,0.0012124839],"category_scores_gemma":[0.004332909,0.00016706932,0.0009929679,0.0005513035,0.00027688185,0.00034739514,0.00035959933,0.00044701304,0.00017784702],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097507946,0.0011942129,0.8584353,0.00041013682,0.0020796352,0.0002460435,0.0002600314,0.00046960215,0.00793394,0.000040050134,0.0002809468,0.03114216],"study_design_scores_gemma":[0.0028485614,0.022943418,0.9707099,0.0000283019,0.0005284555,0.000497031,0.00008909687,0.00070311007,0.0008195072,0.000040987823,0.0007693199,0.000022325727],"about_ca_topic_score_codex":0.00040958505,"about_ca_topic_score_gemma":0.0006423395,"teacher_disagreement_score":0.0039495933,"about_ca_system_score_codex":0.00041838447,"about_ca_system_score_gemma":0.0004158306,"threshold_uncertainty_score":0.020887733},"labels":[],"label_agreement":null},{"id":"W4317567968","doi":"10.1007/s40744-022-00529-7","title":"Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Chugai Pharmaceutical; Genentech; Astellas Pharma; National Institute for Health and Care Research; Biogen; Celgene; Gilead Sciences; Nordic Pharma Group; Eisai; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Rheumatoid arthritis; Medicine; Disease; Dermatology; Arthritis; Internal medicine; Physical therapy","score_opus":0.037912512539651305,"score_gpt":0.3451770614039854,"score_spread":0.3072645488643341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317567968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105763,0.005215978,0.0012432382,0.00019490128,0.000018433471,0.00087691826,0.0008425305,0.000032156153,0.0005181832],"genre_scores_gemma":[0.9931537,0.0010323253,0.0020983124,0.0002980954,0.0000137375055,0.0010221702,0.0021551044,0.000009496337,0.00021712894],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9954306,0.0030461403,0.00043139397,0.00040365136,0.00043514534,0.00025314023],"domain_scores_gemma":[0.9931202,0.0028244343,0.0024372921,0.0004399792,0.00075741776,0.00042071703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012796969,0.00066964334,0.002065365,0.00082016725,0.0006659495,0.0013323271,0.00054055464,0.0007567555,0.0008065846],"category_scores_gemma":[0.009853349,0.00047822183,0.0022425,0.0011723031,0.00038081405,0.00071075873,0.0008578562,0.0010893667,0.00015258258],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15965086,0.0040552393,0.63544667,0.0025837014,0.014226187,0.0004914419,0.0018538177,0.009496743,0.017294597,0.00052071735,0.0021904118,0.1521897],"study_design_scores_gemma":[0.03544969,0.101272106,0.8080519,0.0007647836,0.015142722,0.0011847408,0.0012861264,0.013003299,0.008402209,0.0015713178,0.013586139,0.00028500005],"about_ca_topic_score_codex":0.0010656365,"about_ca_topic_score_gemma":0.0025556474,"teacher_disagreement_score":0.012796969,"about_ca_system_score_codex":0.0010978145,"about_ca_system_score_gemma":0.0019085757,"threshold_uncertainty_score":0.06767762},"labels":[],"label_agreement":null},{"id":"W4321016164","doi":"10.1007/s40744-023-00531-7","title":"Patient Experience of Sjögren’s Disease and its Multifaceted Impact on Patients’ Lives","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Active listening; Quality of life (healthcare); Social media; Medicine; Disease; Throat; Dry mouth; Perspective (graphical); Physical therapy; Psychology; Clinical psychology; Internal medicine; Nursing; Surgery","score_opus":0.017198325909339094,"score_gpt":0.28498128328159084,"score_spread":0.2677829573722517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321016164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938658,0.0016463437,0.00027032482,0.0011796714,0.000020904281,0.00001164613,0.0001626448,0.000010777773,0.0028320265],"genre_scores_gemma":[0.998694,0.00064836844,0.00018548519,0.00016518917,0.000023017386,0.000009273437,0.000049211303,0.0000023765062,0.00022320038],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.998439,0.0009280549,0.0001149093,0.00008229288,0.00032896598,0.000106795436],"domain_scores_gemma":[0.9967648,0.0018081998,0.0008322837,0.000062938336,0.00022162916,0.00031017116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011993371,0.00016785365,0.00026620182,0.00062533206,0.00057251495,0.0012836289,0.00017935962,0.0003861179,0.0021386854],"category_scores_gemma":[0.004976014,0.00008946845,0.00025061745,0.00061615475,0.0007182128,0.0009858175,0.0012997766,0.00051623146,0.00018774961],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005398923,0.00013427758,0.6545292,0.0011655597,0.00026916905,0.0032247344,0.19144972,0.000567155,0.0049404306,0.00091184536,0.004361376,0.13790667],"study_design_scores_gemma":[0.00003149417,0.00085114874,0.73934114,0.0007509886,0.00019302254,0.009673184,0.22059636,0.0009680086,0.0011082756,0.0012582068,0.025095923,0.00013230336],"about_ca_topic_score_codex":0.0007859171,"about_ca_topic_score_gemma":0.0013293828,"teacher_disagreement_score":0.0021386854,"about_ca_system_score_codex":0.00040616575,"about_ca_system_score_gemma":0.00034024878,"threshold_uncertainty_score":0.007154584},"labels":[],"label_agreement":null},{"id":"W4321611533","doi":"10.1007/s40744-023-00533-5","title":"Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Golimumab; Infliximab; Observational study; Rheumatoid arthritis; Medicine; Phase (matter); Physical therapy; Internal medicine; Adalimumab; Tumor necrosis factor alpha","score_opus":0.043906529844289936,"score_gpt":0.32960152492120626,"score_spread":0.2856949950769163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321611533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798834,0.00033260338,0.000099433244,0.000028705816,0.0000041718404,0.00017640695,0.0011419811,0.0000047410495,0.00022351646],"genre_scores_gemma":[0.99440324,0.0002674,0.0005072415,0.0000944272,0.000025907499,0.00039744555,0.0041783103,0.0000031543677,0.0001227555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757856,0.0015116135,0.00026429904,0.00023468358,0.00031037407,0.00010057851],"domain_scores_gemma":[0.9950412,0.0010085977,0.0026036794,0.00064177654,0.00027466312,0.00043008407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003379361,0.0005677157,0.00089508545,0.00041456462,0.00028604653,0.0009417102,0.00053171307,0.0006572401,0.0006346155],"category_scores_gemma":[0.0039005948,0.0004593703,0.0011787602,0.0007042936,0.0003686074,0.0004638512,0.0005427889,0.0006527832,0.0002194818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04025564,0.0034034506,0.93879235,0.00039038024,0.003421599,0.00014130367,0.00038871646,0.0005427634,0.002024935,0.00005210128,0.0005835253,0.010003294],"study_design_scores_gemma":[0.009786587,0.009786605,0.9766757,0.000053179578,0.0010587384,0.00038721503,0.00016500878,0.00042000582,0.0005051127,0.000042959564,0.0010836292,0.000035325174],"about_ca_topic_score_codex":0.00084231567,"about_ca_topic_score_gemma":0.0012339654,"teacher_disagreement_score":0.003379361,"about_ca_system_score_codex":0.00033461308,"about_ca_system_score_gemma":0.000510017,"threshold_uncertainty_score":0.017871976},"labels":[],"label_agreement":null},{"id":"W4322496507","doi":"10.1007/s40744-023-00541-5","title":"Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Barrie Urology Group","funders":"UCB Pharma","keywords":"Certolizumab pegol; Rheumatoid arthritis; Medicine; Term (time); Pooled analysis; Clinical trial; Internal medicine; Arthritis; Meta-analysis; Adalimumab","score_opus":0.045446736948720104,"score_gpt":0.360959686237571,"score_spread":0.31551294928885093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322496507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5466123,0.43457952,0.008687331,0.0006209587,0.00048069065,0.0009790885,0.0063182223,0.0001815666,0.0015403694],"genre_scores_gemma":[0.96901983,0.022956094,0.002681041,0.00035775854,0.00030730953,0.0008658319,0.0035199241,0.000043285938,0.0002490993],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9497415,0.03248694,0.008712474,0.0045507676,0.0038243106,0.0006839885],"domain_scores_gemma":[0.911932,0.056686863,0.023161542,0.005314718,0.002163203,0.0007416404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.064594835,0.001664826,0.0089271525,0.0037331972,0.0003576676,0.0029577832,0.0009180746,0.0014829978,0.0014241624],"category_scores_gemma":[0.052203663,0.0008222626,0.022670705,0.0039926935,0.00056124304,0.0015002855,0.0011460677,0.001093032,0.00017079654],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04897555,0.00014971878,0.13810784,0.010898627,0.77040195,0.0001887948,0.00010858751,0.0030098385,0.00082403654,0.00013481663,0.0005807583,0.026619436],"study_design_scores_gemma":[0.010829871,0.009949237,0.2512789,0.002493444,0.7146785,0.0006773867,0.00013683163,0.004418637,0.0010324384,0.0009559437,0.0034007411,0.00014800503],"about_ca_topic_score_codex":0.0005321294,"about_ca_topic_score_gemma":0.0008081456,"teacher_disagreement_score":0.064594835,"about_ca_system_score_codex":0.0007206316,"about_ca_system_score_gemma":0.0010620872,"threshold_uncertainty_score":0.34161425},"labels":[],"label_agreement":null},{"id":"W4360983727","doi":"10.1007/s40744-023-00545-1","title":"A Narrative Review of Acthar Gel for the Treatment of Myositis","year":2023,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Polymyositis; Medicine; Dermatomyositis; Myositis; Refractory (planetary science); Proximal muscle weakness; Internal medicine; Immunology; Muscle biopsy","score_opus":0.06468238412892124,"score_gpt":0.3852631856699987,"score_spread":0.32058080154107743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360983727","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007380652,0.9990177,0.000043524964,0.0001320339,0.00016175251,0.000009387806,0.000037474343,0.000004634523,0.0005195467],"genre_scores_gemma":[0.00040561575,0.9988726,0.0001212938,0.00019079901,0.000121009114,0.00001117226,0.00004327298,0.0000013631095,0.00023285067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996338,0.00006625271,0.00011374042,0.0000615679,0.000104554696,0.000020141906],"domain_scores_gemma":[0.99926907,0.00044448368,0.0001350494,0.0000131964825,0.0001086022,0.000029475297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005230306,0.0009706629,0.0016891662,0.004222806,0.00035799237,0.0011030913,0.0009658079,0.0009822891,0.007839916],"category_scores_gemma":[0.0018591073,0.00028375429,0.0011624071,0.0036477698,0.0002871734,0.0011385536,0.00059490785,0.0011861541,0.0015809453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012584671,0.00005364029,0.0001937931,0.21045019,0.00039600013,0.00040350118,0.00015308497,0.0003156344,0.00087111094,0.0019324708,0.05448619,0.73061854],"study_design_scores_gemma":[0.000048232567,0.0001392518,0.0014552951,0.0882586,0.0013417902,0.003267112,0.00013093652,0.00010210981,0.0002767853,0.0011884661,0.90375733,0.000034104003],"about_ca_topic_score_codex":0.0018066973,"about_ca_topic_score_gemma":0.0031445601,"teacher_disagreement_score":0.007839916,"about_ca_system_score_codex":0.0006730093,"about_ca_system_score_gemma":0.0015879514,"threshold_uncertainty_score":0.026227117},"labels":[],"label_agreement":null},{"id":"W4366160578","doi":"10.1007/s40744-023-00546-0","title":"Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Genentech; LG Chem; Sun Pharma; University of British Columbia; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company","keywords":"Tolerability; Dosing; Uric acid; Pharmacology; Medicine; Gout; Chemistry; Internal medicine; Adverse effect","score_opus":0.034541394054713535,"score_gpt":0.30171768839830554,"score_spread":0.267176294343592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366160578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946306,0.00072310714,0.0006637617,0.00021713291,0.00007624488,0.002358545,0.000387645,0.00007427617,0.0008687764],"genre_scores_gemma":[0.98935306,0.00070037734,0.002630688,0.0008431551,0.00011350475,0.0032452212,0.0008902614,0.000026989066,0.0021967792],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996835,0.00014208093,0.000013240867,0.00005891616,0.000036623904,0.000065679546],"domain_scores_gemma":[0.9994972,0.00009083805,0.00010295686,0.000045819867,0.000051000014,0.00021225521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015135694,0.0013466201,0.0015905094,0.0003792036,0.00036554714,0.0008655525,0.0006201105,0.0011604445,0.002877828],"category_scores_gemma":[0.00085907086,0.00061444705,0.0010706873,0.0002416589,0.00066151586,0.0008242767,0.00036361816,0.0026026233,0.00068178424],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58561796,0.2154806,0.009625547,0.0007905822,0.0016274417,0.00050779333,0.0008189517,0.0035227009,0.08570207,0.0003894263,0.0041546174,0.09176241],"study_design_scores_gemma":[0.2630886,0.7233162,0.007382247,0.000022563567,0.00020895837,0.0002093164,0.000072655705,0.0009798232,0.0027482496,0.00016643212,0.0017815604,0.000023374492],"about_ca_topic_score_codex":0.0005067946,"about_ca_topic_score_gemma":0.0012577777,"teacher_disagreement_score":0.002877828,"about_ca_system_score_codex":0.00052449934,"about_ca_system_score_gemma":0.00097485987,"threshold_uncertainty_score":0.009627283},"labels":[],"label_agreement":null},{"id":"W4375856191","doi":"10.1007/s40744-023-00548-y","title":"Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Psoriatic arthritis; Medicine; Dermatology; Interleukin; Immunology; Psoriasis; Cytokine","score_opus":0.006998237075083139,"score_gpt":0.22879227441581781,"score_spread":0.22179403734073466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375856191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060703,0.017529452,0.00024792858,0.00015765116,0.000050364124,0.00009501241,0.00018400341,0.000019215238,0.001109233],"genre_scores_gemma":[0.99652976,0.00238593,0.00033221042,0.00017840664,0.00007009168,0.0000580143,0.00015803888,0.0000016158496,0.0002859788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961865,0.00016917643,0.00004807258,0.000040978666,0.0000721659,0.000050879757],"domain_scores_gemma":[0.9993868,0.0001823019,0.00024718523,0.000027205797,0.00005292165,0.00010356378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012489151,0.00026038074,0.00083044305,0.00017829868,0.0001941565,0.0003430618,0.00014199331,0.00017413292,0.0014977326],"category_scores_gemma":[0.0009489282,0.000095708696,0.00038180716,0.0003103737,0.00014340351,0.00018835424,0.00016605161,0.00040363063,0.00027073355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07935692,0.0038243479,0.47821543,0.0025658982,0.0022510563,0.0008298305,0.00035852386,0.0008646104,0.030452624,0.00015641052,0.0024773867,0.398647],"study_design_scores_gemma":[0.016290003,0.119495705,0.82981217,0.00041550412,0.0025236064,0.004787434,0.00033605096,0.0016350506,0.008073842,0.00028108666,0.016310683,0.000038977163],"about_ca_topic_score_codex":0.00024270883,"about_ca_topic_score_gemma":0.00087441725,"teacher_disagreement_score":0.0014977326,"about_ca_system_score_codex":0.0001582982,"about_ca_system_score_gemma":0.0003669518,"threshold_uncertainty_score":0.0066049695},"labels":[],"label_agreement":null},{"id":"W4377091353","doi":"10.1007/s40744-023-00560-2","title":"Patient–Physician Communication and Perception of Treatment Goals in Rheumatoid Arthritis: An Online Survey of Patients and Physicians","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Gilead Sciences","keywords":"Rheumatoid arthritis; Perception; Medicine; Family medicine; Physical therapy; Psychology; Internal medicine","score_opus":0.032642556881457334,"score_gpt":0.3037722516472685,"score_spread":0.27112969476581117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377091353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985469,0.00018911445,0.00007203176,0.0002998829,0.000004804222,0.000018058054,0.00021239504,0.0000042020424,0.0006526842],"genre_scores_gemma":[0.99923456,0.00013871977,0.00016027296,0.00016785988,0.000011381807,0.000022741404,0.0001287849,0.0000012837435,0.00013439577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718744,0.0015812727,0.00034959742,0.00015342986,0.0005217483,0.00020655796],"domain_scores_gemma":[0.9842927,0.006294761,0.006870634,0.00019711728,0.0010043968,0.0013403578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002949891,0.0001410846,0.00031782105,0.00072243006,0.00038603303,0.00072001864,0.0001870959,0.00059692335,0.0027430607],"category_scores_gemma":[0.011431545,0.00015996669,0.00035363692,0.0006123605,0.00024729205,0.0007603478,0.00057477114,0.0004960965,0.00032419406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012656134,0.0001771844,0.99147403,0.00006241767,0.0000504537,0.00007704548,0.0019891327,0.00006086516,0.00018638774,0.000016454207,0.00037462142,0.0054047517],"study_design_scores_gemma":[0.000029179704,0.00043237788,0.9933508,0.000045388777,0.000024961104,0.00039720078,0.004374705,0.000405472,0.00010080404,0.00002297245,0.00080286677,0.000013347471],"about_ca_topic_score_codex":0.0015985462,"about_ca_topic_score_gemma":0.0015793121,"teacher_disagreement_score":0.002949891,"about_ca_system_score_codex":0.00037817162,"about_ca_system_score_gemma":0.00032976235,"threshold_uncertainty_score":0.015600741},"labels":[],"label_agreement":null},{"id":"W4378195026","doi":"10.1007/s40744-023-00552-2","title":"Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Leeds Biomedical Research Centre; Department of Health and Social Care; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Abatacept; Medicine; Rheumatoid arthritis; Spear; Internal medicine; Population; Surgery; Rituximab","score_opus":0.035263739205698995,"score_gpt":0.33111069432484824,"score_spread":0.29584695511914927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378195026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8893916,0.10191972,0.002746875,0.00029679536,0.00016840028,0.00071873365,0.0032765942,0.0000846526,0.001396802],"genre_scores_gemma":[0.99206454,0.004244692,0.00084885873,0.00019324032,0.00012720015,0.0004541404,0.0018654689,0.000020573554,0.00018120767],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9657526,0.023996007,0.0043007024,0.0028154145,0.0024235235,0.00071183394],"domain_scores_gemma":[0.9589126,0.027669152,0.008428489,0.0026796784,0.0016446633,0.000665264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03776434,0.0019441452,0.0062117153,0.0028909524,0.00039939335,0.0021997509,0.0008561112,0.0012824154,0.0016034761],"category_scores_gemma":[0.03670364,0.00071622315,0.01607233,0.0025131758,0.00068484555,0.0011285685,0.0014179744,0.0011187531,0.00017403929],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20850386,0.00032318532,0.16507396,0.0057774894,0.58305526,0.00019663948,0.00015189021,0.0034467427,0.0020028919,0.00014660199,0.0006447265,0.030676708],"study_design_scores_gemma":[0.044594478,0.017170528,0.39896616,0.00083317666,0.5298285,0.000456285,0.00017804005,0.0034557472,0.0013902955,0.0009097065,0.0020812647,0.00013585885],"about_ca_topic_score_codex":0.00061084906,"about_ca_topic_score_gemma":0.0008780842,"teacher_disagreement_score":0.03776434,"about_ca_system_score_codex":0.00064083625,"about_ca_system_score_gemma":0.00077033613,"threshold_uncertainty_score":0.19971931},"labels":[],"label_agreement":null},{"id":"W4380869940","doi":"10.1007/s40744-023-00556-y","title":"Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"Janssen Scientific Affairs","keywords":"Ankylosing spondylitis; Golimumab; Medicine; Spondylitis; Physical therapy; Phase (matter); Psychology; Internal medicine; Physics","score_opus":0.032301350799224554,"score_gpt":0.3684574879036627,"score_spread":0.33615613710443815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380869940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341774,0.004954742,0.00015770782,0.00028205715,0.000055759534,0.00024528723,0.00042681437,0.000024322093,0.00043554747],"genre_scores_gemma":[0.9969042,0.0010427765,0.00033551548,0.0004032101,0.00012716533,0.00032821292,0.00050238514,0.000005385302,0.00035103873],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993406,0.00042311486,0.000038263883,0.0000601065,0.000054183856,0.00008377047],"domain_scores_gemma":[0.9986197,0.00048014714,0.00042362092,0.00009344624,0.000068185065,0.00031487976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021436848,0.0006775264,0.001939457,0.00017342075,0.00021477262,0.0004758618,0.00043525535,0.00076640776,0.0014000649],"category_scores_gemma":[0.001982084,0.00026218683,0.00140739,0.0002540297,0.0003878,0.00046025193,0.00032756338,0.0015891984,0.00024057749],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8457075,0.009016672,0.030761354,0.0009386215,0.002635872,0.00009879242,0.00012595199,0.0010708972,0.0069115255,0.0001205342,0.0011291157,0.10148321],"study_design_scores_gemma":[0.40105432,0.43432543,0.15717068,0.00015467285,0.002351701,0.00016275205,0.0000634712,0.0017588843,0.0010924104,0.00025718904,0.0015642984,0.00004424838],"about_ca_topic_score_codex":0.00037852582,"about_ca_topic_score_gemma":0.0008635482,"teacher_disagreement_score":0.0021436848,"about_ca_system_score_codex":0.00026558532,"about_ca_system_score_gemma":0.00038307154,"threshold_uncertainty_score":0.011336982},"labels":[],"label_agreement":null},{"id":"W4381104181","doi":"10.1007/s40744-023-00564-y","title":"Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Pfizer (Canada)","funders":"Pfizer","keywords":"Ankylosing spondylitis; Tofacitinib; Medicine; Spondylitis; Surgery; Internal medicine; Rheumatoid arthritis","score_opus":0.033452515047247895,"score_gpt":0.32996713202599093,"score_spread":0.29651461697874304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381104181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768563,0.015026182,0.0006503638,0.00067614304,0.00023377466,0.0018330258,0.0022116522,0.00007728054,0.0024352376],"genre_scores_gemma":[0.9815834,0.008037978,0.0014498526,0.00076950225,0.00051512645,0.002161622,0.003474465,0.000026636675,0.0019814188],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992341,0.00039114017,0.000062108484,0.00011056081,0.000109673434,0.00009240503],"domain_scores_gemma":[0.9985833,0.00045515347,0.00044530834,0.000099039644,0.00019499281,0.00022215403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033754301,0.0013276872,0.0020786587,0.00027860253,0.00034418743,0.0010380538,0.0005600789,0.00095557945,0.003644818],"category_scores_gemma":[0.0020763385,0.0003151889,0.0021057916,0.00038658804,0.00051159697,0.00051935087,0.0002196627,0.0014847139,0.00045447293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8665724,0.009642213,0.0066793314,0.0032492648,0.008096538,0.00016429884,0.00019839781,0.0012066825,0.0148415845,0.00018561441,0.00378071,0.08538296],"study_design_scores_gemma":[0.8085379,0.15930808,0.021082446,0.00018817146,0.0040423768,0.00028004491,0.00004782248,0.0005512442,0.0027684947,0.00022149488,0.0029305816,0.000041427975],"about_ca_topic_score_codex":0.0006892646,"about_ca_topic_score_gemma":0.002284036,"teacher_disagreement_score":0.003644818,"about_ca_system_score_codex":0.00064583815,"about_ca_system_score_gemma":0.0011732801,"threshold_uncertainty_score":0.017851174},"labels":[],"label_agreement":null},{"id":"W4384560180","doi":"10.1007/s40744-023-00576-8","title":"Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Tofacitinib; Psoriatic arthritis; Rheumatoid arthritis; Medicine; Dermatology; Arthritis; Internal medicine","score_opus":0.004905192711362207,"score_gpt":0.22037863563510987,"score_spread":0.21547344292374768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384560180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9380586,0.043252,0.0023399377,0.00068938296,0.0000635112,0.0003967539,0.0039040672,0.00012125955,0.011174445],"genre_scores_gemma":[0.99084646,0.0052723037,0.0007729449,0.00033529408,0.00016614296,0.00008763422,0.0020614734,0.000015384354,0.0004423276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98816025,0.003005859,0.0030508703,0.0011487589,0.0042829583,0.00035123827],"domain_scores_gemma":[0.9393269,0.013548433,0.038414653,0.0017879634,0.0062109693,0.000711084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011517825,0.00031062946,0.00062441226,0.0035514897,0.00038189924,0.0013480997,0.00062504073,0.0007119475,0.0018874856],"category_scores_gemma":[0.019805273,0.00021066361,0.00081990665,0.0039588483,0.00057149515,0.0010559337,0.0004902556,0.00051690184,0.0007904393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006567205,0.000060858507,0.94297284,0.00067566574,0.0001835657,0.002274803,0.00046997302,0.00013803616,0.0010776427,0.0001378588,0.0013339932,0.050018054],"study_design_scores_gemma":[0.00005103829,0.00087903335,0.9550827,0.00052072864,0.00043712667,0.029240044,0.0006158023,0.0005473508,0.0023999144,0.00016801272,0.010033076,0.00002515207],"about_ca_topic_score_codex":0.0011026936,"about_ca_topic_score_gemma":0.0009557761,"teacher_disagreement_score":0.011517825,"about_ca_system_score_codex":0.0006844296,"about_ca_system_score_gemma":0.0007905919,"threshold_uncertainty_score":0.060912788},"labels":[],"label_agreement":null},{"id":"W4385064820","doi":"10.1007/s40744-023-00573-x","title":"Is the Rate of Responders to Hyaluronic Acid Injection for Patients with Knee Osteoarthritis Stable Over Time? Post hoc Analyses of a 6-Month Follow-Up Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Post-hoc analysis; Internal medicine; Hyaluronic acid; Sodium hyaluronate; Population; Physical therapy; Body mass index; Surgery","score_opus":0.017844555350789697,"score_gpt":0.2877707440129409,"score_spread":0.2699261886621512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385064820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893206,0.0005495564,0.000093924675,0.000027508482,0.000012575459,0.000031197844,0.00018422102,0.0000042675038,0.00016458736],"genre_scores_gemma":[0.9993961,0.000066444285,0.00004853482,0.000019405961,0.000017136204,0.000034155517,0.00024955047,0.0000015583338,0.00016714942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688137,0.0014654092,0.00033618553,0.0004615809,0.000548879,0.00030657294],"domain_scores_gemma":[0.9937484,0.002125457,0.002667609,0.00064499275,0.0004378691,0.0003757498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048961737,0.00029057055,0.0009103137,0.00063431676,0.0003680238,0.0006143516,0.0004161121,0.00080475205,0.001858932],"category_scores_gemma":[0.0053460645,0.0002544789,0.001959355,0.000513029,0.0002567794,0.00057944236,0.0004237787,0.0007075884,0.00040262664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019736223,0.00053813466,0.96889395,0.00010335335,0.0013716874,0.00012613158,0.00019814199,0.00008423339,0.0009094448,0.00001316622,0.00019956619,0.007826007],"study_design_scores_gemma":[0.00024217989,0.00527055,0.99308866,0.000011074387,0.00045469592,0.0001483814,0.00011721233,0.00022210475,0.00020902194,0.00001132847,0.00021513113,0.000009704607],"about_ca_topic_score_codex":0.0005430875,"about_ca_topic_score_gemma":0.00061900716,"teacher_disagreement_score":0.0048961737,"about_ca_system_score_codex":0.00019416798,"about_ca_system_score_gemma":0.00023290279,"threshold_uncertainty_score":0.025893807},"labels":[],"label_agreement":null},{"id":"W4386001822","doi":"10.1007/s40744-023-00582-w","title":"Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Genentech; Janssen Scientific Affairs; Janssen Research and Development; Novavax; Jazz Pharmaceuticals; Sun Pharma; Regeneron Pharmaceuticals; University of Pennsylvania; Gilead Sciences; Childhood Arthritis and Rheumatology Research Alliance; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Pfizer; CSL Behring; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Psoriasis; Visual analogue scale; Arthritis; Population; Psoriasis Area and Severity Index; Confidence interval; BASDAI; Physical therapy; Dermatology","score_opus":0.030470400480237355,"score_gpt":0.28420683598653346,"score_spread":0.2537364355062961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386001822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995119,0.0006532247,0.00011222403,0.000053067684,0.0000042074034,0.000030782187,0.0035134486,0.0000075376242,0.000506506],"genre_scores_gemma":[0.99532795,0.0001860443,0.00013575601,0.000046396908,0.000012671562,0.00004674894,0.004136704,0.000002996917,0.00010475786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668413,0.0014301811,0.000538089,0.00052667037,0.00064911984,0.00017178866],"domain_scores_gemma":[0.98984104,0.0018299147,0.006684202,0.0006766063,0.0005555385,0.00041262057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004135242,0.00018911654,0.0005950023,0.0005782215,0.00025946507,0.00075498136,0.00046344992,0.0003885064,0.0010936023],"category_scores_gemma":[0.00673428,0.00017381144,0.0008237244,0.0010720423,0.00022791483,0.0006705275,0.00052471913,0.0004800963,0.00031738594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015120945,0.00010228836,0.9933134,0.000059287424,0.00029219218,0.000019566585,0.000059697228,0.00009814636,0.000094453695,0.000011035287,0.00027057296,0.0041672643],"study_design_scores_gemma":[0.00011870549,0.00049492775,0.9982546,0.000019399571,0.00015049677,0.0001367044,0.00007800302,0.00023725627,0.000080365135,0.000013700921,0.00040924974,0.000006621536],"about_ca_topic_score_codex":0.0023957791,"about_ca_topic_score_gemma":0.0035789895,"teacher_disagreement_score":0.004135242,"about_ca_system_score_codex":0.00042432867,"about_ca_system_score_gemma":0.0003852645,"threshold_uncertainty_score":0.02186948},"labels":[],"label_agreement":null},{"id":"W4386438083","doi":"10.1007/s40744-023-00590-w","title":"Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses","year":2023,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Gilead Sciences","keywords":"Medicine; Rheumatoid arthritis; Placebo; Internal medicine; Post-hoc analysis; Methotrexate; Radiography; Surgery; Pathology","score_opus":0.13131910439501193,"score_gpt":0.4747900576888363,"score_spread":0.3434709532938244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386438083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014239566,0.9957553,0.0005879925,0.00038820773,0.00034012517,0.00052123435,0.0004586136,0.000020263473,0.00050437753],"genre_scores_gemma":[0.025257833,0.968665,0.0023310839,0.0013332072,0.000515316,0.00095060794,0.0005748524,0.00003345408,0.00033864146],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881777,0.0051178024,0.004360971,0.0006916565,0.0014688453,0.00018305867],"domain_scores_gemma":[0.93520206,0.045465153,0.012020307,0.0013894724,0.0055559576,0.00036706077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023424609,0.0011648894,0.0063685356,0.0026530784,0.00026582953,0.0027408272,0.001943998,0.001102253,0.002916313],"category_scores_gemma":[0.054554544,0.0006916358,0.0093332715,0.0026258267,0.0007142662,0.0013585782,0.0010355382,0.0017226426,0.00034884346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045814137,0.00008186066,0.0014142701,0.7285131,0.055441342,0.00012213404,0.0002720192,0.00033835508,0.0012652784,0.0007220534,0.0066445484,0.20060365],"study_design_scores_gemma":[0.0044911797,0.003653509,0.012617045,0.55888385,0.2926299,0.00075415644,0.00033911268,0.0004461761,0.003234523,0.0015354815,0.12125606,0.00015908093],"about_ca_topic_score_codex":0.0013004637,"about_ca_topic_score_gemma":0.0038186326,"teacher_disagreement_score":0.023424609,"about_ca_system_score_codex":0.0015946886,"about_ca_system_score_gemma":0.0033809477,"threshold_uncertainty_score":0.12388265},"labels":[],"label_agreement":null},{"id":"W4386591807","doi":"10.1007/s40744-023-00589-3","title":"Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada)","funders":"","keywords":"Psoriatic arthritis; Medicine; Observational study; Clinical Practice; Arthritis; Internal medicine; Physical therapy","score_opus":0.09776755823014459,"score_gpt":0.37334026600450426,"score_spread":0.27557270777435966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386591807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545056,0.0015389184,0.00036574606,0.000046271023,0.0000075768257,0.00016706131,0.0020451327,0.000010709593,0.00036810333],"genre_scores_gemma":[0.9943973,0.00053628784,0.00073364034,0.0000943119,0.000055928118,0.00024891066,0.0036807333,0.000008540883,0.00024444176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604034,0.0014629397,0.000540026,0.0006246499,0.0010355104,0.00029652388],"domain_scores_gemma":[0.991045,0.0019960692,0.0044673835,0.0012344114,0.00059451064,0.0006626403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038638134,0.00050129346,0.001806908,0.0009910025,0.0007269522,0.0012969613,0.0006049858,0.0007910218,0.001089823],"category_scores_gemma":[0.009500554,0.00061669643,0.0011790651,0.002038944,0.0004513599,0.0008173274,0.0008520144,0.0011183955,0.00041305812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019672208,0.0013508986,0.9469742,0.0007788538,0.001099607,0.0005889214,0.0010195802,0.00039920895,0.0023961153,0.00008094616,0.001115632,0.024523843],"study_design_scores_gemma":[0.003102332,0.0068494123,0.98299557,0.00013213654,0.0010261966,0.001305829,0.00027738995,0.00053535565,0.0008592292,0.00007060669,0.002783567,0.000062415565],"about_ca_topic_score_codex":0.0023264051,"about_ca_topic_score_gemma":0.0032079557,"teacher_disagreement_score":0.0038638134,"about_ca_system_score_codex":0.0006149617,"about_ca_system_score_gemma":0.0009648844,"threshold_uncertainty_score":0.020434022},"labels":[],"label_agreement":null},{"id":"W4387529687","doi":"10.1007/s40744-023-00592-8","title":"Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"Janssen Research and Development","keywords":"Psoriatic arthritis; Medicine; Placebo; Dermatology; Randomized controlled trial; Physical therapy; Phase (matter); Placebo-controlled study; Psoriasis; Internal medicine; Alternative medicine; Double blind; Pathology","score_opus":0.009355531925551755,"score_gpt":0.2923530906948628,"score_spread":0.28299755876931104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387529687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889843,0.005766507,0.0003002746,0.00039076005,0.00019012511,0.0014634439,0.0013473587,0.00009493187,0.0014623654],"genre_scores_gemma":[0.9898201,0.0027945833,0.0007472127,0.0008845859,0.00030607928,0.0022383728,0.0014292037,0.000017560309,0.0017622518],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994398,0.00025745653,0.00004073461,0.000091637135,0.000064444415,0.000105880965],"domain_scores_gemma":[0.9990614,0.00017831095,0.0003074729,0.0000747606,0.00007968843,0.00029838094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018195569,0.001201858,0.002422401,0.00033361447,0.00046782632,0.00089272996,0.00066469243,0.0015093539,0.0031224608],"category_scores_gemma":[0.0012669004,0.0005696983,0.0021145088,0.0003694667,0.0006481061,0.0009844501,0.00043031212,0.0020623675,0.0006539078],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95368063,0.009443472,0.0040529254,0.0009874862,0.0013740865,0.00008709035,0.00009765067,0.00031408056,0.0041047535,0.00007671907,0.0012259113,0.024555098],"study_design_scores_gemma":[0.8474747,0.13301234,0.01620649,0.000072617106,0.0010933863,0.00009442574,0.000046878016,0.00029117384,0.0006315573,0.0001283245,0.0009257105,0.000022366543],"about_ca_topic_score_codex":0.000650642,"about_ca_topic_score_gemma":0.0022255648,"teacher_disagreement_score":0.0031224608,"about_ca_system_score_codex":0.0005445002,"about_ca_system_score_gemma":0.00088372437,"threshold_uncertainty_score":0.010445654},"labels":[],"label_agreement":null},{"id":"W4388792712","doi":"10.1007/s40744-023-00625-2","title":"Cross-Sectional and Longitudinal Associations of Comorbidities with Knee Symptoms and Radiographic Abnormalities of Osteoarthritis","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Comorbidity; Odds ratio; Internal medicine; Confidence interval; Physical therapy; Knee pain; Diabetes mellitus; Cross-sectional study; Pathology","score_opus":0.022430055463650674,"score_gpt":0.2754877570209315,"score_spread":0.2530577015572808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388792712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985765,0.00053121656,0.0001798871,0.0000507436,0.000009569548,0.000008042805,0.00042852148,0.0000032168164,0.00021231385],"genre_scores_gemma":[0.9991486,0.00016140938,0.0001378671,0.000032892534,0.000012549117,0.000015228794,0.00038417696,0.0000010719695,0.00010621749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991385,0.00030877962,0.00008544404,0.00018208375,0.00015448178,0.000130749],"domain_scores_gemma":[0.99588734,0.00082611805,0.0019437785,0.00029424095,0.0006013229,0.00044721956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002132427,0.0002404578,0.000282295,0.00054549106,0.00041377282,0.0006312179,0.00030802988,0.00044511913,0.0015786188],"category_scores_gemma":[0.00507467,0.00035695566,0.00045258974,0.00075352227,0.00022541484,0.00042514817,0.00045855017,0.0006458609,0.00018049328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034288554,0.000017910497,0.9994898,0.0000043268446,0.000055029443,0.000011894722,0.00002083738,0.000009637555,0.000038318205,0.0000055988403,0.000022600154,0.00028972316],"study_design_scores_gemma":[0.0000034448944,0.0000801132,0.9995041,0.000006179493,0.000036945585,0.00012375203,0.000060985803,0.00006725215,0.00001940419,0.000016256716,0.00007930144,0.0000021540172],"about_ca_topic_score_codex":0.004605452,"about_ca_topic_score_gemma":0.0067505855,"teacher_disagreement_score":0.004605452,"about_ca_system_score_codex":0.00024269981,"about_ca_system_score_gemma":0.00044798135,"threshold_uncertainty_score":0.011277497},"labels":[],"label_agreement":null},{"id":"W4389273395","doi":"10.1007/s40744-023-00615-4","title":"Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis","year":2023,"lang":"en","type":"erratum","venue":"Rheumatology and Therapy","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Tofacitinib; Psoriatic arthritis; Rheumatoid arthritis; Medicine; Dermatology; Psoriasis; Internal medicine","score_opus":0.06315086854079685,"score_gpt":0.3904287381111574,"score_spread":0.32727786957036054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389273395","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020410209,0.0007888128,0.00088117423,0.072263315,0.91784763,0.000039970037,0.003453589,0.0006647483,0.0038566722],"genre_scores_gemma":[0.017700315,0.008517327,0.0098429825,0.22829811,0.48315307,0.00032488824,0.009044125,0.002862131,0.24025705],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99312145,0.0011838947,0.0014268503,0.0007150899,0.0030570736,0.00049571414],"domain_scores_gemma":[0.9454445,0.015478825,0.0030938361,0.0023348469,0.03174907,0.0018987883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057159606,0.00244479,0.0019953535,0.0040267366,0.0020804487,0.0036147677,0.0029608223,0.006923695,0.04443639],"category_scores_gemma":[0.08219122,0.0013679665,0.0019073416,0.002756766,0.0017354524,0.0019231435,0.0014043495,0.011329585,0.033436865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021766564,0.000005244461,0.00006752436,0.00005668514,0.0000076715,0.00014022899,0.000010932814,0.000029063089,0.00002342313,0.00022916141,0.9961361,0.0032720915],"study_design_scores_gemma":[0.00010372966,0.000033969358,0.0012552427,0.0005520082,0.000060601702,0.0009360194,0.00006305072,0.0003949214,0.00041652253,0.0012799555,0.9948566,0.000047323072],"about_ca_topic_score_codex":0.028886668,"about_ca_topic_score_gemma":0.028588647,"teacher_disagreement_score":0.04443639,"about_ca_system_score_codex":0.004233416,"about_ca_system_score_gemma":0.0062361686,"threshold_uncertainty_score":0.14865458},"labels":[],"label_agreement":null},{"id":"W4390839319","doi":"10.1007/s40744-023-00629-y","title":"Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthritis Research Centre of Canada; McMaster University","funders":"Pfizer","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Rheumatoid arthritis; Health care; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Virology; Economic growth; Immunology; Economics; Disease; Outbreak; Internal medicine; Infectious disease (medical specialty)","score_opus":0.029639278951661466,"score_gpt":0.3618202045383068,"score_spread":0.33218092558664536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390839319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963567,0.00068363606,0.00006061898,0.00108151,0.000026934522,0.000015641133,0.0001021767,0.000003004114,0.0016697246],"genre_scores_gemma":[0.9984475,0.0005493252,0.00007966786,0.00059656496,0.000011473785,0.000016222657,0.00003998387,0.0000018214602,0.00025758732],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9986072,0.0007444221,0.00009551447,0.00008351077,0.00014276024,0.00032663473],"domain_scores_gemma":[0.998216,0.0005066586,0.00041260797,0.00004214033,0.0001744341,0.00064824196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017260958,0.00018817169,0.00036084763,0.00037263896,0.0018153811,0.0014366385,0.00027776152,0.0005139954,0.0025055334],"category_scores_gemma":[0.003621095,0.00021659113,0.0004441991,0.0004619915,0.0011486231,0.0014127553,0.002297232,0.0008776096,0.00022181131],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002985289,0.00020856006,0.5222587,0.0007003621,0.000120785335,0.0018092841,0.4315036,0.00010799295,0.001305275,0.0004555909,0.003916101,0.037315227],"study_design_scores_gemma":[0.00002206007,0.00044005294,0.2121227,0.0004024666,0.0000450876,0.0012129945,0.77731633,0.00009804228,0.00013524262,0.00017008581,0.007986444,0.000048522277],"about_ca_topic_score_codex":0.016301667,"about_ca_topic_score_gemma":0.025659893,"teacher_disagreement_score":0.016301667,"about_ca_system_score_codex":0.0007834794,"about_ca_system_score_gemma":0.0012159171,"threshold_uncertainty_score":0.032413542},"labels":[],"label_agreement":null},{"id":"W4391109334","doi":"10.1007/s40744-023-00631-4","title":"Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Tofacitinib; Psoriatic arthritis; Discontinuation; Dactylitis; Internal medicine; Enthesitis; BASDAI; Psoriasis Area and Severity Index; Leflunomide; Apremilast; Rheumatoid arthritis; Psoriasis; Dermatology","score_opus":0.015451302178369384,"score_gpt":0.2735925287782496,"score_spread":0.2581412265998802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391109334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421857,0.008258271,0.00053020386,0.000634889,0.00003395269,0.00032343925,0.040292513,0.0000712486,0.0076698],"genre_scores_gemma":[0.97209126,0.0019809268,0.0005156898,0.00027561907,0.0000836797,0.00030501673,0.024331914,0.000015004015,0.00040101036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553925,0.0017079071,0.0007174659,0.00054111815,0.001309336,0.00018481041],"domain_scores_gemma":[0.98627484,0.003436298,0.008069392,0.000577429,0.001070294,0.0005717027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062919348,0.00015710155,0.0007200989,0.00070230325,0.00025578222,0.0009206056,0.00045386964,0.00029538092,0.0020081142],"category_scores_gemma":[0.009266949,0.00014299034,0.0008171974,0.001983018,0.00019315939,0.0005351831,0.00037475364,0.00049556076,0.00040718206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061789723,0.00020230703,0.9595981,0.00053068245,0.0009993648,0.000049725964,0.000070953014,0.0004241933,0.00024083052,0.000102171856,0.0042657033,0.027336989],"study_design_scores_gemma":[0.0015624602,0.0010460796,0.9909464,0.00019470553,0.0008481021,0.00033935488,0.000077466306,0.00058003905,0.0003478885,0.00009782149,0.003938298,0.00002128841],"about_ca_topic_score_codex":0.0025996964,"about_ca_topic_score_gemma":0.0043430193,"teacher_disagreement_score":0.0062919348,"about_ca_system_score_codex":0.0005530669,"about_ca_system_score_gemma":0.0011259854,"threshold_uncertainty_score":0.033275366},"labels":[],"label_agreement":null},{"id":"W4391749966","doi":"10.1007/s40744-024-00643-8","title":"Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sodium hyaluronate; Osteoarthritis; Sodium; Hyaluronic acid; Chondroitin sulphate; Medicine; Chemistry; Surgery; Anatomy; Pathology; Alternative medicine; Glycosaminoglycan; Organic chemistry","score_opus":0.00844465405434613,"score_gpt":0.23928414783507942,"score_spread":0.2308394937807333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391749966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515176,0.0038893565,0.00023530505,0.000058857404,0.00001746468,0.00020431513,0.00009906292,0.00001918599,0.0003246767],"genre_scores_gemma":[0.9983012,0.0008005422,0.00030453937,0.00008349817,0.000040570103,0.00016269431,0.0001344445,0.0000024294911,0.00017000905],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995414,0.0002447166,0.00005604384,0.000056212346,0.00006867905,0.000033021934],"domain_scores_gemma":[0.9987348,0.0003878942,0.0005018204,0.000086090884,0.00007378379,0.00021562217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011831959,0.0005015322,0.001078544,0.0002406789,0.00016752443,0.00043065968,0.00036160988,0.0006630784,0.0014511744],"category_scores_gemma":[0.0014230079,0.00021996743,0.0008393403,0.0002859459,0.0003762453,0.00037488103,0.0002299336,0.0008281683,0.00025625454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5984423,0.026430719,0.023305064,0.002294246,0.002274387,0.00036277663,0.00045752,0.0012159523,0.061013695,0.00010944077,0.0008987868,0.2831951],"study_design_scores_gemma":[0.10313553,0.83154935,0.055717465,0.00009903778,0.0007777632,0.000523734,0.00009646295,0.0009919957,0.0059407405,0.000055707485,0.0010825136,0.000029832598],"about_ca_topic_score_codex":0.0002083514,"about_ca_topic_score_gemma":0.00044087533,"teacher_disagreement_score":0.0014511744,"about_ca_system_score_codex":0.00021304697,"about_ca_system_score_gemma":0.0004295097,"threshold_uncertainty_score":0.006257415},"labels":[],"label_agreement":null},{"id":"W4392084347","doi":"10.1007/s40744-024-00642-9","title":"Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto; Memorial University of Newfoundland","funders":"Janssen Biotech; Janssen Research and Development; Janssen Scientific Affairs; Celgene; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Medicine; Randomized controlled trial; Dermatology; Physical therapy; Internal medicine; Psoriasis","score_opus":0.012672494572725464,"score_gpt":0.29787496165604904,"score_spread":0.2852024670833236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392084347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929081,0.0032262665,0.00025609374,0.0004233594,0.00021986941,0.001397136,0.00057537406,0.000064273954,0.0009293908],"genre_scores_gemma":[0.9924779,0.001499611,0.0006249067,0.0005927076,0.00024506217,0.0027427347,0.0005998432,0.0000111686,0.0012060956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993124,0.00040899636,0.000036663874,0.00009002224,0.00005803853,0.00009391886],"domain_scores_gemma":[0.999003,0.00025404457,0.00032675604,0.0000699626,0.00005835735,0.00028788418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019564498,0.001123732,0.0022080452,0.00034520417,0.00041235093,0.00091120787,0.0007485164,0.0012104529,0.0059339036],"category_scores_gemma":[0.0013987662,0.0005573927,0.0018772894,0.00036476896,0.0006731741,0.00071518536,0.00034752648,0.002317676,0.0006913471],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97911423,0.005917066,0.0009447097,0.0003186301,0.0007442483,0.00002870481,0.000034505578,0.0002520444,0.0014359341,0.000041500385,0.00043018203,0.010738338],"study_design_scores_gemma":[0.9326883,0.06245333,0.0037270968,0.00002172594,0.0003442891,0.000022486358,0.000013657266,0.0002327338,0.00017691395,0.000060277882,0.00025097036,0.000008164129],"about_ca_topic_score_codex":0.00062111305,"about_ca_topic_score_gemma":0.0016435323,"teacher_disagreement_score":0.0059339036,"about_ca_system_score_codex":0.00055957516,"about_ca_system_score_gemma":0.0009913406,"threshold_uncertainty_score":0.01985091},"labels":[],"label_agreement":null},{"id":"W4392234510","doi":"10.1007/s40744-024-00644-7","title":"Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Janssen Pharmaceuticals; Janssen Research and Development; Asia Pacific League of Associations for Rheumatology","keywords":"Ustekinumab; Medicine; Psoriatic arthritis; Internal medicine; Odds ratio; Population; Psoriasis Area and Severity Index; Psoriasis; Dermatology; Arthritis; Rheumatoid arthritis; Adalimumab","score_opus":0.13589997253204683,"score_gpt":0.3501018757925874,"score_spread":0.21420190326054056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392234510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94755566,0.035318818,0.007765358,0.00038454766,0.00040237114,0.0008632204,0.0045372816,0.00010571239,0.0030670655],"genre_scores_gemma":[0.9933555,0.001615752,0.0018924593,0.00017592362,0.000122005,0.0008249983,0.0015912886,0.000029712319,0.00039244862],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9730663,0.018514538,0.0028171146,0.0025714375,0.0025160671,0.00051448884],"domain_scores_gemma":[0.98253644,0.011078614,0.003811482,0.0016964929,0.0005302658,0.00034678594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018323842,0.00109703,0.0039611505,0.0011430238,0.00024724088,0.0012619038,0.0008657483,0.0009492148,0.0031758663],"category_scores_gemma":[0.022038532,0.00045212617,0.007819794,0.0016007052,0.00050950627,0.0010787381,0.00081317674,0.0014030361,0.00028291636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59765494,0.00053458114,0.12875113,0.0054274513,0.20763734,0.00022807447,0.00028040665,0.0029101784,0.0052874805,0.0005175511,0.0018877327,0.04888311],"study_design_scores_gemma":[0.09268624,0.086270005,0.56268644,0.00076423085,0.22439776,0.0010803196,0.00039688594,0.011400375,0.005497322,0.0039707315,0.010579924,0.000269656],"about_ca_topic_score_codex":0.00041290635,"about_ca_topic_score_gemma":0.00054398377,"teacher_disagreement_score":0.018323842,"about_ca_system_score_codex":0.00038283493,"about_ca_system_score_gemma":0.0004123938,"threshold_uncertainty_score":0.0969069},"labels":[],"label_agreement":null},{"id":"W4392237848","doi":"10.1007/s40744-024-00641-w","title":"Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); Memorial University of Newfoundland; Université Laval; Vancouver Island University; McGill University; Windsor Regional Hospital; Arthritis Research Centre of Canada; Toronto Western Hospital","funders":"UCB Pharma; Gilead Sciences; Sanofi; Amgen Canada; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Psoriatic arthritis; Tolerability; Observational study; Discontinuation; Dactylitis; Internal medicine; Nausea; Adverse effect; Physical therapy; Enthesitis; Visual analogue scale; Psoriasis; Psoriasis Area and Severity Index; Quality of life (healthcare); Arthritis; Dermatology; Nursing","score_opus":0.03489463385291654,"score_gpt":0.30566172438908634,"score_spread":0.2707670905361698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392237848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787002,0.0056402995,0.00020119459,0.00078765093,0.000031384818,0.0010468063,0.0075556925,0.000017266253,0.00601947],"genre_scores_gemma":[0.9936386,0.0010924281,0.00041295603,0.00036606082,0.000024141083,0.00034373382,0.0034278922,0.000005632588,0.0006885818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964269,0.0010973271,0.0002855593,0.000358683,0.0014757746,0.00035575544],"domain_scores_gemma":[0.99349844,0.00077570847,0.0023302278,0.0002883217,0.0021258586,0.0009814653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007089561,0.00037830597,0.0007887092,0.00059022696,0.0012357027,0.0014022606,0.00067240954,0.000609856,0.0024567284],"category_scores_gemma":[0.009778435,0.00025498332,0.001062858,0.0016802753,0.0006405343,0.0005533509,0.00063343294,0.00072614005,0.0002812004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028233422,0.0019842405,0.9207935,0.00094465545,0.001729702,0.00013147458,0.0012152977,0.000323402,0.00051430124,0.00035221418,0.0065534483,0.037224345],"study_design_scores_gemma":[0.0036816122,0.0022050894,0.98871124,0.00021500063,0.00046436375,0.00012388425,0.00028089975,0.0003528474,0.00011001892,0.00006316324,0.0037395342,0.00005219675],"about_ca_topic_score_codex":0.4003103,"about_ca_topic_score_gemma":0.51775765,"teacher_disagreement_score":0.5996897,"about_ca_system_score_codex":0.0060755755,"about_ca_system_score_gemma":0.00722879,"threshold_uncertainty_score":0.7959605},"labels":[],"label_agreement":null},{"id":"W4392641843","doi":"10.1007/s40744-024-00651-8","title":"Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Hôpital Maisonneuve-Rosemont; McMaster University; University of British Columbia; Lakeridge Health; Université de Montréal; Université Laval","funders":"AbbVie Canada","keywords":"Medicine; Rheumatoid arthritis; Interim analysis; Internal medicine; Observational study; Clinical endpoint; Adverse effect; Population; Interim; Clinical trial; Physical therapy","score_opus":0.033180781732463305,"score_gpt":0.32875538963207657,"score_spread":0.29557460789961326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392641843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627752,0.0025086545,0.0003447787,0.0004688869,0.00003545954,0.00075589115,0.030354375,0.000026947502,0.0027298506],"genre_scores_gemma":[0.9642086,0.00091928407,0.0010894147,0.00040599782,0.000056940025,0.0004971745,0.031785306,0.000012218874,0.0010250567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950446,0.0011407973,0.0003748764,0.0005813146,0.002177031,0.0006814442],"domain_scores_gemma":[0.986691,0.0013896535,0.0038997238,0.0012437953,0.0051176157,0.0016581763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070163747,0.00070990407,0.0014590696,0.0005620455,0.0018550042,0.0014220901,0.001329707,0.0008357451,0.0020190696],"category_scores_gemma":[0.011126409,0.00037150958,0.0022161966,0.0018700786,0.000565863,0.00056036084,0.0010830944,0.0013297695,0.00044865673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03668853,0.0014570778,0.9148927,0.0007295387,0.0027856089,0.00022294787,0.0009274912,0.0008783709,0.0011324572,0.00024858923,0.0071315328,0.032905113],"study_design_scores_gemma":[0.0017817187,0.0020523714,0.9906579,0.00011242443,0.0009737507,0.00012027507,0.00021770695,0.00041842947,0.00021471818,0.000037694765,0.0033494015,0.00006355719],"about_ca_topic_score_codex":0.6822443,"about_ca_topic_score_gemma":0.75321406,"teacher_disagreement_score":0.3177557,"about_ca_system_score_codex":0.009838603,"about_ca_system_score_gemma":0.017464286,"threshold_uncertainty_score":0.63925403},"labels":[],"label_agreement":null},{"id":"W4392910954","doi":"10.1007/s40744-024-00658-1","title":"Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"AbbVie","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Adverse effect; Internal medicine; Rheumatology; Randomized controlled trial","score_opus":0.019400903406484527,"score_gpt":0.28559850141689924,"score_spread":0.2661975980104147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392910954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756646,0.0013536478,0.00013445759,0.000037899397,0.000011821016,0.00007130264,0.00037135836,0.000010880668,0.00044225194],"genre_scores_gemma":[0.99819714,0.00027546543,0.00016114008,0.00008756606,0.000035047495,0.00006602765,0.00091586733,0.000002453428,0.00025930846],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987047,0.00049914705,0.00014525521,0.00017674145,0.00030789175,0.00016631468],"domain_scores_gemma":[0.99706334,0.00069693936,0.0013501261,0.00024212178,0.00026927254,0.00037824153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033727777,0.00036245995,0.0011551324,0.00027590472,0.0003851145,0.00072959403,0.00035342475,0.0005748755,0.0012734914],"category_scores_gemma":[0.001991903,0.00015527895,0.0013797804,0.00035115477,0.00037576226,0.0005435841,0.0003281732,0.0010831538,0.0003269366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44263497,0.014990366,0.37904456,0.0008736141,0.004220622,0.0004064514,0.0005569101,0.002538471,0.012997873,0.00012187914,0.0017997383,0.13981453],"study_design_scores_gemma":[0.03747498,0.32175606,0.6217349,0.0001373265,0.0036414077,0.0010829002,0.00026206498,0.0019049249,0.007687339,0.00016583991,0.0040618693,0.00009030827],"about_ca_topic_score_codex":0.00045986756,"about_ca_topic_score_gemma":0.00080135936,"teacher_disagreement_score":0.0033727777,"about_ca_system_score_codex":0.0004979422,"about_ca_system_score_gemma":0.00047304985,"threshold_uncertainty_score":0.017837167},"labels":[],"label_agreement":null},{"id":"W4392911023","doi":"10.1007/s40744-024-00654-5","title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Placebo; Internal medicine; Psoriatic arthritis; Rheumatology; Cohort; Rheumatoid arthritis; Randomized controlled trial; Gastroenterology; Physical therapy; Pathology; Alternative medicine","score_opus":0.046767378464928115,"score_gpt":0.3733697934603381,"score_spread":0.32660241499541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392911023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826043,0.006321386,0.001000191,0.000991572,0.00038057248,0.0025686314,0.0023282229,0.00019541808,0.0036096487],"genre_scores_gemma":[0.9800546,0.0034048401,0.0025996217,0.001955843,0.00047110135,0.003576079,0.004424805,0.00007018918,0.0034430078],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99854636,0.0009130198,0.00009377414,0.00011724864,0.00019332618,0.00013633481],"domain_scores_gemma":[0.9983347,0.00046445444,0.0005233154,0.00018135383,0.00013364415,0.00036255948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048991763,0.0013084805,0.0019988338,0.00031301845,0.00056512805,0.0010462028,0.0006573193,0.0015866243,0.0037141931],"category_scores_gemma":[0.0026835254,0.00052928115,0.0023218002,0.0003949314,0.0008964737,0.00091274024,0.00043578446,0.003100111,0.00067053677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94081813,0.012102735,0.0023635204,0.000766037,0.0016126857,0.000086244036,0.0000977026,0.0006840935,0.009003812,0.00018141243,0.0035342232,0.028749386],"study_design_scores_gemma":[0.8754284,0.111277,0.008455845,0.0000582745,0.00092420494,0.00012838174,0.000039086583,0.00064761494,0.0013014574,0.0001792164,0.0015229558,0.000037630158],"about_ca_topic_score_codex":0.00038698126,"about_ca_topic_score_gemma":0.0019091609,"teacher_disagreement_score":0.0048991763,"about_ca_system_score_codex":0.00043368712,"about_ca_system_score_gemma":0.0010770352,"threshold_uncertainty_score":0.025909603},"labels":[],"label_agreement":null},{"id":"W4392911057","doi":"10.1007/s40744-024-00657-2","title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Placebo; Psoriatic arthritis; Tolerability; Rheumatology; Randomized controlled trial; Psoriasis; Gastroenterology; Arthritis; Adverse effect; Dermatology; Pathology","score_opus":0.040045974397428304,"score_gpt":0.3479623500081854,"score_spread":0.3079163756107571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392911057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867666,0.0032582816,0.0008447584,0.00075856573,0.00031916698,0.0025984028,0.001684429,0.00016915756,0.0036007415],"genre_scores_gemma":[0.98078865,0.0017600541,0.0019086786,0.0016697694,0.00055823324,0.004572154,0.0033292247,0.000064412896,0.005348809],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99822325,0.001058157,0.00011935162,0.00021100482,0.00020825557,0.00017997444],"domain_scores_gemma":[0.9980742,0.0005103342,0.0004916193,0.0002711913,0.00014410006,0.0005085211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047198115,0.0017818714,0.002869312,0.000405754,0.0005510154,0.0013021475,0.0008548631,0.0024673704,0.0058978274],"category_scores_gemma":[0.0029936186,0.0008148732,0.0022688608,0.00046147406,0.0012690454,0.0016535777,0.0006087538,0.0033305823,0.0010644327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9694984,0.010312984,0.0009927722,0.0003189387,0.0006508298,0.000052835367,0.000057468595,0.00045809482,0.004452306,0.00010293813,0.0011737476,0.011928734],"study_design_scores_gemma":[0.9052443,0.08831774,0.003952036,0.000026921889,0.0003789431,0.000054230408,0.00002140713,0.00049532094,0.0005654866,0.0001520645,0.0007643882,0.000027140857],"about_ca_topic_score_codex":0.00034465583,"about_ca_topic_score_gemma":0.0011030083,"teacher_disagreement_score":0.0058978274,"about_ca_system_score_codex":0.0005023439,"about_ca_system_score_gemma":0.00097242167,"threshold_uncertainty_score":0.024961054},"labels":[],"label_agreement":null},{"id":"W4394911994","doi":"10.1007/s40744-024-00660-7","title":"Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Ankylosing spondylitis; Post-hoc analysis; Medicine; Randomized controlled trial; Physical therapy; Inflammation; Clinical trial; Spondylitis; Internal medicine; Arthritis","score_opus":0.02612725016961004,"score_gpt":0.285099333464549,"score_spread":0.258972083294939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394911994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983914,0.00834566,0.0017725184,0.00039426237,0.00038627692,0.0028535253,0.00122922,0.00008230611,0.001022161],"genre_scores_gemma":[0.98949933,0.002045145,0.0022843326,0.00035441984,0.00035127258,0.0033676308,0.0012530056,0.000031216245,0.0008136957],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9892129,0.008098041,0.0007144502,0.00090971857,0.0005542438,0.00051063084],"domain_scores_gemma":[0.9869142,0.007941517,0.002458679,0.0012899232,0.0007122736,0.0006834599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017238932,0.0021289578,0.0054655513,0.00048281316,0.0004511665,0.0017330848,0.0009531644,0.0011407987,0.0039648926],"category_scores_gemma":[0.011362802,0.00064247055,0.0077403416,0.0006406167,0.0011598129,0.0010868054,0.0007333499,0.0018294766,0.00038364748],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9666917,0.0020598478,0.0035123026,0.00087081967,0.016517326,0.000036573387,0.000044100198,0.00052732823,0.0014768109,0.00005025011,0.00032133257,0.007891625],"study_design_scores_gemma":[0.7638941,0.17382018,0.027715944,0.00013693023,0.029605048,0.000078991616,0.00007591052,0.0018389903,0.0015405496,0.0003469802,0.00088303094,0.00006340687],"about_ca_topic_score_codex":0.0003667612,"about_ca_topic_score_gemma":0.0007424867,"teacher_disagreement_score":0.017238932,"about_ca_system_score_codex":0.00073445385,"about_ca_system_score_gemma":0.0014646644,"threshold_uncertainty_score":0.09116924},"labels":[],"label_agreement":null},{"id":"W4396596535","doi":"10.1007/s40744-024-00662-5","title":"Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data","year":2024,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; Pfizer (Canada)","funders":"Celgene; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Biogen","keywords":"Medicine; Tofacitinib; Psoriatic arthritis; Ankylosing spondylitis; Rheumatoid arthritis; Internal medicine; Psoriasis; Mace; Risk factor; Dermatology","score_opus":0.10360238364189833,"score_gpt":0.4160644502500809,"score_spread":0.31246206660818254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396596535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012174257,0.9953934,0.0000918135,0.0032843763,0.0008353092,0.000010550786,0.00007119659,0.000004333368,0.00018735741],"genre_scores_gemma":[0.0021080892,0.9914846,0.0003277059,0.0039132396,0.001893219,0.00004148036,0.00010390569,0.000004234206,0.00012364266],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99787426,0.00062505685,0.00071994535,0.00022059308,0.0004991983,0.00006102535],"domain_scores_gemma":[0.98969424,0.007363502,0.0010950419,0.00007781462,0.001628924,0.00014041888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030586715,0.00068622245,0.0029706187,0.003033731,0.00034893208,0.0014859976,0.0009816034,0.0014236646,0.0019902599],"category_scores_gemma":[0.014700727,0.0003479744,0.00198384,0.0028283885,0.00044951338,0.0011788505,0.0005338366,0.0018203304,0.0004054101],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042838772,0.000041492916,0.0018070005,0.115559116,0.001991095,0.00015990499,0.00021751349,0.00025143358,0.0002895094,0.0016599437,0.12935893,0.7482357],"study_design_scores_gemma":[0.00043912383,0.00043504994,0.012620412,0.26990527,0.008330187,0.0018673454,0.00049210904,0.00046202567,0.00028704383,0.004312132,0.70070225,0.00014718369],"about_ca_topic_score_codex":0.0032232378,"about_ca_topic_score_gemma":0.007026798,"teacher_disagreement_score":0.0032232378,"about_ca_system_score_codex":0.0012213099,"about_ca_system_score_gemma":0.0027687727,"threshold_uncertainty_score":0.016175985},"labels":[],"label_agreement":null},{"id":"W4399435000","doi":"10.1007/s40744-024-00672-3","title":"Regional Differences in Diagnosis Journey and Healthcare Utilization: Results from the International Map of Axial Spondyloarthritis (IMAS)","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"Novartis Pharma; Celgene; UCB Pharma; Pfizer; Eli Lilly and Company","keywords":"Axial spondyloarthritis; Medicine; Health care; Sample (material); Physical therapy; Cartography; Ankylosing spondylitis; Political science; Geography; Internal medicine; Physics; Sacroiliitis","score_opus":0.06497558158008217,"score_gpt":0.31370339809962555,"score_spread":0.2487278165195434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399435000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925113,0.0004400079,0.00015121969,0.00014953704,0.000007191413,0.000012752915,0.0059391153,0.000008327607,0.0007805535],"genre_scores_gemma":[0.99686664,0.00016160043,0.00015085819,0.000027499687,0.0000064763585,0.000016503582,0.0026693703,0.0000036315082,0.000097409444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993186,0.00019613212,0.000096454896,0.0001423081,0.00012050219,0.00012588815],"domain_scores_gemma":[0.99734515,0.000361279,0.0015410815,0.00016660815,0.00032450008,0.000261485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009601374,0.00026003938,0.00027734155,0.0013439896,0.0002824929,0.00072563,0.0003452348,0.00029050102,0.001749081],"category_scores_gemma":[0.0035137867,0.00016831698,0.0007467691,0.002751007,0.00020113798,0.00073093263,0.0012320611,0.00034816534,0.00038101902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003710988,0.000007696032,0.9983777,0.000024595616,0.000056804893,0.000019545445,0.00018756282,0.00007336105,0.00004503831,0.000014027838,0.00023745917,0.00091907685],"study_design_scores_gemma":[0.000001955039,0.000021647667,0.9989298,0.000012876705,0.000017066543,0.00006751725,0.00050569174,0.00011198218,0.000020140911,0.00001133082,0.0002973123,0.0000025465463],"about_ca_topic_score_codex":0.01860712,"about_ca_topic_score_gemma":0.015256149,"teacher_disagreement_score":0.01860712,"about_ca_system_score_codex":0.0003479152,"about_ca_system_score_gemma":0.00043877988,"threshold_uncertainty_score":0.036997616},"labels":[],"label_agreement":null},{"id":"W4399671356","doi":"10.1007/s40744-024-00686-x","title":"Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial","year":2024,"lang":"en","type":"erratum","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"","keywords":"Ixekizumab; Ankylosing spondylitis; Medicine; Post-hoc analysis; Randomized controlled trial; Physical therapy; Spondylitis; Alternative medicine; Post hoc; Clinical trial; Internal medicine; Secukinumab; Pathology; Arthritis","score_opus":0.01737343005230877,"score_gpt":0.2766401411234276,"score_spread":0.2592667110711188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399671356","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022149546,0.002722006,0.0004997535,0.049256645,0.9418479,0.00015655877,0.0040057953,0.00018257952,0.0011071606],"genre_scores_gemma":[0.0212193,0.012155272,0.006732705,0.20390955,0.6725423,0.0024024018,0.006183344,0.0014779555,0.07337723],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98568684,0.005757311,0.0026,0.0014325383,0.003533861,0.0009893724],"domain_scores_gemma":[0.89331335,0.05618907,0.0069431583,0.004441871,0.035096407,0.004016198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023071826,0.0035417613,0.0050375666,0.0032247151,0.0020754891,0.004920355,0.004522999,0.0071573583,0.060927846],"category_scores_gemma":[0.18312804,0.0019520639,0.0043695206,0.0038566545,0.0022263168,0.0019455336,0.0013859688,0.012623926,0.014806782],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004990538,0.000016757573,0.00014880541,0.0009205404,0.00019829304,0.0000981825,0.000014524644,0.000041439096,0.000025785414,0.00023574442,0.99392456,0.0038762724],"study_design_scores_gemma":[0.014904358,0.0004617593,0.00921261,0.008462105,0.0037721924,0.00097126636,0.00020963042,0.0013867074,0.0009002178,0.003697682,0.9557284,0.00029297514],"about_ca_topic_score_codex":0.016379347,"about_ca_topic_score_gemma":0.02240508,"teacher_disagreement_score":0.060927846,"about_ca_system_score_codex":0.0058833775,"about_ca_system_score_gemma":0.011011239,"threshold_uncertainty_score":0.20382392},"labels":[],"label_agreement":null},{"id":"W4400007994","doi":"10.1007/s40744-024-00684-z","title":"Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"UCB Pharma","keywords":"Secukinumab; Ixekizumab; Medicine; Axial spondyloarthritis; Matching (statistics); Radiography; Internal medicine; Radiology; Arthritis; Psoriatic arthritis; Pathology","score_opus":0.03613181706726756,"score_gpt":0.30800036190621094,"score_spread":0.2718685448389434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400007994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8274204,0.12929484,0.01566818,0.0010127112,0.0024637412,0.0032704093,0.012342214,0.00042536476,0.008102207],"genre_scores_gemma":[0.98677826,0.0043304064,0.0035065573,0.00046569417,0.00021056205,0.0015701344,0.001784196,0.00003808681,0.0013160398],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9813685,0.013596264,0.0015938851,0.0019698325,0.001045113,0.0004265411],"domain_scores_gemma":[0.99114686,0.0053301263,0.0018957541,0.0010248013,0.0004208119,0.00018154611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01714364,0.0025157614,0.0069805933,0.0011106669,0.00030050916,0.0017865151,0.0015333637,0.0016156111,0.005934132],"category_scores_gemma":[0.02577448,0.0010506735,0.025235742,0.0011613402,0.0005929029,0.0009331915,0.0012308969,0.0020609892,0.0004821412],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30358577,0.0003321291,0.011458106,0.013102434,0.64667004,0.00007968039,0.000096606935,0.0038549155,0.001174291,0.00055729557,0.001096094,0.01799269],"study_design_scores_gemma":[0.09084649,0.01648531,0.034706775,0.0012685347,0.8424122,0.00019864246,0.00006739173,0.005632705,0.0024994477,0.0018990231,0.00388144,0.00010212831],"about_ca_topic_score_codex":0.0032709546,"about_ca_topic_score_gemma":0.0025284558,"teacher_disagreement_score":0.01714364,"about_ca_system_score_codex":0.001146866,"about_ca_system_score_gemma":0.00092462206,"threshold_uncertainty_score":0.09066528},"labels":[],"label_agreement":null},{"id":"W4400281428","doi":"10.1007/s40744-024-00677-y","title":"Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Amgen; Pfizer; AstraZeneca; Taichung Veterans General Hospital; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Internal medicine; Placebo; Post-hoc analysis; Erythrocyte sedimentation rate; Janus kinase inhibitor; Odds ratio; Rheumatology; Abatacept; Physical therapy; Pathology; Rituximab","score_opus":0.04824780470720594,"score_gpt":0.403260588564786,"score_spread":0.35501278385758006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400281428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79462224,0.13223848,0.037132733,0.0016941531,0.002650192,0.007954523,0.015918938,0.00068879576,0.0070999726],"genre_scores_gemma":[0.9777338,0.0044368687,0.007121645,0.00075017964,0.00062145246,0.005174769,0.0028516639,0.00017287403,0.0011368141],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9323253,0.05166129,0.0064681363,0.0046838694,0.0035384726,0.0013230448],"domain_scores_gemma":[0.9205985,0.061276723,0.010058457,0.0050492953,0.0024150913,0.0006018452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06925329,0.0027833234,0.006565322,0.002076619,0.0004429587,0.0025859603,0.0010821151,0.0011111748,0.0041908873],"category_scores_gemma":[0.07381795,0.0007169217,0.023234112,0.0019498466,0.00075379806,0.001515927,0.0012654484,0.0012198903,0.00034941593],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1521903,0.00028222956,0.05305494,0.009446,0.75321007,0.00028717096,0.00017538093,0.0032408072,0.0025176015,0.00035389155,0.0021126622,0.023128984],"study_design_scores_gemma":[0.031477515,0.022466872,0.1470508,0.0013000518,0.7722213,0.0005600496,0.00022274513,0.008897294,0.005534029,0.0021526483,0.007893756,0.00022286306],"about_ca_topic_score_codex":0.00063975976,"about_ca_topic_score_gemma":0.0009020065,"teacher_disagreement_score":0.06925329,"about_ca_system_score_codex":0.00088070397,"about_ca_system_score_gemma":0.0018238331,"threshold_uncertainty_score":0.36625075},"labels":[],"label_agreement":null},{"id":"W4400297889","doi":"10.1007/s40744-024-00678-x","title":"Gender Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Medac; Celltrion; Genentech; Celgene; Biogen; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Perception; Medicine; Family medicine; Disease; Psoriasis; Physical therapy; Psychology; Dermatology; Internal medicine","score_opus":0.024416752956582525,"score_gpt":0.305439583707307,"score_spread":0.2810228307507245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400297889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833953,0.00014861487,0.000054719192,0.00009526638,0.000004088571,0.000011035522,0.0006492264,0.0000024346293,0.0006950936],"genre_scores_gemma":[0.9994067,0.0000665271,0.000049713148,0.000071577306,0.000005273395,0.0000115711655,0.0002851136,0.0000011240304,0.00010244521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988932,0.0005209879,0.00010798436,0.00009841731,0.00021663985,0.00016283752],"domain_scores_gemma":[0.9971744,0.0006958003,0.0013753637,0.00008332608,0.00028818057,0.00038298318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016749694,0.00016701675,0.00025838404,0.00076952204,0.00024372662,0.00048942794,0.00014351773,0.0002529959,0.0019112983],"category_scores_gemma":[0.0040022032,0.00011371839,0.0003424018,0.0008208487,0.00023398807,0.00058400107,0.0006206672,0.00028582325,0.0003148078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054607437,0.000030383415,0.9970324,0.000014120062,0.000019924923,0.000025949577,0.00047454468,0.000012662841,0.000056554363,0.000008151253,0.00014780289,0.0021228124],"study_design_scores_gemma":[0.0000052161963,0.00012646717,0.9979394,0.000008906019,0.00000977759,0.0001384252,0.0013540601,0.000051255927,0.000033184584,0.0000112631815,0.00031819535,0.0000037811144],"about_ca_topic_score_codex":0.002059751,"about_ca_topic_score_gemma":0.0029501193,"teacher_disagreement_score":0.002059751,"about_ca_system_score_codex":0.00018887181,"about_ca_system_score_gemma":0.0002060194,"threshold_uncertainty_score":0.008858144},"labels":[],"label_agreement":null},{"id":"W4400426358","doi":"10.1007/s40744-024-00696-9","title":"A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); University of Alberta","funders":"AbbVie Canada","keywords":"Medicine; Methotrexate; Rheumatoid arthritis; Internal medicine; Discontinuation; Tolerability; Rheumatology; Tapering; Infliximab; Antifolate; Prednisone; Concomitant; Surgery; Gastroenterology; Adverse effect; Tumor necrosis factor alpha; Antimetabolite","score_opus":0.015368373917730912,"score_gpt":0.28907250007372454,"score_spread":0.2737041261559936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400426358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9350243,0.017737921,0.00048605312,0.00055155513,0.00006428865,0.001051068,0.03476745,0.000078060366,0.010239249],"genre_scores_gemma":[0.9826126,0.0062306556,0.0007532384,0.00033749078,0.000031195075,0.00021057914,0.009231709,0.000014392213,0.00057818374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997218,0.00021208568,0.0004961816,0.00047915961,0.0012638739,0.0003305869],"domain_scores_gemma":[0.9879411,0.0012066982,0.0045956844,0.00035250734,0.0050651794,0.00083888846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012060204,0.0002765916,0.0005543895,0.0048344177,0.0016086616,0.0010640774,0.00081211654,0.00038716817,0.0023575993],"category_scores_gemma":[0.0064989934,0.00034333832,0.00044035772,0.009913992,0.0005207259,0.000361004,0.00050038786,0.00036467143,0.0002546274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014002867,0.000028021042,0.9815122,0.0006486758,0.00007906906,0.00083687936,0.0006813287,0.000057997142,0.00024703794,0.00008382084,0.004288571,0.01139638],"study_design_scores_gemma":[0.000016295475,0.000052111907,0.9922178,0.00032789883,0.000077292854,0.0011553569,0.00083314517,0.00011571669,0.00014719622,0.000009392251,0.005030012,0.000017761136],"about_ca_topic_score_codex":0.8396274,"about_ca_topic_score_gemma":0.8542983,"teacher_disagreement_score":0.16037261,"about_ca_system_score_codex":0.013087656,"about_ca_system_score_gemma":0.023476843,"threshold_uncertainty_score":0.3226341},"labels":[],"label_agreement":null},{"id":"W4400850096","doi":"10.1007/s40744-024-00694-x","title":"Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"AbbVie","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Adverse effect; Discontinuation; Safety profile; Refractory (planetary science); Surgery","score_opus":0.015729741154186416,"score_gpt":0.27883729372022265,"score_spread":0.26310755256603624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400850096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980844,0.00072744867,0.00008551693,0.00005083762,0.000009189098,0.00017201723,0.00046024207,0.000015236764,0.00039514658],"genre_scores_gemma":[0.99769515,0.00041695256,0.00020478907,0.00013754712,0.0000383418,0.00016971704,0.00083205895,0.000004984323,0.00050042657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996191,0.00014733872,0.000039052793,0.0000628339,0.00006742623,0.00006411328],"domain_scores_gemma":[0.999025,0.00017626445,0.0003359531,0.000082719125,0.000077968354,0.0003020709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014400232,0.00051826565,0.001350396,0.0002702799,0.00024790986,0.000514646,0.00028735775,0.00056387094,0.0015754063],"category_scores_gemma":[0.0010357724,0.0002011445,0.0011334588,0.00033033284,0.00033672914,0.0005044297,0.0002336265,0.00084490323,0.00033043392],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79246575,0.017722083,0.0625314,0.00064020586,0.0016709889,0.00035918166,0.0002406154,0.0014799864,0.023177285,0.000085069594,0.002209004,0.097418554],"study_design_scores_gemma":[0.2657557,0.44102588,0.2743998,0.00009885733,0.0020153886,0.0010841032,0.00014843569,0.0020302476,0.008977836,0.00017861689,0.004184097,0.00010104967],"about_ca_topic_score_codex":0.0005431483,"about_ca_topic_score_gemma":0.0019295602,"teacher_disagreement_score":0.0015754063,"about_ca_system_score_codex":0.0004800837,"about_ca_system_score_gemma":0.0005958865,"threshold_uncertainty_score":0.007615626},"labels":[],"label_agreement":null},{"id":"W4402454833","doi":"10.1007/s40744-024-00702-0","title":"Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; University of Saskatchewan; McGill University","funders":"Janssen Research and Development; National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Psoriatic arthritis; Post-hoc analysis; Medicine; Post hoc; Phase (matter); Arthritis; Dermatology; Internal medicine; Chemistry","score_opus":0.02272486199969252,"score_gpt":0.3481809171652812,"score_spread":0.3254560551655887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402454833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048936,0.0037568905,0.0017435818,0.0001984447,0.00012349381,0.0013235225,0.0011226367,0.0000910265,0.0011511004],"genre_scores_gemma":[0.9944354,0.00054723833,0.0014087596,0.00014825282,0.00012620642,0.0013670826,0.0009926349,0.000037219408,0.0009371122],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9921806,0.0055418867,0.0005316757,0.00073629123,0.0005613376,0.00044824727],"domain_scores_gemma":[0.98253226,0.010094415,0.0031256906,0.0025868195,0.00083070435,0.00083018636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017338555,0.0011964086,0.0026726972,0.00036410676,0.00039169774,0.0014035252,0.00069915794,0.00073794357,0.0032486646],"category_scores_gemma":[0.012653036,0.00042390637,0.00564258,0.00051731564,0.00080382964,0.0009961269,0.00056405907,0.0017638794,0.00043857415],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9358816,0.0028786478,0.017661681,0.000622158,0.015146641,0.000045859044,0.00011793116,0.0010196815,0.003565605,0.00010107726,0.00064284325,0.02231628],"study_design_scores_gemma":[0.3908355,0.3687146,0.18502009,0.0001602182,0.03647185,0.00023910424,0.00013456761,0.0042126034,0.008981377,0.0007738538,0.004312406,0.00014376297],"about_ca_topic_score_codex":0.0004311475,"about_ca_topic_score_gemma":0.0009184022,"teacher_disagreement_score":0.017338555,"about_ca_system_score_codex":0.0006924513,"about_ca_system_score_gemma":0.0015048848,"threshold_uncertainty_score":0.09169614},"labels":[],"label_agreement":null},{"id":"W4402601491","doi":"10.1007/s40744-024-00715-9","title":"Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Observational study; Medicine; Internal medicine","score_opus":0.06738414713985798,"score_gpt":0.3545384091587891,"score_spread":0.28715426201893113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402601491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929454,0.0022461459,0.00067197374,0.000115798895,0.00002938137,0.0004254695,0.0029394545,0.000023569517,0.0006028505],"genre_scores_gemma":[0.9919423,0.00087727915,0.0009296133,0.00021870677,0.00011407257,0.00033990692,0.00532182,0.000010189085,0.0002461199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947956,0.00320083,0.00053508225,0.0005056659,0.00079717056,0.0001657092],"domain_scores_gemma":[0.97932315,0.006048949,0.009496913,0.0018359969,0.0015962877,0.0016987468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010214477,0.0007805389,0.0011194177,0.00041448264,0.00039821345,0.0013034492,0.0006617041,0.0009167936,0.0018835302],"category_scores_gemma":[0.010103784,0.00039888997,0.0019081163,0.0006871399,0.0005160339,0.00090663135,0.0006330554,0.0011831005,0.0005931991],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26652336,0.007819288,0.6523959,0.0019830135,0.013462563,0.00039572635,0.0005887301,0.0015025573,0.004667014,0.00018547525,0.002101249,0.04837514],"study_design_scores_gemma":[0.039019395,0.062139213,0.88578385,0.00017641197,0.0048103775,0.0010261443,0.00019839562,0.0019200459,0.0014395483,0.00018742547,0.0031663706,0.00013286312],"about_ca_topic_score_codex":0.0004040468,"about_ca_topic_score_gemma":0.00058029604,"teacher_disagreement_score":0.010214477,"about_ca_system_score_codex":0.00043896938,"about_ca_system_score_gemma":0.00061584654,"threshold_uncertainty_score":0.054019988},"labels":[],"label_agreement":null},{"id":"W4402851582","doi":"10.1007/s40744-024-00711-z","title":"Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; Pfizer (Canada)","funders":"Pfizer; Eli Lilly and Company; Amgen","keywords":"Tofacitinib; Ankylosing spondylitis; Psoriatic arthritis; Medicine; Dermatology; Spondylitis; Internal medicine; Rheumatoid arthritis; Psoriasis; Physical therapy","score_opus":0.007827520775846628,"score_gpt":0.24537307695558855,"score_spread":0.23754555617974193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402851582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793497,0.015472398,0.0003454804,0.00030033555,0.00006256918,0.00035932846,0.0016265874,0.000029589295,0.0024540098],"genre_scores_gemma":[0.99632037,0.0016412082,0.00022353033,0.00020818852,0.0000905142,0.00020826716,0.0008559131,0.000004967108,0.00044703993],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99832934,0.0006835888,0.00022055565,0.0002641541,0.00034207565,0.0001604041],"domain_scores_gemma":[0.99795496,0.00093111163,0.0006357095,0.00011721319,0.00016188243,0.00019899994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044770744,0.00048346483,0.0015718454,0.00042078795,0.0002933496,0.0006898009,0.0002905232,0.00044284767,0.0029932898],"category_scores_gemma":[0.00310311,0.0002268603,0.0023371486,0.0005948478,0.00032971991,0.00050801627,0.00026062242,0.0008009589,0.0003004078],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5233434,0.002396894,0.24345408,0.0026962871,0.018993812,0.00024616873,0.00023427636,0.0015623645,0.009694981,0.00022185198,0.0029064717,0.1942494],"study_design_scores_gemma":[0.1272576,0.13564199,0.70130485,0.0004006027,0.018927312,0.0010351548,0.00014899697,0.0022939055,0.0055669313,0.0008411239,0.0065012425,0.0000803049],"about_ca_topic_score_codex":0.0004670608,"about_ca_topic_score_gemma":0.0015518662,"teacher_disagreement_score":0.0044770744,"about_ca_system_score_codex":0.0005517653,"about_ca_system_score_gemma":0.0010310138,"threshold_uncertainty_score":0.02367729},"labels":[],"label_agreement":null},{"id":"W4403706766","doi":"10.1007/s40744-024-00714-w","title":"Disease Overlap, Healthcare Resource Utilization, and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A REVEAL Sub-study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent","funders":"AstraZeneca","keywords":"Granulomatosis with polyangiitis; Eosinophilic; Disease; Medicine; Health care; Intensive care medicine; Dermatology; Internal medicine; Pathology; Vasculitis; Political science","score_opus":0.008011648819201663,"score_gpt":0.2404527020619614,"score_spread":0.23244105324275974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403706766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967609,0.00043878873,0.00004306306,0.00007542753,0.000004782398,0.000045765475,0.002343588,0.0000016863116,0.00028604458],"genre_scores_gemma":[0.99587893,0.00034963648,0.00010950644,0.00009055074,0.000040580424,0.00011380365,0.0033130997,0.0000029535345,0.00010095704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985071,0.00038577733,0.00032387063,0.0002823425,0.00022550292,0.0002754569],"domain_scores_gemma":[0.99658775,0.0006409303,0.001726475,0.00023050662,0.00031781045,0.0004965703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013755909,0.00043608368,0.0007431825,0.0018234277,0.00049066584,0.0012040976,0.00057119917,0.0006150048,0.001835382],"category_scores_gemma":[0.0031744537,0.00055436866,0.0020969454,0.0029687467,0.00030411448,0.0010560468,0.0019669768,0.00082851684,0.00036887225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047224085,0.000119539334,0.9971308,0.00007184172,0.0006065205,0.000069301204,0.000085425374,0.000047875576,0.00003980324,0.000025813022,0.00032130542,0.001009601],"study_design_scores_gemma":[0.00011117331,0.00030986883,0.99694294,0.000067052126,0.00048646712,0.00053411373,0.0006026763,0.00032995717,0.000049957092,0.000025073263,0.0005298991,0.000010799549],"about_ca_topic_score_codex":0.008081833,"about_ca_topic_score_gemma":0.00904498,"teacher_disagreement_score":0.008081833,"about_ca_system_score_codex":0.0008917672,"about_ca_system_score_gemma":0.00094375457,"threshold_uncertainty_score":0.016069591},"labels":[],"label_agreement":null},{"id":"W4403988753","doi":"10.1007/s40744-024-00719-5","title":"Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Université de Montréal; Pfizer (Canada); Université du Québec à Rimouski; McGill University; Memorial University of Newfoundland","funders":"Pfizer","keywords":"Tofacitinib; Rheumatoid arthritis; Medicine; Internal medicine; Physical therapy","score_opus":0.0038681404880064976,"score_gpt":0.22067613574712291,"score_spread":0.21680799525911643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403988753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616192,0.0060749077,0.00020671493,0.0005489462,0.0000307375,0.00036239313,0.027597662,0.000023728171,0.0035357978],"genre_scores_gemma":[0.9785299,0.0015205661,0.00039791976,0.0004520789,0.000050017123,0.00023025085,0.01784131,0.000014091653,0.0009639109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961021,0.0006977092,0.00026417203,0.00050143234,0.0016147165,0.00081992877],"domain_scores_gemma":[0.99406284,0.0005426355,0.0016977044,0.0006769638,0.002093495,0.00092649274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038791425,0.00092329277,0.0013848328,0.0012260327,0.0015267971,0.0013651164,0.0016152974,0.00058948685,0.0024333873],"category_scores_gemma":[0.0052816872,0.00038599054,0.0033057907,0.0040557976,0.00074777426,0.00023326038,0.0010418047,0.000938433,0.00020169337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03115944,0.00023503613,0.92012537,0.001135055,0.010988894,0.00019564728,0.00045651998,0.0008730533,0.0012568174,0.00055187935,0.0125178145,0.020504335],"study_design_scores_gemma":[0.0031124623,0.0006162132,0.9867446,0.00012847205,0.0040062345,0.00013386756,0.00020194633,0.00041849,0.00021503163,0.00007247825,0.0042983983,0.000051838295],"about_ca_topic_score_codex":0.88746,"about_ca_topic_score_gemma":0.94130677,"teacher_disagreement_score":0.11254001,"about_ca_system_score_codex":0.014155767,"about_ca_system_score_gemma":0.0259177,"threshold_uncertainty_score":0.2264055},"labels":[],"label_agreement":null},{"id":"W4406065091","doi":"10.1007/s40744-024-00731-9","title":"Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Observational study; Post-hoc analysis; Osteoarthritis; Adverse effect; Incidence (geometry); Placebo; WOMAC; Physical therapy; Internal medicine; Clinical trial; Alternative medicine; Pathology","score_opus":0.02623296896397935,"score_gpt":0.2799841190166003,"score_spread":0.25375115005262094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406065091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943276,0.0016776196,0.0005305224,0.00015971894,0.00007981854,0.0016778716,0.00074355083,0.00003550347,0.0007678399],"genre_scores_gemma":[0.99395543,0.00070071546,0.0009228364,0.000297863,0.00024629923,0.002260031,0.0010728673,0.000008823789,0.0005350802],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979073,0.0012569593,0.0001751485,0.00033624645,0.00017590159,0.00014849147],"domain_scores_gemma":[0.9945819,0.0010658186,0.002107465,0.0005829509,0.00067949627,0.0009824293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059600207,0.0010540837,0.0022689383,0.00028217502,0.0005641209,0.0009622735,0.0006755969,0.0011472796,0.0024441099],"category_scores_gemma":[0.0059715207,0.00041763118,0.0017390928,0.00037346687,0.00072903355,0.00094905973,0.00046674482,0.0018704499,0.00056461256],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94500613,0.012382118,0.014831289,0.00043515526,0.0017791189,0.00005511729,0.00015382013,0.00027721576,0.0036233764,0.00007053725,0.0006239214,0.02076216],"study_design_scores_gemma":[0.46743843,0.46984115,0.056522537,0.000090020025,0.0016918497,0.0001607809,0.00012638481,0.0010501052,0.0011798097,0.00019539613,0.0016515087,0.00005185373],"about_ca_topic_score_codex":0.00049640064,"about_ca_topic_score_gemma":0.00081075844,"teacher_disagreement_score":0.0059600207,"about_ca_system_score_codex":0.0005526435,"about_ca_system_score_gemma":0.0012202843,"threshold_uncertainty_score":0.03151995},"labels":[],"label_agreement":null},{"id":"W4408536924","doi":"10.1007/s40744-025-00751-z","title":"A Response to: Letter to the Editor Regarding Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials","year":2025,"lang":"en","type":"letter","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Tofacitinib; Post-hoc analysis; Rheumatoid arthritis; Post hoc; Medicine; Race (biology); Clinical trial; Internal medicine; Physical therapy; Gender studies; Sociology","score_opus":0.034747275011154606,"score_gpt":0.37721453177436554,"score_spread":0.34246725676321094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408536924","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004675802,0.001112977,0.00012472176,0.9383409,0.05857825,0.000036260808,0.00039325393,0.00004820252,0.0008978053],"genre_scores_gemma":[0.002852099,0.0006925837,0.00028061093,0.9236666,0.06953671,0.00007796788,0.00008543007,0.000046151552,0.0027618117],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98852473,0.004566486,0.0021973508,0.0012550396,0.0026482246,0.0008081147],"domain_scores_gemma":[0.9464162,0.034288477,0.0043799183,0.001421762,0.010179905,0.003313743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014440386,0.0010862858,0.004135686,0.0014182329,0.002619128,0.0046415795,0.0027150295,0.033617333,0.0064177527],"category_scores_gemma":[0.07380166,0.0010010088,0.0025455153,0.0018032256,0.0018773254,0.0024620653,0.0010712286,0.026730178,0.007578708],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040150367,0.000039664836,0.00065642665,0.0001537578,0.00012195569,0.00054268196,0.00006106382,0.000058401085,0.00012272339,0.00038044466,0.99230933,0.005152074],"study_design_scores_gemma":[0.0018498538,0.00046904918,0.0060394225,0.0012339287,0.00076020433,0.0023119138,0.0005931809,0.0013349409,0.00076115766,0.005863188,0.97852707,0.0002561508],"about_ca_topic_score_codex":0.004879947,"about_ca_topic_score_gemma":0.0074714455,"teacher_disagreement_score":0.033617333,"about_ca_system_score_codex":0.0059192507,"about_ca_system_score_gemma":0.0065769674,"threshold_uncertainty_score":0.07636899},"labels":[],"label_agreement":null},{"id":"W4409190435","doi":"10.1007/s40744-025-00752-y","title":"Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents","year":2025,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Lupus nephritis; Disease; Medicine; Narrative review; Systemic lupus erythematosus; Intensive care medicine; Immunology; Internal medicine","score_opus":0.14399775121294558,"score_gpt":0.48083993668567243,"score_spread":0.3368421854727268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409190435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022673747,0.9993205,0.0000378718,0.00009420229,0.00004768252,0.000017317094,0.000029986728,0.0000017680438,0.0002239017],"genre_scores_gemma":[0.0016407667,0.99783933,0.00014640941,0.00018521145,0.00006963655,0.000026099691,0.000034708755,6.628639e-7,0.00005716239],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991103,0.00021413936,0.0003378051,0.00008876274,0.00020989463,0.000039195103],"domain_scores_gemma":[0.996472,0.0026511906,0.00053186255,0.00003880404,0.000261444,0.000044773544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001421091,0.0008094685,0.0021802927,0.0039157756,0.0003623639,0.0016062856,0.0009919003,0.00088968955,0.0025758126],"category_scores_gemma":[0.004306657,0.0003370924,0.0021680417,0.00365379,0.00035664477,0.0012910714,0.0006329601,0.00094186456,0.00027367627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002953553,0.00008014716,0.00061506045,0.5750191,0.0017134037,0.00028758778,0.00027900666,0.00024417727,0.0005988042,0.0014546788,0.010145543,0.40926722],"study_design_scores_gemma":[0.00020636861,0.00060969096,0.0062185894,0.5800635,0.019211983,0.0032027655,0.00048684416,0.00031481741,0.0006252843,0.0014149044,0.3875818,0.00006346288],"about_ca_topic_score_codex":0.0015463503,"about_ca_topic_score_gemma":0.0038451054,"teacher_disagreement_score":0.0039157756,"about_ca_system_score_codex":0.0008692829,"about_ca_system_score_gemma":0.0024512704,"threshold_uncertainty_score":0.008616984},"labels":[],"label_agreement":null},{"id":"W4409255207","doi":"10.1007/s40744-025-00763-9","title":"Burden of Glucocorticoid Use and Risk of Toxicities Among Patients with Immunoglobulin-G4-Related Disease: A Retrospective US-Based Claims Study","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"IgG4-Related and Inflammatory Diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Amgen","keywords":"Glucocorticoid; Medicine; Retrospective cohort study; Disease; Antibody; Internal medicine; Immunology","score_opus":0.00373205175249349,"score_gpt":0.21559729271938205,"score_spread":0.21186524096688855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409255207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970886,0.00035421294,0.00010494307,0.00005469422,0.0000033715467,0.000019174024,0.0019235564,0.0000058899873,0.0004456579],"genre_scores_gemma":[0.9985607,0.00011031364,0.00006249284,0.000038151673,0.000007639427,0.000009830768,0.0011625105,0.0000016467609,0.00004667789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988821,0.00029840306,0.00022266516,0.0002290455,0.00026872434,0.00009895351],"domain_scores_gemma":[0.9958735,0.0006130011,0.0025907853,0.00033356767,0.00030599206,0.0002832324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011721026,0.00021155833,0.00041708173,0.0012058119,0.0003527223,0.00095813704,0.00043849743,0.00045586962,0.0012570735],"category_scores_gemma":[0.003464452,0.00034307994,0.0008457703,0.0024021696,0.0002630672,0.00056620693,0.0005662714,0.0006443841,0.00023697686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008147243,0.000018998873,0.99937004,0.000006828997,0.000057829326,0.0000249511,0.000020710515,0.000033432327,0.000036350993,0.000008421788,0.000053235664,0.00028777253],"study_design_scores_gemma":[0.000011971308,0.000090403344,0.9990521,0.000009619555,0.000052560048,0.0002117255,0.0000804492,0.0003094253,0.000030033589,0.000013178929,0.00013462598,0.0000039965507],"about_ca_topic_score_codex":0.009481408,"about_ca_topic_score_gemma":0.006749243,"teacher_disagreement_score":0.009481408,"about_ca_system_score_codex":0.000606338,"about_ca_system_score_gemma":0.00046946647,"threshold_uncertainty_score":0.018852413},"labels":[],"label_agreement":null},{"id":"W4410206040","doi":"10.1007/s40744-025-00768-4","title":"In-Person and Virtual Clinic Visit Frequency to Rheumatologists for Rheumatoid Arthritis at an Academic Medical Center Before, During, and After COVID Lockdown","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Rheumatology Research Foundation","keywords":"Coronavirus disease 2019 (COVID-19); Rheumatoid arthritis; Center (category theory); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Medicine; Family medicine; Physical therapy; Medical education; Internal medicine; Virology","score_opus":0.012851642142652499,"score_gpt":0.3207925192025876,"score_spread":0.3079408770599351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410206040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984865,0.00008028987,0.00011235194,0.00006081754,0.0000047887956,0.000009523357,0.0007731916,0.000010786923,0.00046175305],"genre_scores_gemma":[0.99906415,0.000041234824,0.00010703784,0.000027932769,0.000014457041,0.000013720469,0.0005298409,0.0000026121572,0.00019899517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908566,0.00022011608,0.000117083066,0.00018893249,0.00017962062,0.00020862145],"domain_scores_gemma":[0.99455464,0.0008502993,0.003578377,0.00014363082,0.00031379334,0.0005591763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006175705,0.00018281283,0.00017149239,0.00072034285,0.00036901102,0.0007822619,0.0004583472,0.0002405642,0.0028348188],"category_scores_gemma":[0.003969716,0.00017226594,0.0002750973,0.000849986,0.00025318775,0.00064594223,0.00081856357,0.00048076143,0.0002891716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000975225,0.000030209245,0.99653983,0.000013589571,0.000017645481,0.000034717512,0.00030128757,0.00007907296,0.000121860234,0.000010575759,0.00019839377,0.0025553415],"study_design_scores_gemma":[0.0000033160259,0.00007305269,0.99888355,0.000007907776,0.0000058860337,0.000068042544,0.00046860968,0.00020190394,0.000065614164,0.0000053763674,0.00021327524,0.0000035397584],"about_ca_topic_score_codex":0.025546089,"about_ca_topic_score_gemma":0.029262561,"teacher_disagreement_score":0.025546089,"about_ca_system_score_codex":0.001028694,"about_ca_system_score_gemma":0.00068528,"threshold_uncertainty_score":0.05079478},"labels":[],"label_agreement":null},{"id":"W4410928453","doi":"10.1007/s40744-025-00771-9","title":"A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Janssen Research and Development","keywords":"Secukinumab; Psoriatic arthritis; Medicine; Dermatology; Matching (statistics); Arthritis; Psoriasis; Internal medicine; Pathology","score_opus":0.007757000574110243,"score_gpt":0.25900967527913876,"score_spread":0.25125267470502854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410928453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98458326,0.0046930034,0.0050150305,0.00020844577,0.0002638693,0.0010991625,0.001805651,0.000064554035,0.0022670508],"genre_scores_gemma":[0.99524385,0.00031353472,0.0022364908,0.00015004518,0.000048198814,0.00072988536,0.000728669,0.000008210165,0.00054115977],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9831185,0.013629207,0.0008651342,0.0011202001,0.0007838749,0.000483075],"domain_scores_gemma":[0.9875514,0.008352541,0.0021422745,0.0011815524,0.0004500219,0.00032216441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016759925,0.0013990519,0.0023945929,0.0008085334,0.0003243508,0.0010264242,0.0011886898,0.0011507077,0.0064975587],"category_scores_gemma":[0.02351509,0.00056858157,0.0075651235,0.00072298216,0.00052184716,0.0007797003,0.0012734005,0.0013026027,0.00040461702],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7902214,0.0018529707,0.046885997,0.0036803277,0.08785891,0.00016413146,0.0003761581,0.013226694,0.00296963,0.0015414027,0.001366742,0.0498556],"study_design_scores_gemma":[0.23733136,0.27576512,0.19987564,0.0008026882,0.20144218,0.0008067626,0.00053970766,0.056268882,0.010246546,0.0077735023,0.008794817,0.00035287024],"about_ca_topic_score_codex":0.0013428433,"about_ca_topic_score_gemma":0.0012125751,"teacher_disagreement_score":0.016759925,"about_ca_system_score_codex":0.00092196144,"about_ca_system_score_gemma":0.0008081402,"threshold_uncertainty_score":0.08863598},"labels":[],"label_agreement":null},{"id":"W4411959730","doi":"10.1007/s40744-025-00780-8","title":"The Efficacy and Safety of Single Injections of Hybrid HA in the Treatment of Symptomatic Knee Osteoarthritis: A Case Series","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osteoarthritis; Medicine; Series (stratigraphy); Surgery; Alternative medicine; Pathology; Biology","score_opus":0.00967497359764782,"score_gpt":0.25288295560163165,"score_spread":0.24320798200398383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411959730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940764,0.0035512669,0.0011318086,0.00017135259,0.000055621975,0.00009401166,0.000030322815,0.0000186593,0.00087068835],"genre_scores_gemma":[0.99825627,0.00074963155,0.0003957064,0.00013130941,0.00014240637,0.00003304427,0.00003411757,0.000004076139,0.00025339198],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9993432,0.00014411937,0.00013607834,0.00012462481,0.00011565605,0.00013634059],"domain_scores_gemma":[0.998379,0.0005568723,0.0004099048,0.00019375666,0.00007929244,0.00038123492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004997327,0.0008096297,0.0010914167,0.00091298897,0.0009732424,0.0008000081,0.0008124572,0.0032107441,0.0011432818],"category_scores_gemma":[0.0026623127,0.00044958427,0.0013724909,0.0006737277,0.001248645,0.000570407,0.0005671032,0.0009433145,0.0005496911],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007771011,0.0013930443,0.05503428,0.00027087392,0.00011188201,0.9201427,0.00096385105,0.0003043006,0.006137139,0.00015307048,0.0002472623,0.014464593],"study_design_scores_gemma":[0.00018862383,0.0057097203,0.048549972,0.0000475259,0.00010040549,0.941066,0.00039564207,0.0008775271,0.0021797211,0.00008322192,0.0007563087,0.00004529516],"about_ca_topic_score_codex":0.0005649194,"about_ca_topic_score_gemma":0.000575436,"teacher_disagreement_score":0.0032107441,"about_ca_system_score_codex":0.0005112769,"about_ca_system_score_gemma":0.0004980913,"threshold_uncertainty_score":0.0038246512},"labels":[],"label_agreement":null},{"id":"W4412505388","doi":"10.1007/s40744-025-00777-3","title":"Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Johnson and Johnson; Gilead Sciences; Yale University; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Psoriatic arthritis; Post-hoc analysis; Medicine; Disease; Post hoc; Psoriasis; Dermatology; Internal medicine","score_opus":0.019156977982540794,"score_gpt":0.32475580562745837,"score_spread":0.3055988276449176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412505388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938252,0.0009524765,0.0011867052,0.00009034497,0.000077722994,0.0017258582,0.0011518834,0.0000665612,0.0009233246],"genre_scores_gemma":[0.9911835,0.00035212896,0.0019624338,0.00023028038,0.00008860185,0.0036181388,0.0013761829,0.000038968774,0.0011498316],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966845,0.002327844,0.00018279404,0.0003117802,0.00025484912,0.00023829995],"domain_scores_gemma":[0.99611557,0.0014033465,0.0010392185,0.00072496204,0.0003473811,0.00036956565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008816737,0.0009553395,0.0021576108,0.00025305574,0.00049116043,0.0007829395,0.0006677662,0.0005651394,0.0040960116],"category_scores_gemma":[0.0046182093,0.00039298082,0.00285875,0.00035713593,0.0005869262,0.0006391156,0.00048275103,0.0013248206,0.00059541356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9306808,0.008089433,0.014902661,0.00058825116,0.0062726685,0.00008401041,0.00019206094,0.00086967536,0.01247594,0.00009393246,0.0010949487,0.024655635],"study_design_scores_gemma":[0.30992332,0.537462,0.12554798,0.0000925581,0.010733498,0.00024215129,0.00015346812,0.002088847,0.00833751,0.00047280075,0.00486341,0.00008254631],"about_ca_topic_score_codex":0.00052598777,"about_ca_topic_score_gemma":0.0014004643,"teacher_disagreement_score":0.008816737,"about_ca_system_score_codex":0.00056642987,"about_ca_system_score_gemma":0.001837662,"threshold_uncertainty_score":0.04662788},"labels":[],"label_agreement":null},{"id":"W4414358510","doi":"10.1007/s40744-025-00788-0","title":"Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Bioinformatics Solutions (Canada); Memorial University of Newfoundland; NOSM University; University of Alberta; Université Laval; University of Saskatchewan","funders":"Johnson and Johnson","keywords":"Golimumab; Rheumatoid arthritis; Psoriatic arthritis; MEDLINE; Clinical trial","score_opus":0.004615602569895753,"score_gpt":0.22349841932752182,"score_spread":0.21888281675762605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414358510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918799,0.0040261876,0.00012712639,0.0003086028,0.000009785692,0.00008311954,0.0017344811,0.000010939605,0.0018197942],"genre_scores_gemma":[0.99749976,0.0011831014,0.00012914094,0.00011974585,0.000014035835,0.00001832709,0.00091659446,0.0000024451247,0.00011683792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974617,0.0005966441,0.00020470249,0.00024111109,0.0011875773,0.00030831492],"domain_scores_gemma":[0.9941759,0.00073544175,0.0025872176,0.0002316736,0.0018065926,0.00046309098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032510785,0.00030229133,0.0004345346,0.0005402976,0.00079469936,0.0009137069,0.0004898543,0.00031754936,0.001240438],"category_scores_gemma":[0.0060436367,0.00015179561,0.0008127936,0.0015897152,0.0005075132,0.00027229582,0.0004494478,0.00043218135,0.00014224388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035474196,0.00022429663,0.970134,0.00039232985,0.00072611007,0.0001008015,0.00029591488,0.0004704594,0.00046736043,0.00005879307,0.00078993913,0.022792567],"study_design_scores_gemma":[0.00045453638,0.0008202694,0.99602664,0.00008406041,0.00030174214,0.00019760728,0.00023249036,0.0003840742,0.00017548054,0.000021355083,0.0012818197,0.000019962292],"about_ca_topic_score_codex":0.49983603,"about_ca_topic_score_gemma":0.5448787,"teacher_disagreement_score":0.500164,"about_ca_system_score_codex":0.0052298214,"about_ca_system_score_gemma":0.008260152,"threshold_uncertainty_score":0.99385333},"labels":[],"label_agreement":null},{"id":"W4414651921","doi":"10.1007/s40744-025-00793-3","title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"AbbVie","keywords":"Randomized controlled trial; Clinical trial; Psoriasis; Adverse effect; MEDLINE","score_opus":0.0501710238633082,"score_gpt":0.3756606611824898,"score_spread":0.3254896373191816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414651921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98345023,0.009483837,0.0008863079,0.00057202514,0.0002769292,0.0020613603,0.0010731963,0.00009249007,0.0021036575],"genre_scores_gemma":[0.98552936,0.004653229,0.001799878,0.0008677691,0.00039146966,0.002478219,0.0014574383,0.000027431042,0.0027951447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984274,0.00086830487,0.000212599,0.00016542991,0.00020394406,0.00012235528],"domain_scores_gemma":[0.997693,0.00070496777,0.0008276218,0.00021072225,0.00018745958,0.00037611747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036328149,0.000908923,0.0020515898,0.00037910257,0.00032988153,0.00090137415,0.0005065787,0.0013415278,0.0030468134],"category_scores_gemma":[0.0031016367,0.00042016027,0.0021294786,0.00040541086,0.000741912,0.0009287772,0.0003142126,0.002008014,0.00059010886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9374437,0.009504679,0.0022330433,0.0013040933,0.0015910715,0.0000596536,0.000075382326,0.00051358383,0.009727857,0.0001153416,0.0010611353,0.03637038],"study_design_scores_gemma":[0.82873064,0.15469958,0.010545415,0.00011536064,0.0012561313,0.00010454835,0.00003924319,0.0005045309,0.0020155031,0.0001965527,0.0017509984,0.000041542742],"about_ca_topic_score_codex":0.0002343967,"about_ca_topic_score_gemma":0.00089934445,"teacher_disagreement_score":0.0036328149,"about_ca_system_score_codex":0.00041812554,"about_ca_system_score_gemma":0.0007164747,"threshold_uncertainty_score":0.019212365},"labels":[],"label_agreement":null},{"id":"W4415614649","doi":"10.1007/s40744-025-00800-7","title":"Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Post-hoc analysis; Psoriatic arthritis; Post hoc; Clinical trial; Rheumatoid arthritis; Phases of clinical research","score_opus":0.00871651732288529,"score_gpt":0.2905204589120947,"score_spread":0.2818039415892094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415614649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93605995,0.03887751,0.0050504245,0.0008674886,0.00052207476,0.0072977487,0.007395365,0.0002355452,0.0036938263],"genre_scores_gemma":[0.9834548,0.0030851567,0.0034146511,0.00074959156,0.00033001963,0.0043997327,0.0033844789,0.00010932167,0.001072256],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98066634,0.014153944,0.001716406,0.0014197746,0.0012905541,0.00075307436],"domain_scores_gemma":[0.970642,0.018741218,0.0057101916,0.0024236396,0.0016148369,0.00086818455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028619038,0.0014980206,0.0041940548,0.00090851996,0.00044154093,0.0021040568,0.0007399914,0.0009453682,0.0043299478],"category_scores_gemma":[0.022701306,0.00045072808,0.012724271,0.0010945246,0.0006891556,0.0012937482,0.0006987852,0.0017646503,0.0004001418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7708012,0.0014022157,0.0303171,0.0052460576,0.13721074,0.00023719779,0.00017891213,0.0020029375,0.0058469693,0.00022926372,0.002753665,0.043773793],"study_design_scores_gemma":[0.3914015,0.1690337,0.21832755,0.0011688481,0.19114558,0.0009932102,0.00025987078,0.0054049236,0.007389895,0.0012168549,0.013407257,0.0002506992],"about_ca_topic_score_codex":0.000397312,"about_ca_topic_score_gemma":0.0012275542,"teacher_disagreement_score":0.028619038,"about_ca_system_score_codex":0.001045013,"about_ca_system_score_gemma":0.002220091,"threshold_uncertainty_score":0.15135372},"labels":[],"label_agreement":null},{"id":"W4415928440","doi":"10.1007/s40744-025-00802-5","title":"Effectiveness and Safety of Upadacitinib in Treating Oligoarticular and Polyarticular Psoriatic Arthritis: Primary Analysis from the UPJOINT-Study","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; ABB (Canada)","funders":"AbbVie","keywords":"Clinical trial; MEDLINE; Psoriatic arthritis; Disease; Rheumatoid arthritis","score_opus":0.005525044665966135,"score_gpt":0.2539336185536883,"score_spread":0.24840857388772217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415928440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685781,0.010767701,0.00064652425,0.00024637525,0.000065955224,0.0006375719,0.01739657,0.000034937275,0.0016261635],"genre_scores_gemma":[0.9777353,0.0018341969,0.0005103796,0.00038989636,0.00020123676,0.0004616864,0.018404417,0.000024300132,0.00043865145],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941567,0.0027616657,0.0005995594,0.0009314731,0.0010752096,0.0004753347],"domain_scores_gemma":[0.9845791,0.005927086,0.0053001973,0.0014419724,0.0015537322,0.0011978542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008280834,0.0007705938,0.0033589033,0.00057314115,0.0003562618,0.001631865,0.0008344022,0.0009630284,0.0026774819],"category_scores_gemma":[0.010693612,0.0003499927,0.0043737544,0.0012320377,0.00046819574,0.0008254054,0.0010464261,0.001970932,0.0004995977],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39827487,0.0049176225,0.45130736,0.010159912,0.05083415,0.0006198357,0.00035245306,0.003612671,0.0029379395,0.00041406977,0.01064505,0.065924145],"study_design_scores_gemma":[0.03281162,0.03335472,0.8646199,0.0009263741,0.05023331,0.0017995356,0.0002730424,0.0032778431,0.0025508387,0.00039493394,0.009573431,0.00018446715],"about_ca_topic_score_codex":0.0010156895,"about_ca_topic_score_gemma":0.0019702709,"teacher_disagreement_score":0.008280834,"about_ca_system_score_codex":0.00071540184,"about_ca_system_score_gemma":0.0012927449,"threshold_uncertainty_score":0.043793738},"labels":[],"label_agreement":null},{"id":"W4416994387","doi":"10.1007/s40744-025-00811-4","title":"Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; LEO Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Genentech; Children's Hospital of Philadelphia; Chugai Pharmaceutical; Amgen; Pfizer; Rheumatology Research Foundation","keywords":"Tofacitinib; Psoriatic arthritis; Rheumatoid arthritis; Clinical trial; Psoriasis","score_opus":0.011150234441843463,"score_gpt":0.2540121528060775,"score_spread":0.24286191836423401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416994387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859649,0.005874055,0.00019606303,0.000268215,0.000023989076,0.000092582544,0.0046279333,0.000026008873,0.0029262286],"genre_scores_gemma":[0.9944659,0.0011952416,0.0002804031,0.00017436447,0.000072123854,0.000073485375,0.0035644257,0.0000053810113,0.00016885098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954802,0.0019123389,0.00055686,0.0007138944,0.0011610292,0.00017570655],"domain_scores_gemma":[0.9924765,0.0022753808,0.0041102236,0.00030943402,0.00043486888,0.00039354424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051555396,0.0001936093,0.0010087793,0.00047890263,0.00027682088,0.00083100743,0.000368518,0.00036052836,0.0017318701],"category_scores_gemma":[0.0068875495,0.00014760606,0.0011196822,0.0011803445,0.00019927145,0.00058349036,0.00034482015,0.00051121163,0.0003082199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017370954,0.0005181087,0.9161868,0.000498911,0.0021510993,0.000069593334,0.00007829059,0.0008618925,0.0006395846,0.0000707881,0.002299721,0.05925431],"study_design_scores_gemma":[0.0032208501,0.0069711925,0.9812656,0.00016931024,0.0021273368,0.0007488029,0.00014624967,0.0016915436,0.00068838906,0.00011874241,0.0028171402,0.000034940047],"about_ca_topic_score_codex":0.0015587424,"about_ca_topic_score_gemma":0.0032069723,"teacher_disagreement_score":0.0051555396,"about_ca_system_score_codex":0.00059186795,"about_ca_system_score_gemma":0.0007369782,"threshold_uncertainty_score":0.02726537},"labels":[],"label_agreement":null},{"id":"W4417329339","doi":"10.1007/s40744-025-00812-3","title":"Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Women's College Hospital; Toronto Western Hospital","funders":"Johnson and Johnson; Swedish Orphan Biovitrum; University of Pennsylvania; Biogen; Gilead Sciences; Amgen; Pfizer; Yale University; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Post-hoc analysis; Post hoc; Randomized controlled trial; Clinical trial; Cohort study; Placebo","score_opus":0.039729753033510104,"score_gpt":0.34537721506629826,"score_spread":0.30564746203278814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417329339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94789094,0.02441953,0.008413435,0.0005812042,0.0013554433,0.010282214,0.0035693333,0.00031489416,0.0031730975],"genre_scores_gemma":[0.9795537,0.001978543,0.004748526,0.00040746594,0.00021857784,0.010460336,0.0011503993,0.00008924373,0.0013931287],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.94711757,0.04001557,0.0051313867,0.0034806917,0.002394101,0.001860626],"domain_scores_gemma":[0.9376389,0.044860426,0.007687493,0.006254097,0.0023090206,0.0012501135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05415794,0.0022904866,0.008124013,0.00095556263,0.00061011856,0.0028592856,0.0015774079,0.0022696275,0.0065800645],"category_scores_gemma":[0.055006724,0.00087308144,0.022110341,0.0012895782,0.0014089596,0.0018221611,0.0014409065,0.0022944051,0.00047381435],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89534944,0.00082822103,0.008383276,0.0025328945,0.082287595,0.00007916967,0.0001320477,0.0005529257,0.0011582139,0.00016365867,0.0004312981,0.0081012435],"study_design_scores_gemma":[0.5088634,0.11986117,0.07623965,0.0007651253,0.27876619,0.00021622637,0.00030342353,0.005098154,0.003955559,0.0016605622,0.004048231,0.00022233823],"about_ca_topic_score_codex":0.000895954,"about_ca_topic_score_gemma":0.0013391223,"teacher_disagreement_score":0.05415794,"about_ca_system_score_codex":0.0011688498,"about_ca_system_score_gemma":0.0026996224,"threshold_uncertainty_score":0.28641802},"labels":[],"label_agreement":null},{"id":"W4417501165","doi":"10.1007/s40744-025-00810-5","title":"Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Ixekizumab; Clinical trial; Placebo; Action (physics); MEDLINE","score_opus":0.018256243702722115,"score_gpt":0.3018775763154586,"score_spread":0.2836213326127365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417501165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9171793,0.076321684,0.00039128214,0.0012595437,0.00022687308,0.0006514159,0.0009989034,0.000017099239,0.0029539654],"genre_scores_gemma":[0.98373264,0.0127477925,0.00051256304,0.00075483345,0.00031442384,0.00042675025,0.00088734104,0.000011075109,0.00061256957],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971827,0.0018671614,0.0003708682,0.00022797714,0.00020963237,0.00014175943],"domain_scores_gemma":[0.9936872,0.0033530416,0.0018484109,0.0003559815,0.00038830025,0.0003670508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061699594,0.00041607703,0.0018182531,0.00017721139,0.00024252842,0.0008227007,0.0005933411,0.0009693293,0.0024090642],"category_scores_gemma":[0.005438207,0.00024429476,0.0031645512,0.00041369174,0.00076899905,0.0006484922,0.00029428833,0.0013489646,0.00029360704],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84474164,0.0016202725,0.025653586,0.006537481,0.014811764,0.00007774297,0.00018167708,0.0007072667,0.005591639,0.000287722,0.0020785802,0.097710654],"study_design_scores_gemma":[0.5953534,0.21433768,0.13667269,0.0024686581,0.036773838,0.0003849817,0.00023447577,0.0010679534,0.0038537455,0.00075355475,0.008028162,0.0000707805],"about_ca_topic_score_codex":0.0005639336,"about_ca_topic_score_gemma":0.0013312794,"teacher_disagreement_score":0.0061699594,"about_ca_system_score_codex":0.00035042272,"about_ca_system_score_gemma":0.0007850635,"threshold_uncertainty_score":0.032630265},"labels":[],"label_agreement":null},{"id":"W7117152485","doi":"10.1007/s40744-025-00817-y","title":"Treatment Patterns and Clinical Outcomes for Patients Living with Active Giant Cell Arteritis in Canada","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"AbbVie Canada","keywords":"Giant cell arteritis; Adverse effect; Disease; Inflammatory bowel disease; Vasculitis; Epidemiology","score_opus":0.0079639979188784,"score_gpt":0.2647403501134255,"score_spread":0.2567763521945471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117152485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873607,0.0014814279,0.00009494529,0.0010984502,0.000029843086,0.0000650019,0.0065762764,0.000013709312,0.0032795982],"genre_scores_gemma":[0.9970584,0.00051593845,0.00007804623,0.00023976808,0.000014339376,0.000016459377,0.0016959594,0.00000503784,0.00037605906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991097,0.000047866255,0.0000620676,0.00017535184,0.00024205295,0.00036304235],"domain_scores_gemma":[0.9980958,0.00005742989,0.00069174345,0.000033822682,0.0004774712,0.0006437503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032540885,0.00027298153,0.00038703845,0.00086991437,0.0020454407,0.0011262075,0.00096968777,0.00047423798,0.0030494742],"category_scores_gemma":[0.0018083318,0.00022034043,0.0005248414,0.0027544128,0.000655587,0.00039338053,0.00078030874,0.0007710213,0.00023117028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006280771,0.000022039107,0.99651045,0.000021830801,0.000034314286,0.00007962887,0.00015164376,0.00007349544,0.00008763279,0.000047175352,0.00086310547,0.0020458181],"study_design_scores_gemma":[0.000016545406,0.000044018572,0.9976369,0.00005858224,0.000033503697,0.00020604691,0.0008077602,0.00021721816,0.000038629467,0.000042142,0.00088490424,0.000013642261],"about_ca_topic_score_codex":0.9598525,"about_ca_topic_score_gemma":0.9693001,"teacher_disagreement_score":0.040147483,"about_ca_system_score_codex":0.018075407,"about_ca_system_score_gemma":0.022349903,"threshold_uncertainty_score":0.13114685},"labels":[],"label_agreement":null},{"id":"W764221726","doi":"10.1007/s40744-015-0013-z","title":"The Tissue-Selective Estrogen Complex: A Review of Current Evidence","year":2015,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Raloxifene; Medicine; Placebo; Vasomotor; Osteoporosis; Estrogen; Internal medicine; Hormone therapy; Oncology; Breast cancer; Tamoxifen; Cancer; Alternative medicine; Pathology","score_opus":0.07359831280667199,"score_gpt":0.3990371314819447,"score_spread":0.3254388186752727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W764221726","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006233831,0.9995895,0.000021131043,0.00011995186,0.00005004879,0.000006949034,0.000022489075,0.0000021882126,0.00012546378],"genre_scores_gemma":[0.00047210205,0.99916005,0.00008239371,0.00015921277,0.000049726103,0.000010386383,0.000023271397,8.7067934e-7,0.00004200072],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990054,0.00018243142,0.00035812124,0.00014271968,0.00026010117,0.000051247396],"domain_scores_gemma":[0.995262,0.0034119333,0.0006944507,0.00005556217,0.00046487528,0.00011120656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002177793,0.0012232803,0.0040959553,0.0065031387,0.00047867466,0.0023335824,0.001863065,0.0019685745,0.0051837363],"category_scores_gemma":[0.00547495,0.0007689895,0.0023600322,0.0067990413,0.0006397037,0.0018063929,0.0009899325,0.0017702028,0.00095941045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030966886,0.00008455229,0.00042950994,0.49394852,0.0011163352,0.00025979514,0.00014543519,0.00022340845,0.00050881895,0.0011050359,0.013796158,0.48807278],"study_design_scores_gemma":[0.00015943045,0.00050169625,0.0039607547,0.47238472,0.009158735,0.0022473917,0.0004029928,0.00017616402,0.0004653636,0.0021037573,0.5083744,0.000064461936],"about_ca_topic_score_codex":0.002803712,"about_ca_topic_score_gemma":0.0050951825,"teacher_disagreement_score":0.0065031387,"about_ca_system_score_codex":0.0012460307,"about_ca_system_score_gemma":0.003856759,"threshold_uncertainty_score":0.017341316},"labels":[],"label_agreement":null}]}